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The lack of appropriately authorised and formulated medicines for use in the pediatric popula-
tion is a longstanding problem and cause for concern. As a result, most medicines are prescribed 
to children on an off -label or an unlicensed
basis [1]. Dosing regimens approved for adults are extrapolated to pediatric age
groups, for example on the basis of proportionality of weight, without pediatric pharma-
cokinetic or pharmacodynamic data. Safety and effi  cacy are presumed to be the same as in 
adults, but this may not be the case. Evidence-based information in children is often not readily 
available, and prescribing decisions may have to be based on accepted practice presented in 
formularies.
On January 26, 2007, the new regulation of the European Union (EU) on medicinal products 
for pediatric use came into force [2]. The overall aim of the regulation is to improve the health 
of children in the EU. More specifi cally the objectives include: increasing the development of 
medicines for use in children; ensuring that medicines used to treat children are subject to 
high quality research and appropriately authorised for use in children; improving the informa-
tion available on the use of medicines in children; and achieving the above objectives without 
subjecting children to unnecessary clinical trials or delaying the authorisation of medicines in 
the adult population.
Previously, pharmaceutical industry had been free to restrict a particular medicine’s develop-
ment to the adult population; the development of pediatric medicines was solely at the indus-
try’s discretion. The new regulation requires that all applications for marketing authorisation for 
new medicines, must contain the results of all studies and information required in a previously 
agreed pediatric investigation plan (PIP) The PIP will contain a full proposal of all the studies 
(and their timings) necessary to support the pediatric use of an individual product and will 
cover all pediatric age groups and all necessary age-appropriate formulations. In some case, 
pharmaceutical companies can obtain a deferral of waiver from a PIP, for example where there 
is no pediatric therapeutic need or where pediatric use of the product is not appropriate. Unless 
a deferral or a waiver has been granted, pediatric data must be provided in all applications for 
the authorisation of new medicinal products. 
The regulation also establishes a new type of marketing authorisation, called the pediatric 
use marketing authorization (PUMA), intended to stimulate the development of off -patent 
products for use in the pediatric population. Only medicines that are intended solely for use in 
children will be eligible for a PUMA.
The new legislation obliges the European Medicines Agency to build one European network 
from the diff erent existing networks and collaborative projects, investigators, and specifi c 
Centers of Excellence.
TEDDY
The Task-force in Europe for Drug Development for the Young (TEDDY) Network of Excellence 
was established in 2005 through funding of the European Community’s sixth Framework 
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Programme to contribute to the promotion of safe and effi  cacious medicines for children in 
the context of the impending European Paediatric Regulation that came into force in January 
2007 [3, 4]. The overall aim of the TEDDY NoE is to promote the availability of safe and eff ective 
medicines for children in Europe by integrating existing expertise and good practices, as well 
as stimulating pediatric drug development. The work presented in this thesis is a spin-off  of the 
TEDDY activities.
Respiratory medicines
Respiratory medicines contain a wide variety of medicines and are amongst the most frequently 
used medicines in children [5]. In this thesis we will focus on the use and safety of two groups of 
respiratory medicines in particular, namely asthma medicines and cough and cold medicines.
Asthma medicines
Asthma is defi ned as a chronic infl ammatory disorder of the airways and is associated with 
airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, 
chest tightness, and coughing [6]. Asthma is the most common chronic disease of childhood 
and the leading cause of childhood morbidity from chronic disease as measured by school 
absences, emergency department visits and hospitalizations [7]. As a result, asthma medicines 
are used widely in the pediatric population. According to the Global Initiative for Asthma 
(GINA), bronchodilators (inhaled short-acting ß2-mimetics: SABA; long-acting ß2-mimetics: 
LABA; anticholinergics: ACH), inhaled corticosteroids (ICS) and alternative (add-on) treatments 
such as leukotriene receptor antagonists (LTRA), xanthines and anti-allergics (cromones) all 
have a place in the treatment of childhood asthma, although at various stages depending on 
severity of illness [6]. Apart from these respiratory drugs, systemic glucocorticoids are also used 
in the treatment of asthma. However, due to side eff ects such as potential adrenal suppression 
and growth impairment with long term use [6, 8], use of systemic glucocorticoids in asthmatic 
children is restricted to asthma exacerbations and very severe persistent asthma [6].
Despite the widespread use of these medicines by children very little is know about the long 
term safety. The Pediatric Committee of the European Medicines Agency has recently published 
a pediatric needs list, containing drugs that are being used in children and where information 
on pharmacokinetics, effi  cacy and safety is urgently needed [9]. This list includes asthma medi-
cines such as salbutamol, fl uticasone, montelukast and many others. 
The missing information on the pediatric needs list is mostly addressed by through performing 
clinical trials in children, aimed to obtain a PUMA. However, a TEDDY study has shown that a lot 
of data on pediatric drug usage is readily available in many healthcare databases throughout 
Europe [10]. These databases provide an enormous potential to conduct pediatric pharmaco-
epidemiological research, without subjecting children to unnecessary clinical trials.
In this thesis, we will demonstrate that data on use and safety of asthma medicines in pediatrics 
can be obtained by using healthcare databases which are readily available.
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Cough and cold medicines
Cough and cold medicines (CCMs) are frequently used to treat upper respiratory tract symp-
toms in children and have been on the market for many decades. This group of medicines 
includes expectorants, mucolytics, opium alkaloids (for cough), nasal sympathicomimetics and 
anti-histamines.
In the past years, safety issues have been raised about the use of these drugs in young children. 
In the United States poison-control centers have reported more than 750,000 calls of concern 
related to cough and cold medicines since January 2000 [11]. A report from the Centers for 
Disease Control and Prevention identifi ed more than 1500 emergency room visits in 2004 and 
2005 for children under 2 years of age who had been given cough or cold medicines [12]. A 
review by the Food and Drug Administration (FDA) identifi ed 123 deaths related to the use of 
such products in children under six during the past several decades [13]. A growing number 
of studies associated the use of CCMs to serious adverse events in children, such as cardiac 
arrhythmias, depressed levels of consciousness and even death [14].
In 2007, a citizen petition was sent to the FDA, urging the agency to review the eff ects of cough 
and cold medicines in young children. As a result, the FDA released a recommendation that 
cough and cold medicines should not be used in children below two years of age [15]. Con-
sequently, Canada and the United Kindgom also posted warnings against the use of CCMs in 
young children [16, 17]. 
In this thesis, we studied the eff ects of these regulatory actions on prescription rates of CCMs. 
We also investigated the type of adverse eff ects related to the use of CCMs in children that were 
reported to the Vigibase database on spontaneous reporting.
Data sources used in this thesis
Although randomized controlled trials (RCTs) are the gold standard to assess the effi  cacy of 
a drug, observational studies, using data from large health care databases are ideal to assess 
the utilization and safety of a drug. [18]. As previously mentioned, a TEDDY study showed that 
many European healthcare databases are readily available, providing an enormous potential 
for pediatric pharmacoepidemiological research [10]. The conclusion of that study was that 
future research should focus on methods to bring data from diff erent databases together to 
use the full capacity eff ectively.
In this thesis, we combined data from some of these databases to obtain data on utilization and 
safety of asthma medicines and cough cold medicines.
Three diff erent types of data sources were used for the studies presented in this thesis: primary 
care physician databases (IPCI, Pedianet and IMS), the PHARMO Record Linkage System, and 
the Vigibase database of the WHO-UMC which collects spontaneous reports on adverse drug 
reactions. 
These data sources allowed us to perform large scale pharmacoepidemiologic and pharmaco-
vigilance studies, without limitations mostly observed in RCTs, such as small sample sizes and 
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short duration of follow-up [19]. We demonstrate that an enormous amount of healthcare data 
is available in databases throughout Europe and that these databases can be used to provide 
valuable information on use and safety of medicines in children.
Aims and outline of this thesis
In this thesis we aimed to analyse the use and safety of asthma medicines and cough and cold 
medicines in children through large scale observational studies, by combining readily available 
healthcare databases. In chapter 2 we describe the utilization of medicines in children and in 
particular, the utilization of asthma and cough and cold medicines. For these studies we used 
the IPCI, Pedianet and IMS-DA databases 
In chapter 3 safety studies are presented. To get a broader understanding of the adverse drug 
reactions causes by asthma medicines and CCMs, two studies focus on adverse drug reactions 
for reported to Vigibase.
In two other studies we assess the association between steroids (both inhaled and oral) and 
two outcomes: fractures and pancreatitis, by means of case control studies. For these studies 
we used the IPCI and Pedianet databse and PHARMO RLS. 
The meaning and limitations of the studies are discussed in chapter 4 and recommendations 
are made for future research.
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Summary
Not only do we have limited drug effi  cacy data for children, but also little is known about the 
extent, types and safety of drugs that are actually being used in pediatrics. The TEDDY network 
aims to improve pediatric drug development. To help in prioritizing research the network has 
started out to describe available datasources for pharmacoepidemiologic research and the 
actual description of drug utilization in children. This paper describes these TEDYY activities in 
more detail.
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Introduction
The Taskforce in Europe for Drug Development for the Young (TEDDY) is a Network of Excel-
lence funded under the 6th EU Framework (www.teddyoung.org). The overall aim of TEDDY is 
to promote the availability of safe and eff ective medicines for children in Europe by integrating 
existing expertise and good practices, as well as stimulating pediatric drug development. One 
of the objectives of TEDDY is to set up a harmonised, integrated and reliable European database 
containing information on the types and extent of drugs used in children. This paper reviews 
activities related to assessing pediatric drug use. The European Medicines Evaluation Agency 
(EMEA) has drafted lists of drugs in need of pediatric research, however with this list of more 
than 100 drugs it is necessary to prioritize, since it will be impossible to conduct all requested 
research in parallel (reference necessary!! EMEA site). Using data on which types of drugs are 
actually used in children may help in choosing for which drugs we should most urgently dem-
onstrate effi  cacy in children, fi nd adequate formulations and provide data on short and long 
term safety. 
Datasources
Information on drug use in general can be obtained from market research sources, but these 
do not provide information on age, or other clinical details such as the type of prescriber, 
indication, dose and off -label use. Pharmacoepidemiology (the study of the utilization and 
eff ects of drugs in large populations) relies heavily on health care databases as data source 
for adult drug use and eff ects. To understand better whether databases would be suitable 
for pediatric postmarketing drug research a survey was conducted within the TEDDY NoE to 
describe the characteristics of existing European healthcare databases and to assess whether 
the databases can be used for pediatric medicines research [1]. Siventeen healthcare databases 
from 10 diff erent European countries were identifi ed, together covering a source population 
of about 9 million children from 0-18 years of age. Almost exclusively these databases covered 
only out-patient drug use, Ten out of the 17 databases previously published studies specifi cally 
addressing the paediatric population, but only three databases (PEDIANET, GPRD, IPIC) were 
already used to investigate the safety of paediatric drugs. [2-9]. An international collaboration 
or network of databases as foreseen in the TEDDY project would allow for the extraction of 
important information from data already available and enhance our knowledge about pediat-
ric drug use and safety of e.g. off -label used drugs. 
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Outpatient drug use
To demonstrate the possibilities of such an international collaboration and to provide informa-
tion on pediatric drug use in Europe, TEDDY started describing drug prescription patterns in 
primary care by using established medical record databases in the UK, Netherlands and Italy. 
These databases contain information on more than fi ve million paediatric prescriptions during 
2.3 million pediatric person years). The prevalence of drug use (number of users per year) could 
be divided in three categories of use namely high use (>10% of children using the drug at least 
once in a year), moderate use (1-10% users per year) and low use (<1% of users per year). For 
all age categories, anti-infectives (ATC J), dermatological (ATC D) and respiratory drugs (ATC R) 
were in the high use group, whereas cardiovascular and anti-neoplastic drugs were always in 
the low use group[10] (fi gure 1).
Since the primary care database may miss prescriptions written by specialists we also searched 
for databases that could provide insight in drug use by type of prescriber. The PHARMO record 
linkage database in the Netherlands comprises pharmacy dispensing data on more than 
360.000 children (www.pharmo.nl). A study on all drugs dispensed in the year 2005 showed 
that the majority of pediatric drug dispensings (78%) are prescribed by the general practitio-
ners (fi gure 2). The high volume categories dermatological, respiratory and anti-infective drugs 
are mostly prescribed by GPs (all less than 15% by specialists). Categories with a relative high 
percentage of prescribing by specialists are the alimentary tract drugs (ATC A: 49% by special-
ists), drugs for blood and blood forming organs (ATC B: 46% by specialists), hormones (ATC H: 
40% by specialists), antineoplastic and immunomodulating drugs (ATC L: and neuropsychiatric 
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Figure 1: Pediatric drug use in Netherlands, UK and Italy, by age and anatomic class
Legend: ATC A: Alimentary tract, ATC B: Blood and bloodforming organs, ATC C: cardiovascular, ATC D: 
Dermatological, ATC G: Genitourinary tract, ATC H: Hormones (excl sex), ATC J: Anti-infectives, ATC L: 
Anti-neoplastic and immunological, ATC M: Musculoskeletal, ATC N: Nervous system, ATC P: Anti-parasitic 
drugs, ATC R: Respiratory, ATC S: Sensory organs, ATC V: various. 
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drugs (ATC N: 47%). Within the alimentary drug class, the stomatological preparations group 
(A01) was responsible for most of the specialist prescriptions, within the ATC B class special-
ists prescribed mostly antihemorrhagics (B01) and antianemic (B02) drugs, within the class of 
hormones oral steroids (H02) and thyroid therapy (H03) were mostly prescribed by specialists, 
within the antineoplastic and immunomodulating class all four groups (antineoplastic drugs, 
endocrine therapy, immunostimulants and immunosuppressive drugs) were prescribed mostly 
by specialists, within the neuropsychiatric drugs, antiepileptics (N03), psycholeptics (N05) and 
psychoanaleptics (N06) were mostly prescribed by specialists (fi gure 3).
Prescription data from general practices is a reliable source to assess drug exposure in countries 
where the general practitioner acts as gatekeeper to further care, dispensing data (including 
outpatient specialists) is available as claims data in countries with a national health system (e.g. 
Scandinavia, and Italy) but frequently are government owned and more diffi  cult to access. 
Apart from some ad hoc studies very little is known about pediatric drug use in the hospital 
[11], whereas it has been demonstrated that most of the inpatient pediatric drugs are used 
off -label [12, 13]. There is an urgent need for collaboration between pediatric hospital pharma-
cies and paediatric researchers to perform quantitative and qualitative studies on this subject. 
TEDDY is currently looking for partners that can participate in such studies.
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Figure 2: Percentages of pediatric drug dispensings written by specialists or GPs (percentages calculated 
on the basis of the total number of drug prescriptions)
Legend: ATC A: alimentary tract, ATC B: Blood and bloodforming organs, ATC C: cardiovascular, ATC D: 
dermatological, ATC G: genitourinary, ATC H: hormones, ATC J: anti-infectives, ATC L: anti-neoplastic 
and immunological, ATC M: musculoskeletal, ATC N: nervous system, ATC P: anti-parasitic drugs, ATC R: 
respiratory, ATC S: sensory organs, ATC V: various.
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Unlicensed and off -label
Because of the lack of research on safe and eff ective drugs in children, unlicensed and off -label 
drug use in children is widespread [11-14]. Previous investigations have shown that various 
defi nitions for “off -label and unlicensed drug use” are used, which makes it diffi  cult to compare 
data in children. A Delphi method based survey was recently conducted by TEDDY to better 
defi ne the concepts off -label and unlicensed drug use in children [15]. The defi nition concluded 
from the survey has been discussed with the European Agency for the Evaluation of Medicinal 
Products (EMEA) and is agreed by a panel of European experts in the fi led. Off -label is now 
defi ned as all uses of a marketed drug that are not included in the Summary of Products Char-
acteristics (SPC) with reference to indication, dosage, formulation, routine of administration, 
etc. This defi nition is adopted by the TEDDY expert group and also endorsed by the EMEA. 
To quantify the extent of off -label use according to the new defi nitions, TEDDY is investigating 
the number of off -label users and percentage of off -label drug use for the drugs prescribed in 
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Figure 3: Percentage of pediatric dispensed drug prescriptions written by specialists and GPs, as 
percentage of total number of prescriptions within anatomic level 
Legend: ATC A01: Stomatological preparations, A02: Drugs for acid related disorders, A03: Drugs for 
functional gastrointestinal disorders, A04: Antiemetics and antinauseants, A05: Bile and liver therapy, 
A06: Laxatives, A07: Antidiarrheals, intestinal anti-infl ammatory/anti-infective agents, A08: Antiobesity 
preparations, excluding diet products, A09: Digestives, including enzymes, A10: Drugs used in diabetes, 
A11: Vitamins, A12: Mineral supplements, A16: Other alimentary tract and metabolism products, B01: 
Antithrombotic agents, B02: Antihemorrhagics, B03: Antianemic preparations, B05: Blood substitutes 
and perfusion solutions, H01: Pituitary and hypothalamic hormones and analogues, H02: Corticosteroids 
for systemic use, H03: Thyroid therapy, H04: Pancreatic hormones, H05: Calcium homeostasis, L01: 
Antineoplastic agents, L02: Endocrine therapy, L03: Immunostimulants, L04 Immunosuppressive agents, 
N01: Anesthetics, N02: Analgesics, N03: Antiepileptics, N04: Anti-parkinson drugs, N05: Psycholeptics, N06: 
Psychoanaleptics, N07: Other nervous system drugs.
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primary care in the Netherlands, Italy and the UK according to the new defi nitions. This scheme 
can be applied to any type of datasource and demonstrate the areas of greatest pediatric 
research needs.
Conclusion
To better guide prioritization of pediatric research it is useful to have information about the 
extent to which various drugs are actually being used in children in both primary care as well 
as in secondary and tertiary care. Observational databases consisting of drug prescriptions or 
dispensings are a good resource to describe which specifi c types and formulations of drugs 
are actually being used in outpatient settings, TEDDY is providing important information on 
resources, and outpatient drug use in children However, resources on in-hospital drug use is 
lacking and collaboration is being sought to create an international network on in-hospital 
drug databases. Pharmacists being aware of patient level databases of drug use and diagnoses 
in their hospital can contact the authors to collaborate in creating a pan-European network of 
in-hospital data for pediatric drug use.
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Abstract
Context: The new European legislation concerning paediatric drugs has been conceived in 
order to stimulate research into children’s medicines, but little is known about the patterns of 
general and chronic drug use in children.
Objective: To provide an overview of drug use in children in three European countries.
Design: A r etrospective cohort study covering the years 2000-2005
Setting: Three primary care research databases in the Netherlands (IPCI), United Kingdom (IMS-
DA) and Italy (Pedianet) 
Patients: All children up to 14 (Italy) or 18 years of age (United Kingdom and The Netherlands).
Main outcome measure. Prevalence of use per year was calculated by drug class (anatomic 
and therapeutic levels). Within each therapeutic drug level, we estimated the prevalence of 
“recurrent/chronic” use (>3 prescriptions per year) or “non-recurrent” or “acute” use (<3 pre-
scriptions per year). Within each anatomic class the top fi ve most frequently used drugs are 
described and evaluated for off -label status.
Results: Three levels of drug use could be distinguished in the study population of 675,868 
children: high (>10 per year), moderate (1-10 per year) and low (<1 per year). For all age catego-
ries, anti-infectives, dermatological and respiratory drugs were in the high use group, whereas 
cardiovascular and anti-neoplastic drugs were always in the low use group. Emollients, topical 
steroids and asthma drugs had the highest prevalence of recurrent use, but low prevalence 
drugs were relatively more often used recurrently than acutely. In the top fi ve of highest preva-
lence drugs topical inhaled and systemic steroids, oral contraceptives and topical or systemic 
antifungals were most frequently off -label 
Conclusion: This paper provides an overview of outpatient pediatric prescription patterns in 
a large European population. As these data are population-based and cover all types of drugs 
they may support prioritising research needs concerning long-term paediatric drug safety, as 
well as areas for need of extra effi  cacy and eff ectiveness studies in paediatric medicine.
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BACKGROUND 
Recent years have seen growing concerns about the incompleteness of the evidence relating 
to the effi  cacy and safety of the drugs used in children. Almost all of the drugs prescribed to 
children are the same as those originally developed for adults. They are frequently prescribed 
to children on an unlicensed or ‘off -label’ basis (percentages ranging from 11-80 )1 simply by 
extrapolating adult data, without conducting any pediatric clinical, kinetic, dose-fi nding or for-
mulation studies. However, childhood diseases may be very diff erent from their adult equiva-
lents, and the processes underlying growth and development may lead to a diff erent eff ect or 
an adverse drug reaction unseen in adults (Reye’s syndrome is an outstanding example).
In order to provide legitimate and appropriate treatment for children’s diseases, new legisla-
tion was approved in the US in 2003 and the European Union in 20072. Both the Food and 
Drug Administration (FDA) and the European Medicines Agency for the Evaluation of Medicinal 
Products (EMEA) now off er license extensions to marketing authorisation holders who provide 
evidence concerning the effi  cacy and safety in children of new drugs or ‘off -label’ drugs3-6. The 
World Health Organization underlines the need for these actions and has launched a global 
campaign in December 2007 to ‘make medicines child size’ with the purpose to address the 
need for improved availability and access to safe child-specifi c medicines for all children7 
In an attempt to assist public authorities and the research community in specifying the research 
needs, we investigated the use of paediatric drugs in children in three European countries, 
using population-based primary care prescription data in order to describe the current patterns 
of drug prescribing for children by primary care physicians (general practitioners or paediatri-
cians).
METHODS
Setting
The primary care of children is entrusted to general practitioners in the UK and The Netherlands, 
and to paediatricians in Italy8 9. Access to health care is free in Italy and the UK, and fully covered 
by healthcare insurance in The Netherlands. In these countries, primary care physicians are the 
guardians of children’s health, which means that all clinical information concerning the patients 
(including summaries of specialist and hospital care) is kept in their medical records. Since all 
children need to be registered with a GP in NL and UK, and with a family paediatrician in Italy, 
the databases are population-based9. 
Data collection
We used the same protocol to study prescription patterns in Italy (IT), The Netherlands (NL) and 
the United Kingdom (UK), making use of the Pedianet database (paediatric electronic medical 
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records from 150 paediatricians since 2000) in Italy10, the Integrated Primary Care Information 
(IPCI) database (comprising adult and paediatric electronic medical records from more than 
400 doctors since 1996) in The Netherlands8 11 12, and the IMS Disease Analyzer database (IMS-
DA: electronic medical records on adults and children from 670 doctors) in the UK13 . All of these 
databases include the complete automated medical records of primary care, physicians and 
have been used and proven valid for pharmacoepidemiological research9. The age and gender 
distribution in the various databases is representative for the country they originate from. 
Study population
The dynamic study population in each country consisted of all children aged 0-18 years (0-14 
years in Italy) who had a database history of at least six months, or who were born during 
the study period (1 January 2000 – 31 December 2005), and we calculated the person-time 
of follow-up of each child, stratifi ed by calendar year and age group. Age was assessed on 1 
January of each year and grouped according to the Guidelines of the International Conference 
of Harmonization (ICH) in <2, 2-11, and 12-18 years of age 14 The <2 year age category could 
not be further stratifi ed into newborns (<1 month) and infants (1-24 months) as exact dates of 
birth were not available because of privacy regulations. Each child was followed from the start 
of the study period or the date of registration with the primary practice (whichever was the 
latest), until the cancellation of the registration with the practice or the end of the study period. 
The persontime accumulated in each calendar year was used as denominator for calculation 
of prevalence rates. Over the study period children could contribute to more than one age 
category.
Drug prescriptions
All prescribed drugs in children during follow-up were retrieved from the prescription data 
in the database. The drug prescriptions were grouped on the basis of the WHO’s Anatomical 
Therapeutic Chemical (ATC) classifi cation system which made comparison between countries 
possible. 
Statistical analysis
User prevalence rates (per 1,000 PY) were estimated by counting the number of children 
using a specifi c drug in a specifi c calendaryear. The prevalence rates were calculated by age 
and country to account for diff erences in distributions between populations and to allow for 
direct within stratum comparisons. User prevalence rates should be interpreted as the number 
of children per 1,000 children who use a specifi c drug class in one year. Drug use prevalence in 
Italy was not calculated for children aged 15-18 years because all of the children were censored 
at the age of 15 years. The use of person-years rather than persons as the denominator was due 
to the dynamic nature of age and the population.
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For each anatomic drug category we assessed the age and country specifi c user prevalence 
rates for all individual drugs in 2005. The fi ve drugs with the highest prevalence per anatomic 
class in each country are reported and were evaluated for off -label status considering age only. 
A drug was considered to be off -label for age if the child’s age at the time of use, was below the 
lowest approved age as mentioned in the Summary of Product Characteristics of that drug per 
country15. Within each therapeutic drug level, we separately estimated the prevalence of chil-
dren presenting “recurrent/chronic” (>3 prescriptions per year) versus “non-recurrent” or “acute” 
drug use (<3 prescriptions per year), and the ratio between them in order to help identify the 
treatments that are more frequently used for chronic than acute paediatric diseases. 
Comparisons between user prevalence rates were done by means of the Chi-square test.
RESULTS
Study population
Our population of 675,868 children generated 2,334,673 person-years of follow-up (Table 1); 
the mean individual follow-up was 3.5 years per child. Most of the children (65%) came from the 
IMS database in the UK, 19% from Italy and 16% from The Netherlands. The databases recorded 
more than fi ve million paediatric prescriptions. The prescription rate was highest for the chil-
dren aged less than two years in all three countries and, in each age group, was signifi cantly 
higher in the UK and Italy than in The Netherlands (p-values <0.001),(table 1).
Drug use by anatomically grouped drug classes 
The highest prevalence rates among the children aged less than two years were for anti-
infectives (ATC code J), respiratory drugs (R) and dermatologicals (D), which were used by 48% 
, 30% and 30% of the children, respectively (Figure 1). The other frequent prescriptions were 
for gastrointestinal drugs (A, with a user prevalence of 20%), drugs for the nervous system (N, 
14%) and drugs for sensory organs (S, 19%). ATC classes B (blood and blood forming organs), H 
(hormones) and M (musculoskeletal system) were used by between 1 and 10% of the children, 
and cardiovascular (C), genitourinary (G), anti-neoplastic (L) and anti-parasitic (P) drugs by less 
than 1%. 
Among the children aged 2-11 years, the prevalence of use of anti-infectives, respiratory drugs 
and dermatologicals decreased to respectively 30%, 21% and 17% ; that of the drugs belonging 
to ATC classes A, H, M, N, P and S was between 1 and 10% ; and that of drugs belonging to class 
B, C, G and L was less than 1%. 
In adolescents (12-18 years of age), anti-infectives, respiratory and dermatologicals were used 
by more than 10% per year. Most of the other drug classes were used by 1-10%, but the preva-
lence of use of cardiovascular and anti-neoplastic drugs was less than 1%. 
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Table 1: Characteristics of the study population 
Patient characteristics Children N PY N (% ) Rx N Rx per PY
Italy
<2 years# 56000 87408 (22) 286597 3.3
2-11 years# 103195 296148 (73) 690688 2.3
12-18 years#* 18154 22599 (6) 35883 1.6
Females 61962 194744 (48) 462580 2.4
Males 67525 211412 (52) 550588 2.6
2000 11188 369 (0) 1150 3.1
2001 73364 45330 (11) 140764 3.1
2002 95712 78850 (19) 220207 2.8
2003 103987 94131 (23) 242261 2.6
2004 106555 96388 (24) 206535 2.1
2005 102911 91086 (22) 202251 2.2
Total 129,487 406,156 (100) 1,013,168 2.5
UK
<2 years# 95060 106250 (6) 494353 4.7
2-11 years# 262306 855678 (52) 2011153 2.4
12-18 years#* 229959 683900 (42) 1549372 2.3
Females 219669 804646 (49) 2047616 2.5
Males 225153 841182 (51) 2007262 2.4
2000 307884 288450 (18) 659067 2.3
2001 306923 286483 (17) 677373 2.4
2002 305088 285664 (17) 670690 2.3
2003 303594 280085 (17) 679216 2.4
2004 287287 259219 (16) 674389 2.6
2005 265273 245927 (15) 694143 2.8
Total 444,822 1,645,828 (100) 4,054,878 2.5
Netherlands
<2 years# 25694 36601 (13) 78983 2.2
2-11 years# 62326 159010 (56) 208134 1.3
12-18 years#* 40364 87078 (31) 147250 1.7
Females 49709 138262 (49) 230466 1.7
Males 51850 144427 (51) 203901 1.4
2000 56423 48752 (17) 76319 1.6
2001 53274 46822 (17) 76059 1.6
2002 57998 50219 (18) 81919 1.6
2003 62216 49279 (17) 73462 1.5
2004 60315 50882 (18) 75399 1.5
2005 52252 36735 (13) 51209 1.4
Total 101,559 282,689 (100) 434,367 1.5
PY=person-years; Rx=prescriptions;. #The number of children in the various age groups does not add 
up to the total since one child can contribute to more than one age category. * for Italy the age range 
included only 12-14 years.
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Regarding gender diff erences, in the youngest age groups, most of the drugs were equally 
prescribed to both genders or more frequently prescribed to boys than girls (rate ratio (RR) <1), 
particularly anti-infectives and respiratory drugs. This pattern reversed in adolescence, when 
user prevalence for almost all drug classes (except non-sex hormones) was higher among girls 
than boys. This gender pattern, which was consistent across countries, was most pronounced 
for genitourinary drugs (G), whose user prevalence was more than 60-fold higher in girls 
because they include oral contraceptives, which accounted for 95% of the girls’ use of G drugs. 
The use of drugs for blood and blood forming organs (mainly iron preparations) was also mark-
edly higher among adolescent girls. 
The age trend of prevalence of use was consistent across countries, although there were some 
variations in the age-specifi c rates (Figure 2). In particular, the UK showed the highest preva-
lence of alimentary drug use (class A) in children aged less than two years, and the prevalence 
of prescriptions of dermatological drugs (class D) was 3-4 fold higher in the UK and the NL than 
in Italy (both p-values <0.001). The prevalence of genitourinary drugs (almost all oral contra-
ceptives) was very high in adolescent girls in the NL (p<0.001). In Italy, the use of hormones 
(almost all systemic corticosteroids) was 10-fold higher in children aged <2 years (p<0.001) 
and 5-fold higher in those aged 2-11 years (p<0.001); respiratory drug use was also greater in 
Italy than in the other two countries (p<0.001). The prevalence of the use of anti-infectives and 
drugs for musculoskeletal disorders was much lower in the NL; the prescription prevalence of 
nervous system drugs (including paracetamol that is on prescription in UK) was much higher in 
the UK; and the use of drugs for the sensory organs was much less in Italy. 
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Figure 2: Year prevalence of drug use (per 1000 PY) by age (<2, 2-11, 12-18 years), database (IMS=UK, 
IPCI= Netherlands, Pedianet=Italy) and anatomic level for the most prevalently used drug classes 
(PEDIANET data are excluded for the age category 12-18 years)
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Prevalence of drug use in therapeutic drug class
Within the most frequently used anatomic drug classes, the therapeutic class of anti-bacterials 
(J01) accounted for most of the anti-infective drug use; and the therapeutic classes anti-
asthmatics (R03), other respiratory products (R07) and nasal preparations (R01) were the most 
frequently used drugs in the respiratory group (Table 2). Topical corticosteroids (D07) and 
emollients and protectives (D02) were the therapeutic classes with the highest prevalence 
of use among the dermatological drugs. Many therapeutic classes in the group of alimentary 
drugs (laxatives, anti-diarrheals, drugs for acid disorders) had a considerable prevalence of use. 
The most prescribed drugs in the other classes were anti-anemia medications (ATC class B03), 
cardiac therapy (ATC class C01, mainly digoxin), sex hormones (ATC class G03), oral corticoste-
roids (ATC class H02), non-steroidal antiinfl ammatory drugs (ATC class M01), analgesics (ATC 
class N02) and ophthalmologicals (ATC class S01). 
Ranking of age-specifi c user prevalence rates of therapeutic classes over the entire range of 
drugs showed that antibacterials (J01) are the most frequently prescribed drugs in all age 
groups (table 3), and are at least prescribed to twice as much children as the number two most 
frequently used drug in each age category. The second most used drug changed by age from 
ophtalmologicals (S01) (<2 years), drugs for obstructive airway disease (R03) (2-11 years) to sex 
hormones (G03)(12-18 years).
When the therapeutic classes within each anatomic class were ranked on the basis of the ratio 
between recurrent (chronic) and non-recurrent(acute), a diff erent pattern was observed (table 
2). The drugs with a ratio of >1 (indicating mostly chronic/recurrent use) were often those with 
a low prevalence of use (except for sex hormones): antidiabetics (A10), digestives (A09), bile 
and liver therapy (A05), anti-thrombotic agents (B01), agents acting on the renin-angiotensin 
system (C09), lipid-lowering drugs (C10), sex hormones (G03), thyroid therapeutic agents (H03), 
immunosuppressive agents (L04), muscle relaxants (M03), anti-epileptics (N03), and psychoa-
naleptics (N06) (Table 2). In absolute terms, emollients (D02), topical corticosteroids (D07), sex 
hormones (G03), anti-infectives (J01) and drugs for obstructive airways disease (R03) showed 
the highest prevalence of recurrent use. 
Most frequently used drugs in each anatomic drug class 
In the most frequently used anatomic classes (D, J and R), the most frequently used individual 
dermatological drugs were fusidic acid (except for Italy), topical steroids and topical imidazole/
triazole derivatives (table 4). The topical triazoles/imidazoles were off -label in most countries 
for at least one or more age categories. In the anti-infectives group (J), penicillin derivatives 
(amoxicillin, amoxicillin+clavulanic acid and phenoxymethylpenicillin) followed by macrolides 
(erythromycin, clarithromycin) were the most frequently used drugs, cefalexin (UK, < 2 year) 
was the only off -label drug. Oral acyclovir was one of the top 5 anti-infective drugs in Italy. 
In the respiratory drug group salbutamol, and inhaled steroids (beclomethasone, fl uticasone, 
fl unisolide), antihistaminics (cetirizine, loratidine, clorpheniramine) and xylometazoline were 
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Table 2: Prevalence of acute use (<3 prescriptions per year) and recurrent use (>3 prescriptions per 
year) by age and therapeutic level (prevalence per 1000 PY), ranked by the ratio of recurrent/acute 
use prevalence.4
Acute use prevalence per 
1000 PY
Recurrent use 
prevalence per 1000 PY
Ratio re-
current/
acute
Total 
preva-
lence
ATC Explanation <2 
yrs.
2-11 
yrs.
12-18 
yrs.
All 
ages
<2 
yrs.
2-11 
yrs.
12-
18 
yrs.
All 
ages
A Alimentary tract
A10 Drugs used in diabetes 0.0 0.2 0.3 0.2 0.0 0.9 2.5 1.3 7.0 1.5
A09 Digestives, including 
enzymes 
0.1 0.0 0.0 0.0 0.1 0.2 0.2 0.2 4.9 0.2
A05 Bile and liver therapy 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 1.7 0.1
A12 Mineral supplements 1.1 0.8 0.5 0.7 0.2 0.3 0.2 0.2 0.3 1.0
A06 Laxatives 24.7 13.3 6.2 12.0 3.3 4.7 1.8 3.6 0.3 15.6
A02 Drugs for acid-related 
disorders 
27.0 3.5 9.6 7.9 12.6 0.8 1.7 2.3 0.3 10.1
A11 Vitamins 24.2 3.6 1.4 4.9 3.5 0.7 0.5 0.9 0.2 5.8
A04 Anti-emetics and anti-
nauseants 
1.4 0.6 3.7 1.8 0.7 0.1 0.2 0.2 0.1 2.0
A03 Drugs for functional 
gastrointestinal 
disorders 
25.9 10.6 9.7 11.8 1.4 0.4 0.9 0.6 0.1 12.4
A01 Stomatological 
preparations 
56.3 6.6 4.2 10.7 3.2 0.2 0.2 0.5 0.0 11.2
A07 Antidiarrheals 64.9 11.6 3.2 14.0 1.9 0.3 0.6 0.5 0.0 14.5
B Blood and blood 
forming organs
B01 Anti-thrombotic 
agents
0.2 0.2 0.3 0.3 0.2 0.3 0.3 0.3 1.1 0.5
B03 Anti-anemic 
preparations 
20.8 3.6 6.8 6.4 2.9 0.5 1.2 1.0 0.2 7.4
B02 Anti-hemorrhagics 5.5 1.0 1.6 1.6 0.2 0.1 0.2 0.1 0.1 1.8
C Cardiovascular 
system
C09 Agents acting on the 
rennin-angiotensin 
system
0.1 0.1 0.1 0.1 0.1 0.2 0.3 0.2 2.5 0.3
C10 Lipid modifying 
agents
0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.1 1.7 0.1
C03 Diuretics 0.6 0.1 0.1 0.2 0.6 0.1 0.2 0.2 1.2 0.4
C08 Calcium channel 
blockers
0.0 0.0 0.2 0.1 0.0 0.0 0.2 0.1 0.8 0.2
C07 Beta blocking agents 0.1 0.2 2.2 0.8 0.1 0.2 0.7 0.3 0.4 1.2
C01 Cardiac therapy 1.3 2.2 1.6 1.9 0.2 0.3 0.3 0.3 0.2 2.2
D Dermatologicals
D10 Anti-acne preparations 0.3 1.0 31.2 11.2 0.0 0.1 15.0 5.2 0.5 16.3
D02 Emollients and 
protectives
98.8 45.1 25.6 43.8 48.5 21.8 8.1 19.8 0.5 63.6
D05 Anti-psoriatics 3.9 3.1 4.8 3.7 0.2 0.5 2.0 1.0 0.3 4.7
D07 Corticosteroids, 
dermatological 
preparations
140.4 74.1 55.9 74.4 24.4 11.9 8.7 12.0 0.2 86.5
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Acute use prevalence per 
1000 PY
Recurrent use 
prevalence per 1000 PY
Ratio re-
current/
acute
Total 
preva-
lence
ATC Explanation <2 
yrs.
2-11 
yrs.
12-18 
yrs.
All 
ages
<2 
yrs.
2-11 
yrs.
12-
18 
yrs.
All 
ages
D03 Preparations for 
treatment of wounds 
and ulcers
1.1 0.7 1.0 0.8 0.0 0.1 0.1 0.1 0.1 0.9
D08 Antiseptics and 
disinfectants
3.9 2.4 2.8 2.7 0.1 0.1 0.2 0.1 0.1 2.8
D01 Anti-fungals for 
dermatological use
50.8 18.4 19.6 22.0 1.6 0.6 1.5 1.0 0.0 23.0
D06 Antibiotics and 
chemotherapeutics 
43.6 36.4 23.6 32.8 0.8 0.9 0.9 0.9 0.0 33.7
D11 Other dermatological 
preparations
5.3 8.9 9.8 8.9 0.2 0.1 0.4 0.2 0.0 9.1
G Genito-urinary 
system and sex 
hormones 
G03 Sex hormones, 
modulators of the 
genital system
1.7 0.4 32.3 11.3 0.3 0.1 49.7 17.0 1.5 28.3
G04 Urologicals 0.5 1.1 1.8 1.3 0.1 0.6 0.6 0.5 0.4 1.8
G01 Gynecological 
anti-infectives and 
antiseptics
1.1 1.3 9.2 4.0 0.0 0.0 0.5 0.2 0.0 4.2
H Systemic hormonal 
preparations, 
excluding sex 
hormones and 
insulins 
H03 Thyroid therapy 0.3 0.2 0.3 0.2 0.4 0.5 1.1 0.7 3.1 0.9
H01 Pituitary and 
hypothalamic 
hormones 
0.1 2.2 1.5 1.7 0.0 1.3 1.4 1.2 0.7 3.0
H02 Corticosteroids for 
systemic use
51.0 23.2 8.0 20.7 6.0 2.2 1.0 2.2 0.1 22.9
H04 Pancreatic hormones 0.0 0.3 0.7 0.4 0.0 0.0 0.1 0.0 0.1 0.4
J Anti-infectives for 
systemic use 
J01 Anti-bacterials for 
systemic use
340.0 241.4 166.3 225.6 95.2 47.0 27.6 45.2 0.2 270.7
J04 Anti-mycobacterials 0.5 0.5 0.3 0.4 0.1 0.0 0.0 0.0 0.1 0.5
J07 Vaccines (exc. 
routine childhood 
vaccinations)
11.8 10.6 14.3 12.0 0.8 0.4 1.0 0.6 0.1 12.6
J02 Antimycotics for 
systemic use
1.1 0.6 3.7 1.7 0.0 0.0 0.2 0.1 0.0 1.8
J05 Antivirals for systemic 
use
9.8 4.2 1.7 3.9 0.1 0.0 0.1 0.1 0.0 4.0
Table 2: Continue
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Acute use prevalence per 
1000 PY
Recurrent use 
prevalence per 1000 PY
Ratio re-
current/
acute
Total 
preva-
lence
ATC Explanation <2 
yrs.
2-11 
yrs.
12-18 
yrs.
All 
ages
<2 
yrs.
2-11 
yrs.
12-
18 
yrs.
All 
ages
L Anti-neoplastic and 
immunomodulating 
drugs 
L04 Immunosuppressive 
agents
0.0 0.0 0.1 0.1 0.0 0.1 0.4 0.2 3.8 0.3
L01 Anti-neoplastic agents 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.9 0.2
M Musculoskeletal 
system
M03 Muscle relaxants 0.1 0.1 0.2 0.1 0.0 0.1 0.2 0.2 1.7 0.2
M01 Anti-infl ammatory 
and anti-rheumatic 
products
38.8 32.0 53.6 40.0 1.2 1.2 3.0 1.8 0.0 41.8
N Nervous system
N03 Anti-epileptics 0.7 0.7 0.8 0.7 1.1 2.6 3.6 2.8 3.9 3.5
N06 Psychoanaleptics 0.1 1.1 6.8 2.9 0.0 1.7 6.8 3.3 1.1 6.2
N04 Anti-parkinson drugs 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 1.1 0.1
N05 Psycholeptics 7.3 2.2 5.0 3.6 0.4 0.4 1.6 0.8 0.2 4.5
N07 Other nervous system 
drugs
0.1 0.2 2.0 0.8 0.0 0.0 0.4 0.2 0.2 1.0
N02 Analgesics 109.9 55.0 38.7 54.9 24.2 8.5 5.6 9.0 0.2 63.9
N01 Anaesthetics 2.1 4.2 4.2 4.0 0.1 0.1 0.2 0.1 0.0 4.1
P Antiparasitic 
products 
P03 Ectoparasiticides 2.9 14.9 10.6 12.2 0.1 1.5 0.8 1.1 0.1 13.4
P01 Anti-protozoals 1.8 1.7 2.2 1.9 0.0 0.0 0.0 0.0 0.0 1.9
P02 Ant-helmintics 4.4 12.2 3.1 8.4 0.1 0.2 0.0 0.1 0.0 8.5
R Respiratory system
R03 Drugs for obstructive 
airway diseases
126.3 69.3 39.2 64.7 34.8 39.1 31.8 36.2 0.6 100.9
R07 Other respiratory 
system products
45.4 55.1 53.0 53.4 2.8 8.1 14.1 9.6 0.2 63.0
R06 Anti-histamines for 
systemic use
50.4 29.1 17.4 27.3 3.5 2.1 2.6 2.4 0.1 29.7
R01 Nasal preparations 79.1 36.2 43.7 43.0 3.9 2.1 4.4 3.1 0.1 46.1
R05 Cough and cold 
preparations
4.1 2.2 1.7 2.2 0.2 0.1 0.0 0.1 0.0 2.3
R02 Throat preparations 1.1 1.4 4.0 2.3 0.0 0.0 0.1 0.0 0.0 2.3
S Sensory system
S01 Ophthalmologicals 164.9 60.7 42.9 64.9 10.3 3.1 4.0 4.1 0.1 69.0
S03 Ophthalmological 
and otological 
preparations
3.2 3.5 4.0 3.7 0.1 0.2 0.1 0.1 0.0 3.8
S02 Otologicals 15.7 15.0 13.5 14.6 0.4 0.5 0.6 0.5 0.0 15.1
All ATC therapeutic levels with prevalence of both acute and recurrent use below 0.1 per 1000 PY have 
been excluded.
Table 2: Continue
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most frequently prescribed. Beclomethasone, xylometazoline and cetirizine were off -label in 
the youngest children (< 2 years) in either UK or NL. 
In the moderately used drugs (anatomic groups A, G, N, S), the most frequently prescribed 
alimentary tract drugs (A) were laxatives (lactulose), nystatin, domperidone, mebeverine or 
ranitidine. Only ranitidine and laurilsulfate were off -label in children < 2 years of age. For the 
genito-urinary drugs, oral contraceptives and topical anti-fungals (miconazole) determined the 
top fi ve in NL and UK, whereas Italy (only until age 12) had estrogens, drugs for treatment of 
incontinence and antiseptics as most frequently pescribed drugs. The percentage of off -label 
Table 3: Top ten of most frequently used therapeutic classes in various age categories
< 2 years
Therapeutic class users per 1000 PY
J01 Antibacterials for systemic use 435
S01 Ophthalmologicals 175
D07 Corticosteroids, dermatological preparations 165
R03 Drugs for obstructive airway diseases 161
D02 Emollients and protectives 147
N02 Analgesics 134
R01 Nasal preparations 83
A07 Antidiarrheals, intestinal anti-infl ammatory/anti-infective agents 67
A01 Stomatological preparations 59
H02 Corticosteroids for systemic use 57
2-11 years
Therapeutic class users per 1000 PY
J01 Antibacterials for systemic use 288
R03 Drugs for obstructive airway diseases 108
D07 Corticosteroids, dermatological preparations 86
D02 Emollients and protectives 67
S01 Ophthalmologicals 64
N02 Analgesics 63
R07 Other respiratory system products 63
R01 Nasal preparations 38
D06 Antibiotics and chemotherapeutics 37
M01 Anti-infl ammatory and antirheumatic products 33
12-18 years
Therapeutic class users per 1000 PY
J01 Antibacterials for systemic use 194
G03 Sex hormones and modulators of the genital system 82
R03 Drugs for obstructive airway diseases 71
R07 Other respiratory system products 67
D07 Corticosteroids, dermatological preparations 65
M01 Anti-infl ammatory and antirheumatic products 57
R01 Nasal preparations 48
S01 Ophthalmologicals 47
D10 Anti-acne preparations 46
N02 Analgesics 44
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use of oral contraceptives and antifungals was high in NL and UK. In the group of nervous 
system drugs paracetamol is clearly the most used (but underestimated due to high OTC use 
in NL and IT) drug, methylphenidate (NL and UK), lidocaine (NL), pizotifen (UK), fl uoxetine (UK) 
diazepam, niaprazine (IT) and valproic acid (IT) were also in the top 5 of at least one country. 
None of them was off  label, except diazepam < 12 years of age in NL. In the group of sensory 
organ drugs many diff erent drugs were used in the various countries, the most frequently 
prescribed drugs in NL (fusidic acid, levocabastine) and UK (chloramphenicol) were off  label.
The low prevalence drugs comprised many classes (groups B, C, H, L. M, P). In the blood form-
ing organs group (B), phytomenadione, iron, tranexamic acid, platelet inhibitors and vitamin 
K antagonists were most frequently prescribed. Salicylic acid derivatives were off -label. In the 
cardiovascular drug group topical steroids (anti-hemorrhoidal crèmes), topical anesthetics 
(lidocaine, oxetacaine), B-blockers (propanolol, atenolol), furosemide, disopyramide, epineph-
rine and enalapril were most frequently prescribed. Furosemide, B-blockers, epinephrine and 
topical (antihemorrhoidal) steroids were off -label in at least one country. For the non-sex 
hormones (H) desmopressin, oral steroids, (dexamethasone, prednisolone and prednisone), 
levothyroxine and glucagons) were the most frequently prescribed drugs. Only the oral 
steroids were off -label (NL and UK only). The most frequently prescribed anti-neoplastic and 
immunomodulating drugs (L) diff ered substantially between countries but were almost always 
off -label. In the musculoskeletal drug group (M) NSAIDs were the most frequently prescribed 
drugs, with important sequence diff erences between countries but little off -label use except 
in Italy where the number one and two drugs (ibuprofen and mornifl umate) were off -label. 
The number one anti-protozoal drug (P) was mebendazole in all countries, there was very little 
off -label drug use. 
DISCUSSION
This study describes age-specifi c paediatric drug prescribing in three diff erent European coun-
tries from a very high aggregation level of anatomic classes to the level of individual drugs. This 
information could facilitate the prioritisation of paediatric research by regulatory authorities. 
Prioritisation of drug safety research in paediatrics
Prioritising the research needs in medicines for children has currently been done mostly on 
the basis of one component, whereas we recommend two important assessments: The fi rst is 
public health assessment16 comprising the severity and prevalence of disease and the avail-
ability of treatment alternatives. In addition to the public health assessment a second assess-
ment should be done which is utilisation assessment. Utilisation assessment may comprise the 
frequency or volume of use and the licensing/labelling status of medicines for children. The 
use of off -label and unlicensed medicines implies that there are no proper labelling and dosing 
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recommendations, which can potentially be harmful to children 17 18 19 20. Therefore off -label 
and unlicensed medicines should be of higher priority for research than licensed/on-label 
medications, especially if no data on safety, effi  cacy in children is available. Our study focused 
on assessing the volume and labelling status in order to provide knowledge to experts and 
facilitate research prioritisation that includes both the public health as well as the utilisation 
assessment. 
The utilisation data from this study underline the conclusions of the recently published EMEA 
consensus/expert derived list of research priorities concerning off -patent medicinal products16, 
which emphasized the need for paediatric studies of the safety of topical, systemic and inhaled 
steroids. Steroids are associated with impairment of growth21, abnormalities in the metabolism 
of glucose22 and adrenal suppression23 24. Of these adverse eff ects, growth retardation is the 
most common and is of particular concern in children. The extent of growth suppression var-
ies with the method of administration (e.g., inhaled or oral) and the duration of treatment as 
well as with the type and dose of glucocorticoid used21 25. Topical and systemic antifungals 
(imidazoles/triazoles), acid-reducing drugs and antineoplastic drugs are also listed as research 
priorities by EMEA. Our utilization data found that these drugs are frequently or recurrently 
used and are mostly off -label. Many other drugs that are listed on the priority list of EMEA did 
not appear as frequently used drugs in this study, and would not be considered priorities on the 
basis of frequency of use in primary care alone, but apparently were considered priorities for 
other reasons. On the other hand sex hormones are not listed on the priority list of the EMEA, 
whereas they are frequently and recurrently prescribed, and mostly off -label. Few long term 
safety studies on the use of sex hormones in adolescents are available and to our knowledge 
no RCTs on the safety and effi  cacy of sex hormones in adolescents have been conducted. The 
use of oral anticonceptives in adolescents has been associated with an increased risk of lower 
bone mineral density, higher serum cholesterol and triglyceridemia26-28. Similar to adults, the 
use of oral anticonceptives by teenagers has also been associated with an increased risk of 
cardiovascular events (eg myocardial infarction, stroke) as well as an increased risk of venous 
thrombo-embolism29-33. As the use of sex hormones in young adolescents is relatively high, 
implying a long duration of use, further studies on the effi  cacy and long term safety eff ects of 
these drugs when used by youngsters are warranted. 
Although drug use patterns and labeling status can inform decisions on prioritization of research, 
these data inform us also about suboptimal use and even may demonstrate undesirable pre-
scribing practices. For example fusidic acid and chloramphenicol are frequently used and often 
off -label (table 4). Fusidic acid is known to be prescribed for the treatment of conjunctivitis in 
the Netherlands similarly to chloramphenicol which is used in the UK. However, the benefi cial 
eff ect of antibiotics in the treatment of this condition is not convincingly proven34 35. Indeed 
the literature shows that acute bacterial conjunctivitis is frequently a self-limiting condition 
and topical antibiotic use off ers only marginal benefi t in improving clinical outcomes; hence 
the emphasis should be on educating clinicians not to prescribe such treatment rather than a 
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call for more research 36 37. Another example underlining the need for education rather than 
research is the cough and cold medications. These drugs are not only available over the counter 
but are also frequently prescribed which should be strongly discouraged due to reports of 
death and lack of effi  cacy38.
Drug use patterns
We show that the prevalence of the most frequently prescribed drugs in primary care is high-
est in children aged less than two years, that the most frequently used drugs (anti-infectives, 
dermatolologicals and respiratory drugs) are the same in all three age categories, and 
that almost all other drugs are used by less than 10% of children per year. In general, three 
groups can be distinguished: drugs used by more than 10% of children per year, those used 
by 1-10%, and those by less than 1%. The use of the high prevalence drug classes decreases 
with increasing age but remains high, whereas the use of the lowest prevalence drug groups 
increases to a moderate prevalence rate in adolescence except in the case of cardiovascular 
and anti-neoplastic agents. Only a few therapeutic drug classes accounted for the majority of 
use in a specifi c anatomic drug class: anti-bacterials, topical corticosteroids, anti-asthma and 
anti-anemia medications, cardiac drugs, sex hormones, oral corticosteroids, non-steroidal 
anti-infl ammatory drugs, analgesics and ophthalmologicals. The high prevalence drugs were 
relatively more often used for acute use. Only 12 drug classes (anti-diabetics, digestives, bile 
and liver therapy, anti-thrombotic agents, drugs aff ecting the renin-angiotensin system, lipid-
lowering drugs, sex hormones, thyroid therapeutic agents, immunosuppressive agents, muscle 
relaxants, anti-epileptics and psychoanaleptics) were prescribed more frequently for recurrent 
than acute use.
An interesting age-related gender reversal was observed: female adolescents had consistently 
higher drug use prevalence rates than adolescent boys (except in the case of non-sex hor-
mones), whereas the opposite was true in the younger age categories this was in line with a 
previous Dutch and Danish study39 40.
Interestingly, the percentage of off -label use varied highly between countries and similar 
drugs diff ered in off -label status between countries. This confi rms that the diff erences in the 
Paediatric Status of the drugs, instead of the diff erent prescription habits or medical cultures as 
postulated by many authors represent the real reason for the variability reported by years and 
from many European studies and surveys on the off -label use in children.41
Previous studies
Our study was population-based, had a very large sample size, and covered diff erent European 
countries. Previous European studies have been country or region specifi c, and have concen-
trated on specifi c conditions except for previous Swedish, Dutch and Danish studies in the late 
nineties and a recent Italian study covering 2000-2006 data40 42-44. These studies all took all 
types of drugs into account but the methodologies to calculate prevalence and ranking (on 
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the basis of number of dispensed boxes or user prevalence) and age ranges vary largely which 
complicates direct comparisons. The overall results: highest drug use in lowest age category, 
ranking of the most frequently used drugs (anti-infectives, respiratory and dermatological 
drugs), and the gender pattern (more prescriptions for girls than boys after the age of 10) are 
consistent with the fi ndings of our study39 45 46. 
Potential of multi-country database studies
Our study shows the potential of studying the primary care prescribing of a wide range of 
drugs using multiple databases. As all databases include outcome data such as morbidity and 
mortality data, they can also be used for studies of paediatric drug safety. The country-specifi c 
estimates provide insights into prescription diff erences and allow a search for high prevalence 
countries regarding drug prescribing. 
Limitations
One limitation of this study is the fact that it captured only outpatient, primary care drug 
prescriptions and no use of over the counter drugs (which has resulted in a substantial under-
estimation of the use of paracetamol and phytomenadione, and potentially other drugs such 
as cough and cold medications). At least in the Netherlands, the UK and Italy, most health 
problems are dealt with in primary care8 and, as drug prescriptions by a specialist for a chronic 
disease are often continued by general practitioners or paediatricians, most of them are picked 
up. However, hospital medication administration and the monitoring of chemotherapeutic 
and biological drugs are unlikely to be fully captured by our databases. Despite diff erences in 
the absolute prevalence rates of drug prescribing and the types of drugs that were prescribed, 
age and gender patterns were very consistent in the three countries considered in this study. 
However, as the UK accounted for 60 percent of the study population, the pooled results are 
inevitably dominated by UK prescription patterns, therefore stratifi ed analyses were conducted 
as much as possible. Due to the nature of the databases, we studied drug prescriptions rather 
than drug intake, and so the prevalence of actual drug exposure may be lower than estimated 
here.
In brief, this paper provides a unique overview of primary care prescription patterns in a large 
multinational European paediatric population. The data could be used to improve the priori-
tisation of research into long-term paediatric drug safety, as well as effi  cacy and eff ectiveness 
studies in paediatric medicine. Off -label use in some of the most frequently and recurrently 
used drugs is high (e.g. oral contraceptives) and these should be considered for prioritisation.
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What is already known
· Asthma drugs are among the most prescribed drugs to children
·  Most frequently used asthma drugs are short-acting beta2-mimetics and inhaled 
steroids
· There is a large variability in prescription rates between countries
What this study adds
· Off -label use of asthma drugs in children is low
·  L inking multi-country databases makes it possible to study country specifi c pedi-
atric drug use in a systematic manner without being hampered by methodological 
diff erences
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Abstract
Asthma drugs are amongst the most frequently used drugs in childhood, but international 
comparisons on type and indication of use are lacking. The aim of this study was to describe 
asthma drug use in children with and without asthma in the Netherlands (NL), Italy (IT), and the 
United Kingdom (UK). We conducted a retrospective analysis of outpatient medical records of 
children 0-18 years from 1 January 2000 until 31 December 2005. For all children, prescription 
rates of asthma drugs were studied by country, age, asthma diagnosis and off -label status. 
One-year prevalence rates were calculated per 100 children per patient year (PY). The cohort 
consisted of 671,831 children of whom 49,442 had been diagnosed with asthma at any time 
during follow-up. ß2-mimetics and inhaled steroids were the most frequently prescribed 
asthma drug classes in NL (4.9 and 4.1/100 PY), the UK (8.7 and 5.3/100 PY) and IT (7.2 and 
16.2/100 PY), respectively. Xanthines, anticholinergics, leukotriene receptor antagonists and 
anti-allergics were prescribed in less than 1 child per 100 per year. In patients without asthma, 
ß2-mimetics were used most frequently. Country diff erences were highest for steroids, (Italy 
highest), and for ß2-mimetics (the UK highest). Off -label use was low, and most pronounced 
for ß2-mimetics in children < 18 months (IT) and combined ß2-mimetics+anticholinergics in 
children <6 years (NL).
Conclusion: This study shows that among all asthma drugs, ß2-mimetics and inhaled steroids 
are most often used, also in children without asthma, and with large variability between 
countries. Linking multi-country databases allows us to study country specifi c pediatric drug 
use in a systematic manner without being hampered by methodological diff erences. This study 
underlines the potency of healthcare databases in rapidly providing data on pediatric drug use 
and possibly safety.
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Introducti on
Respiratory drugs are amongst the most frequently prescribed drugs in children, and espe-
cially asthma drugs are frequently prescribed (36). Prevalence rates of asthma drug use range 
between 4 and 26 percent, depending on country, age range, and study period (Table 1) (8, 12, 
16-18, 20, 22, 23, 25, 26, 41, 43). Asthma is defi ned as a chronic infl ammatory disorder of the 
airways and is associated with airway hyperresponsiveness that leads to recurrent episodes 
of wheezing, breathlessness, chest tightness, and coughing (1). In children aged 5 years and 
younger the clinical symptoms of asthma are variable and non-specifi c. Furthermore, routine 
testing for main asthma features is not possible in this age group, which hampers making a 
diagnosis.
According to the Global Initiative for Asthma (GINA), bronchodilators, (inhaled short-acting 
ß2-mimetics: SABA; long-acting ß2-mimetics: LABA; anticholinergics: ACH), inhaled corticoste-
roids (ICS) and alternative (add-on) treatments such as leukotriene receptor antagonists (LTRA), 
xanthines and anti-allergics (cromones) all have a place in the treatment of childhood asthma, 
although at various stages depending on severity of illness (1). In pediatrics, asthma is one of 
the main indications for which these drugs are used. 
Apart from these respiratory drugs, systemic glucocorticoids are also used in the treatment 
of asthma. However, due to side eff ects such as potential adrenal suppression and growth 
impairment with long term use (1, 37), use of systemic glucocorticoids in asthmatic children is 
restricted to asthma exacerbations and very severe persistent asthma (1).
Use of asthma drugs varies largely between countries as observed from the literature (Table 
1). Part of this variability may be explained by diff erences in age distribution and type of data 
(i.e. surveys, prescriptions, dispensing), which hampers good comparisons between studies. 
To better explore diff erences in prescription rates of asthma drug use between countries, we 
conducted a retrospective cohort study in three European countries: the Netherlands, Italy 
and United Kingdom, using the same methodology and stratifying by age, sex and asthma 
diagnosis. 
Methods
Data collection
Data were obtained from general practice medical record databases in three countries accord-
ing to a common protocol. Databases were the Pedianet database in Italy (29), the Integrated 
Primary Care Information (IPCI) database in the Netherlands (40), and the Mediplus Disease 
Analyzer-Mediplus database (IMS-DA) in the UK (42). Details are described elsewhere (36). 
Primary care in children is provided by the GP in the UK and the Netherlands, and by a family 
pediatrician in Italy. These primary care medical record databases were chosen because they 
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Table 1: Overview of studies that have investigated the prevalence of asthma-related drug use in children
Author Type of data Country
Years 
studied
# children
in study
Age
Prevalence 
estimate
Study drugs
Bianchi et 
al (8)
Pharmacy 
dispensing 
records (NHS 
claims data)
Italy 2003 55,242 0-<18 11.9 All asthma 
drugs (R03)
Bollinger 
et al (12)
Pharmacy 
dispensing 
records 
(Medicaid 
claims data)
USA 1997-2000
57,586 – 
282,402
0-<18 10.4 – 13.2
ß2-mim, 
ICS, LTRA, 
xanthines, OS
Clavenna 
et al (16)
Pharmacy 
dispensing 
records (NHS 
claims data)
Italy 2006 923,353 0-<14 26 All asthma 
drugs (R03)
Clavenna 
et al (17)
Pharmacy 
dispensing 
records (NHS 
claims data)
Italy 2000 417,559 0-<14 22.2
All drugs, 
including ATC 
R03
Khaled et 
al (25)
Pharmacy 
dispensing 
records 
(Claims 
data from 
administrative 
databases)
Canada 1999-2000 1,031,731 0-<18 18
ß2-mim, 
ICS, LTRA, 
xanthines, 
cromones, 
ketotifen
Korelitz et 
al (26)
Pharmacy 
dispensing 
records (IL 
Claims data IL)
USA 2004-2005 4,259,103 0-<18 14.58
ß2-mim, 
ICS, ACH, 
cromones, 
xanthines, OS
Goodman 
et al (22)
Pharmacy 
dispensing 
records (GHC)
USA 1984-1993
83,232 (in 
93)
0-<18 4.0 – 8.1
ß2-mim, ICS, 
cromones, 
xanthines, 
fi xed 
combinations
De Vries 
et al (18)
Pharmacy 
dispensing 
records (IADB)
Netherlands 2002 73,416 0-<15 4.9
ß2-mim, 
ICS, LTRA, 
ACH, fi xed 
combinations, 
antihistamines, 
OA
Furu et al 
(20)
Pharmacy 
dispensing 
records (NPD)
Norway 2004 1,192,841 0-<20 9.1
All asthma 
drugs (R03)
Joesch et 
al (23)
Pharmacy 
dispensing 
records 
(MEPS)
USA 1996 6789 0-<18 6.5
ß2-mim, ICS, 
LTRA, ACH, 
cromones, 
xanthenes
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contain detailed information on the population, diagnoses and prescriptions. The geographic 
location of the databases allowed us to study North and South European diff erences in drug 
prescribing.
Study population
The study population consisted of all children aged 0-18 years (0-11 years in Italy) during the 
study period 1 January 2000– 31 December 2005 (1 January 2001– 31 December 2005 for Italy).
All persons needed to have a database history of ≥ 6 months, except for children born during 
the study period. For each child the person years of follow-up were calculated, stratifi ed by 
calendar year, age group, sex, and asthma diagnosis. For privacy issues, some databases only 
contain the year of birth, therefore age was assessed at the 1st of January of each year, and in 
order to identify infants, preschoolers and adolescents separately. We used modifi ed ICH (the 
International Conference of Harmonization) age categories to stratify by age (<2, >2-<4, 5-11 
and >12 years of age) (2). Each child was followed from study start until the patient left practice 
or end of study period (whichever was earliest).
Assessment of asthma
For each child we assessed whether a diagnosis of asthma was made at anytime in its medical 
records using the following diagnostic codes: ICPC code R96 in IPCI, ICD-9 code 493 in Pedianet 
and ICD-10 code J45 in IMS and free text (4, 5, 27). If at any time during the follow-up asthma 
was diagnosed, the child was considered asthmatic for the entire perio
Classifi cation of prescriptions
Drug prescriptions were categorized based on the World Health Organization’s Anatomical 
Therapeutic Chemical (ATC) classifi cation system (6). All prescriptions for “obstructive airway 
Author Type of data Country
Years 
studied
# children
in study
Age
Prevalence 
estimate
Study drugs
Wang et al 
(41)
Survey, claims, 
prescriptions 
(MEPS)
USA ‘96+’98+2000 15,554 5-17 5.2
ß2-mim, ICS, 
LTRA, ACH, 
cromones, 
xanthines, OS
Zuidgeest 
et al (43)
Prescription 
data (GP)
Netherlands 2001 74,580 0-<18 7.5
ß2-mim,ICS, 
cromones, 
LTRA
Legend: 
Study drugs: ß2-mim = ß2-mimetics, ICS = inhaled corticosteroids, LTRA = leukotriene-receptor 
antagonists, ACH = anticholinergics ATC R03 = drugs for obstructive airway diseases, OS = oral steroids, 
OA = oral adrenergics Type of data: NHS = national health service, NPD = Norwegian Prescription 
Database, GHC = Group Health Cooperative of Puget Sound, MEPS = Medical Expenditur Panel Survey, IL 
= Ingenix LabRx, IADB = InterAction DataBase
Table 1: Continue
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diseases” (ATC R03) and “glucocorticosteroids for systemic use” (ATC H02AB) were obtained from 
the prescription fi les and further categorized into: ß2-mimetics (either short-acting [SABA] 
or long-acting [LABA]), inhalation glucocorticosteroids, inhalation anticholinergics, fi xed 
combination of SABA + short-acting anticholinergics, fi xed combination of LABA + inhalation 
glucocorticosteroids, anti-allergic agents (best known as cromones), xanthines and leukotriene 
receptor antagonists (LTRA). Use of ß2-mimetics+ICS was classifi ed as a non-fi xed combination 
if the child used ß2-mimetics and an ICS in the same year. For each drug class, we calculated 
prevalence rates for the most frequently prescribed drugs (top 3) by country.
Due to diff erences in labeling status between countries, off -label use was assessed per country. 
A drug was classifi ed as being “off -label” if the child receiving the prescription had an age below 
the minimum age as specifi ed in the summary product characteristics (SPC) or the drug was 
given for a diff erent indication than specifi ed in the SPC. This is in line with the new defi nition of 
pediatric off -label use provided by the Task Force in Europe for Drug development for Young (31). 
Statistical analysis
Annual prevalence rates (per 1000 PY or per 100 PY) of asthma drug use were calculated by 
counting the number of children using each drug or drug class by calendar year, age, sex, 
asthma status and country and dividing this number by the number of person years attributed 
by the diff erent strata. User prevalence rates can be interpreted as the number of children per 
1,000 children that uses a specifi c drug (class) during one year. If expressed per 100 PY it can be 
freely translated as the percentage of children using these drugs in one year. The fact that we 
used annual prevalence rates means that a child who uses one drug (class) multiple times in 
one year, will be counted only once for that year. The use of person-years rather than persons in 
Table 2: Population size by country, age, sex and asthma diagnosis
  NL Italy$ UK Total
Patient 
characteristics
Children 
with asthma
Total 
pop.
Children 
with asthma
Total 
pop.
Children 
with asthma
Total 
pop.
Children 
with asthma
No.# (% of 
total)
No.# (% of 
total)
No.# (% of 
total)
No.# (% of 
total)
Age
<2 years 2,165 (8.4) 25.694 2,539 (4.6) 54,999 2,977 (3.8) 79,246 7,681 (5.7)
≥2-≤4 years 2,820 (11.8) 23,902 4,269 (7.3) 58,735 7,610 (7.5) 101,835 14,699 (8.0)
5-≤11 years 5,545 (11.7) 47,435 5,399 (7.5) 72,264 19,856 (12.8) 155,488 30,800 (11.2)
12-≤18 years 3,689 (8.3) 44,636 19,809 (13.3) 149,093 23,498 (12.1)
Sex
Females 3,940 (7.9) 49,709 2,851 (4.7) 60,089 14,377 (6.5) 219,669 21,167 (6.4)
Males 5,419 (10.5) 51,850 4,730 (7.2) 65,361 18,125 (8.1) 225,153 28,274 (8.3)
Total 9,359 (9.2) 101,559 7,581 (6.0) 125,450 32,502 (7.9) 444,822 49,442 (7.4)
PY=person-years; #The number of children in the various age groups does not add up to the total since 
one child can contribute to more than one age category during the study period.
$ For Italy the age range included only 0-11 years for the years 2001-2005
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the denominator was necessary due to the dynamic nature of the cohort where persons could 
have variables durations of follow-up. 
Diff erences in prescription rates between countries were tested by means of the X2-test.
Results
Patient characteristics
Our population consisted of 671,831 children (66% UK, 19% IT, 15% NL) of whom 49,442 (7.4%) 
had asthma at any point during follow-up. 
Asthma drug classes
The user prevalence rate of any asthma drug was highest in young children and decreased with 
age (Figure 1), it was highest in Italy for each age category. The diff erence between NL, the UK 
and IT is largest for the youngest age categories with user prevalence rates of 25-30/100 PY in 
Italy, rates of 12 in the UK, and 10/100 PY in NL (Figure 3-4). In the youngest age groups, pre-
scription rates were higher for boys. This pattern switched in adolescence (between the ages 
14 to 16), where user prevalence rates for almost all drug classes were higher in girls (Figure 1). 
ß2-mimetics and ICS were each used by 1-10 children/100 PY in all age categories in each 
country (Figure 2). In Italy, prevalence of use of ICS was higher than use of ß2-mimetics 
and even exceeded 10 /100 PY in the youngest age group. The fi xed combinations of 
anticholinergics+SABA were frequently used in the Netherlands and Italy but not in the UK, 
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Figure 1: Age, country and sex specifi c user prevalence rates of asthma drugs (all ATC R03) 
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where mostly anticholinergics were used as single compound. Leukotriene receptor antago-
nists, anti-allergics and xanthines were used by less than 1 child/100 PY in each country and 
each age category, which is in concordance with protocols concerning asthma treatment. Fixed 
combinations of ICS+LABA were infrequently used in young children but exceeded 1/100 PY 
in adolescents in the Netherlands. Systemic use of steroids was very heterogeneous between 
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Figure 2: Annual user prevalence rates of the most frequently prescribed respiratory drugs 
NL: the Netherlands, IT: Italy, UK: the United Kingdom, ß2-mimetics: inhaled ß2-mimetics (this can be 
single or non-fi xed combination use), ICS: inhalation corticosteroids, ACH: anticholinergics, SABA+ACH: 
fi xed combinations of short-acting ß2-mimetics+anticholinergics, LABA+ICS: fi xed combinations of long-
acting ß2-mimetics+inhalation corticosteroids, ß2+ICS(non fi xed): non-fi xed combination of ß2-mimetics 
(LABA or SABA)+inhalation corticosteroids 
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Figure 3: Prevalence of respiratory drug use by age category and country in children with asthma
b2-mim= ß2-mimetics; ics=inhalation corticosteroids; ach=anticholinergics; saba+ach= fi xed combination 
of short-acting ß2-mimetics+anticholinergics; laba+ics= fi xed combination of long-acting ß2-
mimetics+inhalation corticosteroids; scort=systemic corticosteroids 
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countries. User rates exceeding 10/100 PY were observed in Italy, especially in the youngest 
children, whereas user rates were 5-8 folds lower in the UK and almost 20 fold lower in the 
Netherlands.
User prevalence rates for individual drugs
The prevalence of SABA use in children with asthma was similar in the Netherlands and Italy but 
much higher in the UK (30 vs. 60/100 PY). In children without asthma diagnosis the prevalence 
was between 1 and 8/100 PY. The most frequently prescribed SABAs were salbutamol and 
terbutaline in NL and the UK, whereas terbutaline was not frequently used in Italy (Table 3). 
User rates of LABA (this can be combined or single use) were very low (< 1/100 PY), but strongly 
increased with age in children with asthma. Most frequently used drugs were salmeterol and 
formoterol. In children without asthma, use of LABA was negligible (Table 3 and Figure 3). 
Single use of ß2-mimetics (without a prescription for ICS in the same year) was highest in the UK 
(195/1000 PY in children with asthma and 23 in children without). In NL and IT prevalence rates 
were 127 and 75/1000 PY in children with asthma and 12 and 18/1000 PY in children without an 
asthma diagnosis. In both countries prevalence rates decreased gradually with increasing age. 
ICS were most frequently prescribed in Italy, especially in children < 2 years of age. In children 
with asthma, ICS use was highest in the UK. The choice of drug diff ered; fl uticasone was most 
often prescribed in NL and beclomethasone in the UK and Italy. Among the children with 
asthma who used ß2-mimetics, 42% were not prescribed ICS in that year in NL, 26% in Italy, and 
33% in the UK. In children without asthma, ICS use was low in NL and the UK but reached rates 
of more than 10/100 PY in Italy. 
Oral corticosteroid use was highest in Italy, with prescription rates of 26 /100 PY in children with 
asthma and 7 /100 PY in children without asthma. Rates were especially high in the younger 
age categories. In the other countries, prescription rates in children with asthma were much 
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Figure 4: Prevalence of respiratory drug use by age category and country in children without asthma
b2-mim= ß2-mimetics; ics=inhalation corticosteroids; ach=anticholinergics; saba+ach= fi xed combination 
of short-acting ß2-mimetics+anticholinergics; laba+ics= fi xed combination of long-acting ß2-
mimetics+inhalation corticosteroids; scort=systemic corticosteroids
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Table 3: Prevalence of respiratory drug use per country by treatment class and asthma diagnosis
Netherlands Italy United Kingdom
asthma
no 
asthma
asthma
no 
asthma
asthma
no 
asthma
SABA 
Salbutamol 276 19 Salbutamol 283 59 Salbutamol 519 32
Terbutaline 39 2 Terbutaline 1.4 0.1 Terbutaline 88 2.8
Overall 293 17 284 59 596 35
LABA 
Salmeterol 14 0.4 Salmeterol 13 0.5 Salmeterol 40 0.6
Formoterol 7.6 0.2 Formoterol 1.6 0.1 Formoterol 2.5 0.02
Overall 21 0.6 15 0.6 42 0.6
ICS 
Fluticasone 162 8 Beclomethasone 239 98 Beclomethasone 313 11
Budesonide 68 4 Fluticasone 122 10 Budesonide 72 1.9
Beclomethasone 50 2 Flunisolide 76 32 Fluticasone 63 1.5
Overall 271 14 404 143 437 14
LTRA
Montelukast 5.5 0.1 Montelukast 37 1.7 Montelukast 15 0.3
Zafi rlukast 0.0 0.0 Zafi rlukast 0.2 0.02
Overall 5.5 0.1 38 1.7 15 0.3
Short-acting anticholinergics 
Ipratropium 
bromide 
15.7 1.6 Ipratropium 6.2 2.4 Ipratropium 9.1 2.7
Oxitropium 0.3 0.1 Oxitropium 0.04 0
Overall 16 1.6 6.4 2.5 9.1 2.7
ß2-agonists+ICS (non fi xed)
177 5 217 42 404 12
SABA+SACH (fi xed)
Fenoterol+
Ipratropium 
19 4.1
Salbutamol+
Ipratropium 
104 25
Salbutamol+
Ipratropium
0.7 0.06
Salbutamol+
Ipratropium 
0.9 0.9
Fenoterol+
Ipratropium 
0.1 0.0
Fenoterol+
Ipratropium
0.05 0
Overall 20 4.4 104 25 0.07 0
LABA+ICS 
(fi xed) 
Salmeterol+
Fluticasone 
33 1.3
Salmeterol+
Fluticasone 
37 1.3
Salmeterol+
Fluticasone
31 0.5
Formoterol+
Budesonide 
6.8 0.3
Formoterol+
Budesonide 
2.1 0.1
Formoterol+
Budesonide
6.1 0.07
overall 60 2.3 38 1.4 37 0.6
Asthma = prevalence in children with asthma; no asthma = prevalence in children without asthma; 
SABA= short-acting ß2-mimetics; LABA= long-acting ß2-mimetics; ICS=inhalation corticosteroids; 
LTRA= leukotriene-receptor antagonists; ß2-agonists+ICS (non fi xed) = non-fi xed combination of 
ß2-mimetics+inhalation corticosteroids; SABA+SACH (fi xed) = fi xed combination of short-acting 
ß2-mimetics+short-acting anticholinergics; LABA+ICS (fi xed) = fi xed combination of long-acting ß2-
mimetics+inhalation corticosteroids. * Could either be the combination of LABA+ICS are SABA+ICS but 
always a loose combination (more than 1 device)
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lower in each age category, both in children with and without asthma. The most frequently 
prescribed drugs were betamethasone in Italy and prednisolone in NL and the UK.
Combination preparations
Use of the fi xed combinations of short acting SABA+ACH was low overall, but most frequent in 
Italy. Prescription rates decreased with age. 
For the fi xed combinations of ICS+LABA, use was highest in NL with 6/100 PY in children with 
asthma. A clear increase of prescription rates with age was seen in all 3 countries. 
Use of the loose combination of ß2-mimetics+ICS was highest in IT (55/1000 PY), followed by 
the UK (48/1000 PY) and NL (24/1000 PY). In children with asthma prevalence rates were high-
est in the UK (404/1000 PY), followed by IT (217) and NL (177)
Off -label use
Off -label use defi ned by use below the minimum age as specifi ed in the SPC was investigated 
in Italy and NL. In Italy, salbutamol is indicated for use in children from the age of 18 months 
onwards, however user rates were 22.7 /100 PY in children with asthma and 7.5 in children 
without asthma diagnosis below 18 months. In NL off -label use was observed for the fi xed 
combinations of ß2-mimetics+anticholinergics. The minimum age for use of these drugs is 6 
years in NL, however, prescription rates in children <6 years were 0.5-3.5 /100 PY in NL (data 
not shown).
Off -label use defi ned as use for other indications than specifi ed in the SPC (for drugs that 
only had asthma or COPD as indication) in children without recorded asthma diagnosis was 
observed in all 3 countries for several drugs (Table 4). In Italy budesonide had the highest off -
label prescription rate, in NL salbutamol, and in the UK beclomathesone.
Discussion
This paper provides detailed information on asthma drug use in three European countries, and 
clearly demonstrates the similarities and diff erences in prescription rates.
Whereas short-acting ß2-mimetics are the most frequently used drugs for treatment of asthma 
in the Netherlands and the UK, inhaled and systemic corticosteroids are most frequently used in 
Italy, especially in the youngest age groups. Long-acting products, anticholinergics, xanthines, 
and LTRAs were in general infrequently prescribed in all countries.
Our data are in line with previous studies on asthma drug use in children, which also dem-
onstrated that short-acting ß2-mimetics and inhaled corticosteroids were prescribed most, 
but these studies often considered only one country or a region (20, 21), whereas our study 
captures multiple countries in diff erent European regions. Our data also confi rm fi ndings of 
a recent survey showing high use of inhaled ß2-mimetics in northern Europe and high usage 
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of corticosteroids in southern Europe (11). The north south gradient that we observed in the 
prescription of asthma drugs can not be explained by country specifi c diff erences in asthma 
treatment protocols, as the protocols in the Netherlands; the UK and Italy are all based on the 
GINA guidelines.
There are various prescribing behaviors which deserve specifi c attention since they may 
be associated with a diff erential risk of adverse drug reactions. First of all, SABA use is high 
in the lower age categories which may at least partly be explained by the fact that they are 
recommended on an as-needed basis for acute wheezing in preschool children (13). However, 
paradoxical responses like deterioration of asthma with use of these drugs have been reported 
in infants (38). 
Secondly, prescription rates for long-acting ß2-mimetics were low for all 3 countries, which is 
in line with guidelines and recommendable since a black box warning was issued by the FDA 
due to safety issues in children, especially in mono-use (19). Thirdly, in children with asthma the 
percentage of children using β2-mimetics without ICS as controller was substantial, especially 
in the UK and Netherlands. A possible explanation could be that these children were intermit-
tently treated with SABA’s on an as-needed basis as defi ned in the 1st step of the guidelines (1). 
However, chronic use of ß2-mimetics without ICS is contraindicated in children with asthma 
because it may lead to increased airway infl ammation and worsening of asthma control, and is 
in severe cases even associated with death (28, 33). 
Fourth, use of ICS was very high in children under the age of 5 in Italy; this level of use certainly 
raises a question about potential overprescription, especially in children without asthma. How-
ever, a recent survey among children 1-5 years of age showed that southern Europe had the 
highest rate of wheezing symptoms (48%) compared with northern Europe (29%), which may 
explain some of the high use of ICS (11). Although there is some evidence supporting the eff ec-
tiveness of regular inhaled corticosteroids in preschool wheeze (9) its use remains controversial 
(13, 24). Long term use of steroids (inhaled and specifi cally oral) might cause side eff ects such 
as temporary growth retardation and adrenal suppression (1, 7). Less severe but more frequent 
and relevant side eff ects in children treated with ICS are oropharyngeal candidiasis, dysphonia, 
refl ex cough and pharyngitis (14). 
Fifth, systemic corticosteroids are not the fi rst choice of treatment in asthma and should only 
be used for exacerbations. A recent study showed that oral prednisolon and placebo did not 
diff er in duration of hospitalization in children with mild to moderate wheezing associated with 
a viral infection (32). Although the high use of oral steroids in Italy is consistent with previ-
ous study fi ndings (1, 8, 15), it may be slightly overestimated. Betamethasone (dispensed as 
capsules) is often administered via a nebulizer meaning that the actual oral use will be lower 
than reported, unfortunately we could not distinguish between these modes of administration. 
Fixed combination therapies of an ICS+LABA are relatively new in the treatment of childhood 
asthma and their long term safety is not well known. Use was highest in NL, similar to a recently 
reported increase in use of the fi xed combination of ICS+LABA in Denmark (10). Although fi xed 
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combination products of ICS+LABA are only licensed for use in children over 4 years, these 
drugs were also prescribed to children <2 years in the Netherlands. We found only 1 small 
retrospective study investigating the eff ect of a fi xed combination of ICS+LABA in children <4 
years, reporting a reduction in morbidity and an acceptable safety profi le (34). So far, the safety 
and effi  cacy data of the fi xed combination of ICS+LABA in children <2 years is too scarce to 
justify prescribing these drugs in young children. 
In general, off -label use of asthma drugs defi ned as use below the minimum age as reported in 
the SPCs was low except for the fi xed combination of ß2-mimetics+anticholinergics in children 
<6 years in the Netherlands and the use of SABA in children <18 months in Italy. Prescription 
rates for asthma drugs in children without an asthma diagnosis are much lower than in children 
diagnosed with asthma but still surprisingly high, especially for ICS and SABA. These drugs 
may have been used to treat wheezy young children with other respiratory conditions, such 
as respiratory tract infections (e.g. bronchiolitis) or fi rst symptoms of undiagnosed asthma in 
young preschool children, but still, overuse cannot be excluded.
Use of asthma drugs is high, although very few long-term safety studies are available for chil-
dren. The Pediatric Committee of the European Medicines Agency has recently published a 
pediatric needs list, containing drugs that are being used in children and where information on 
pharmacokinetics, effi  cacy and safety is urgently needed (3). This list includes frequently used 
respiratory drugs such as salbutamol, fl uticasone, montelukast and many others. Although 
RCTs are the gold standard for effi  cacy assessment, safety studies are more eff ectively con-
ducted through large scale postmarketing observational studies (35). Clinical trials are often 
small and too short for safety assessment. Pharmacoepidemiological studies are a valid tool for 
assessing safety under real life circumstances and often rely on secondary use of routine care 
data from claims databases and medical records. This study, as well as a previous inventory on 
databases with pediatric data, shows that exposure and outcome information is available on a 
large pediatric population (30, 36). Pharmacoepidemiological studies should be promoted to 
improve the safety assessment of pediatric drugs since RTCs are hampered by methodological 
diffi  culties, especially in the pediatric subpopulation, and consequently, results may not be 
prompt and suffi  cient enough for safety assessment. 
As for all observational research, our data has some limitations. First of all, as we used primary 
care data, we may not capture all specialist prescriptions in the UK and the Netherlands. This 
will minimally infl uence our results since asthma is a condition often dealt with in primary care, 
and asthma drugs originally prescribed by a specialist are often continued or prescribed by 
general practitioners (39). Also, the health care provider in the studied countries diff ered: GP 
data from the UK and NL and family pediatrician data from IT. However, we do not believe that 
this would hinder comparability between databases as the nature of the databases is the same. 
If there are diff erences between countries, this refl ects diff erences in primary care prescribing 
behavior and not in the type of data.
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Furthermore, it is not possible to diagnose asthma in young pre-school children and the diag-
nosis of asthma is often made at a later age, which could lead to misclassifi cation of the indica-
tion in young children. However, to minimize the possibility of misclassifi cation, we searched 
the entire medical record of a child for the diagnosis of asthma. If the diagnosis was made at a 
later age, the child was counted as having asthma during the whole study period.
To conclude, our results show high use of SABA and ICS, although not always combined, and 
low use of other asthma drugs. Safety data on specifi c asthma drugs are needed according to 
the European Medicines Agency (3). This study underlines the potency of healthcare databases 
in rapidly providing data on pediatric drug use and possibly safety.
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What is already known
· Cough and cold medicines are frequently used in children to treat upper respiratory 
tract infections without solid proof of benefi ts.
· Safety issues have been raised about the use of these drugs in young children
· In 2007 international warnings have been issued advising against use of these drugs in 
young children
What this study adds
· Cough and cold medicines prescribing by primary care physicians has not really been 
infl uenced by international warnings in the Netherlands, where no additional national 
warnings were made and only partially in Italy.
· A concerted action should be taken in Europe to strongly advice against the OTC use and 
prescription of cough and cold medicines in young children.
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Abstract
Aim: To assess the infl uence of national and international warnings on the prescription rates of 
cough and cold medicines (CCMs) in the youngest children (<2 years) in the Netherlands (NL) 
and Italy (IT) countries.
Methods: Analysis of outpatient electronic medical records of children <2 years in IT and NL. 
Age and country specifi c prescription prevalence rates were calculated for the period 2005-
2008.Comparisons of prescription rates in 2005 (pre) and 2008 (post) were done by means of a 
Chi-square test.
Results: The cohort consisted of 99,176 children < 2 years of age. After international warnings, 
overall prescription rates for CCMs decreased slightly from 83 to 77/1000 person years (p=0.05) 
in Italy and increased in NL from 74 to 92/1000 children per year. Despite the international 
warnings, prescription rates for nasal sympathomimetics and opium alkaloids increased in NL 
(p<0.01). In Italy a signifi cant decrease of the rates of opium alkaloids and other cough suppres-
sants (p<0.01) was observed, and also a signifi cant reduction in use of combinations of nasal 
sympathomimetics.
Conclusion: Despite the international safety warnings and negative benefi t-risk profi les, pre-
scription rates of cough and cold medicines remain substantial and were hardly aff ected by 
the warnings, especially in the Netherlands where no warning was issued. The hazards of use 
of these medicines in young children should be explicitly stipulated by European Medicines 
Agency and all national agencies, in order to increase awareness amongst physicians and 
caretakers and reduce heterogeneity across the EU. 
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Introduction
Cough and Cold Medicines (CCMs) are frequently used to treat upper respiratory tract symp-
toms in children. This group of medicines includes expectorants, mucolytics, opium alkaloids 
(for cough), nasal sympathomimetics and anti-histamines. CCMs carry a risk of serious and 
potentially life-threatening adverse events, such as cardiac arrhythmias, depressed levels of 
consciousness, and encephalopathy, and should be avoided in the very young [1]. 
As a result of these safety issues, in 2007 various regulatory actions have been taken in many 
countries: in the United States, the Food and Drug Administration (FDA) has issued a recom-
mendation advising parents and caregivers not to use these drugs in children younger than 2 
[2]; in the United Kingdom, the Medicine and Healthcare Products Regulatory Agency (MHRA) is 
advising against the use of many CCMs in children under the age of 6 [3], and Health Canada is 
requiring manufacturers to re-label certain over-the-counter (OTC) CCMs to indicate that these 
should not be used in children under the age of 6 [4]. In Italy a warning was issued in September 
2007 only regarding the use of nasal sympathomimetics in children <12 years. However in the 
Netherlands and many other countries, no national warning was issued. The safety concerns on 
the use of CCMs in young children, and the regulatory actions, also received a lot of attention 
by the scientifi c community. Sharfstein et al published an important paper in the New England 
Journal of Medicine which was followed by publications in many lay press journals and media 
attention in most countries [1].
Most of the utilization data that have been published focus on OTC use of CCMs, as this is the 
major market in the USA [5-10]. Although CCMs can be bought as OTC in many countries, they 
are also regularly prescribed by physicians, especially when they would be reimbursed. Previ-
ous studies have shown that prescription rates of e.g. antidepressants and antipsychotics drop 
after regulatory warnings. However, to our knowledge, no studies have been performed that 
evaluated the eff ect of regulatory warnings on CCMs prescription rates [11-13]. We aimed to 
investigate the extent of use and to study the eff ects of the warnings on the prescription rates 
of CCMs to children under the age of two (since this is the group included in all international 
warnings) in the Netherlands and Italy, two countries with diff erent types of direct national 
warnings (NL none, and Italy only on nasal sympathomimetics).
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Methods
Data collection
Data were obtained from general practice medical record databases in two countries and were 
extracted and elaborated according to a common protocol. Databases comprised the Pedianet 
database in Italy [14] and the Integrated Primary Care Information (IPCI) database in the Neth-
erlands [15]. These databases include complete automated medical records of primary care 
physicians. The patient population in each database is representative of the respective Dutch 
and Italian population regarding age and gender. The electronic records contain anonymous 
and coded information on patient demographics, symptoms and diagnoses, referrals, clinical 
fi ndings, laboratory assessments, drug prescriptions, and hospitalisations. Details of these 
databases regarding their pediatric data are described elsewhere [16].
Study population
The study period was from 1 January 2005 to 31 December 2008. The study population in each 
country consisted of all children aged 0-2 year (up to 24 months) Each patient was followed 
from start of the study period or date of registration with the primary care practice (whichever 
was latest), until the patient left the practice or end of the study period (whichever was earliest). 
Classifi cation of prescriptions
Cough and cold medicines of interest comprised the following medicines: expectorants (ATC 
R05CA: althea root, thyme, combinations containing promethazine, oxomemazine, terpenes, 
guaiacol, and eucalyptus), mucolytics (ATC R05CB: ambroxol, bromhexine, acetylcysteine, car-
bocisteine, sobrerol, erdosteine, dornase alpha), opium alkaloids and derivatives (ATC R05DA: 
codeine, dextromethorphan, dihydrocodeine, noscapine, and opium combinations containing 
pentetrazol, pseudoephedrine, triprolidine, or codeine), other cough suppressants (ATC R05DB: 
pentoxyverine, levodropropizine, clobutinol, butarimate, dropropizine, cloperastine, and 
combinations containing pentoxyverine, terpenes, or thyme), nasal sympathomimetics (ATC 
R01AA: xylometazoline, oxymetazoline, phenylephrine, naphazoline) and combinations of 
nasal sympathomimetics (ATC R01AB). These drug classes were extracted from the databases 
using the World Health Organization’s Anatomical Therapeutic Chemical (ATC) classifi cation 
system [17]. 
Statistical analysis
Annual prescription rates (users per 1000 person years [PY]) of CCMs were estimated by count-
ing the number of children being prescribed each drug or drug class divided by the number 
of person years attributed, categorized by calendar year, age, and country. Prescription rates 
can be interpreted as the number of children per 1,000 children who get a specifi c drug (class) 
prescribed in one year. Because we used annual prescription rates, a child that uses one drug 
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(class) multiple times in one year will be counted only once for that year. To inspect seasonal 
variability monthly rates were calculated by dividing the number of users per month by the 
person months attributed. 
To study the eff ect of the international warnings in 2007 on prescription rates, we compared 
prescription rates between 2005 and 2008 for each individual drug and drug class by a Chi-
square test. P-values below 0.05 were considered to be signifi cant.
Results
Patient characteristics
Our population of 99,176 children under the age of 2 generated 110,169 person years of 
follow-up (Table 1). The overall distribution of children per country was fairly equal, 52% of the 
patients were from Italy (IT) and 48% from the Netherlands (NL).
Prescription rates of cough and cold medicines
In the Netherlands CCMs prescription rates increased signifi cantly between 2005 and 2008 
from 74 to 92/1000 PY (p<0.01), but decreased slightly from 83 to 77/1000 PY (p=0.05) in Italy 
(fi gure 1). In both countries a strong seasonal prescription pattern could be observed, with 
peaks during winter time (fi gure 2). The seasonal patterns of CCMs prescription rates were 
similar before and after the international warnings in Italy and the Netherlands. 
When looking at classes of CCMs, diff erent patterns were observed, both in terms of preferred 
medicines between countries and changes in annual prescription rates. Expectorants were 
mostly prescribed in NL, and rates decreased signifi cantly from 10.8 to 4.3/1000 PY (p<0.01) 
(table 2), mostly because of a decrease in prescription of both thyme syrup (p<0.01) and 
Table 1: Number of children in the study population and persontime by gender and calendar year
  Italy NL
Patient
characteristics
Children# PY GP 
practices*
Children# PY GP 
practices*
Females 24532 (48%) 33862 23406(49%) 19741
Males 26890 (52%) 37002 24348 (51%) 19564
 
2005 19070 16338 158 11331 8422 134
2006 19424 18780 176 12189 8340 136
2007 18611 18234 160 13128 10845 138
2008 17596 17512 170 13219 11698 138
Total 51422 70864 47754 39305
PY=person-years;
*= the number of contributing general practitioner’s databases to the study population
 #The number of children in various years does not add up to the total since one child can contribute in 
more than one year during the study period.
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combination products (p<0.01) (Table 3). In Italy the only expectorants prescribed were combi-
nation products, and prescription rates for these increased slightly. 
Figure 1: Prescription rates of cough and cold medicines by database and year with 95% confi dence intervals
IPCI= Dutch database 
Pedianet = Italian database
Figure 2: Prescription rates of cough and cold medicines by database and calendar month
IPCI= Dutch database 
Pedianet = Italian database
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Mucolytics were ten times more often prescribed in Italy than in NL. In both countries, overall 
rates did not change before and after the warning, but small changes occurred in prescription 
Table 2: Prescription rates of cough and cold medicines per 1000 person years by year and country 
CCMs Cough relievers Cough suppressants Nasal decongestants
Year
Overall Expectorants Mucolytics
Opium 
alkaloids
and 
derivatives
Other Sympatho-
mimetics
Sympathomimetic
Combinations
NL IT NL IT NL IT NL IT NL IT NL IT NL IT
2005 74 83 10.8 4.1 6.6 54 4.2 7.4 7.7 21 51 0.9 - 7.3
2006 91 82 9.4 5.6 7.1 56 6.4 5.4 7.2 22 67 1.1 - 4.6
2007 93 78 6.8 5.2 8.6 58 10.9 3.6 9.7 17 70 0.3 - 1.4
2008 92 77 4.3 5.0 5.2 58 13.4 3.6 6.2 16 73 0.1 - 0.3
Overall 88* 79 7.1* 5.0 6.8 57 9.3* 5.0* 7.7 19* 66* 0.6* - 3.3*
NL: the Netherlands, IT: Italy,
- = not available in NL
*= signifi cant change between 2005 and 2008 (p<0.05)
Table 3: Pre- and post-warning prescription rates per 1000 person years of individual cough and cold medicines
Class of CCM Netherlands Italy
2005 2008 p-value 2005 2008 p-value
Expectorants
Combinations* 4.3 1.7 <0.01 Combinations# 4.1 5.0 0.24
Thyme syrup 14.8 0.8 <0.01
Althea root 0 0.08 0.40
Mucolytics
Bromhexine 4.4 3.2 0.16 Ambroxol 17.6 19.8 0.13
Acetylcysteine 2.0 2.0 0.93 Sobrerol 16.0 20.2 <0.01
Carbocisteine 0.2 0 0.47 Carbocisteine 13.4 14.0 0.65
Dornase alpha 0 .08 0.40 Bromhexine 9.7 8.2 0.14
Opium alkaloids and 
Derivatives
Noscapine 3.7 14.1 <0.01 Dextromethorphan 3.8 1.8 <0.01
Codeine 0.8 0.4 0.88 Codeine 2.3 0.9 <0.01
Combinations## 0.7 0.2 0.01
Other cough 
suppressants
Pentoxyverine 7.4 6.2 0.30 Levodropropizine 14.8 10.8 <0.01
Combinations** 0.6 0 0.28 Cloperastine 5.6 5.0 0.40
Clobutinol 0.2 0 0.42
Nasal 
Sympathomimetics
Xylometazoline 51 73 <0.01 Phenylephrine 0.8 0.1 <0.01
Oxymetazoline 0.1 0.4 0.21 Naphazoline 0.1 0 0.48
Combinations 
of nasal 
sympathomimetics
- Ephedrine based 4.6 0.2 <0.01
Tuaminoheptane 
based
2.9 0.1 <0.01
- = not available in NL
* combinations containing: promethazine, oxomemazine, guaiacol, ipecacuanha
** combinations containing: pentoxyverine, terpenes, thyme
# combinations containing: terpenes, eucalyptus, guaiacol, thyme
## combinations containing: pentetrazol, dihydrocodeine, codeine, dextromethorphan, 
pseudoephedrine, triprolidine
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of individual products. Especially prescription rates of sobrerol increased in Italy and dornase 
alpha in NL (tables 2 and 3).
Opium alkaloids and derivatives for cough suppression were most frequently prescribed in NL 
and prescription rates even tripled between 2005 and 2008 from 4.2 to 13.4/1000 PY (p<0.01). 
This increase was due to a substantial rise in prescription rates of noscapine. In contrast, in Italy 
prescription rates of opium alkaloids dropped by half from 7.4 in 2005 to 3.6/1000 PY in 2008 
(p<0.01). This decrease was seen for all products in this class (Tables 2 and 3). Prescription rates 
for other (non-opioid) cough suppressants were highest in Italy, and this was mostly accounted 
for by levodropropizine. Rates decreased by one third after the warning (p<0.01 (Table 2 and 
3)). In NL, use of other cough suppressants did not change signifi cantly. 
Single product nasal sympathomimetics (mostly xylometazoline) were primarily prescribed in 
NL, and prescription rates increased signifi cantly from 51 in 2005 to 73/1000 PY in 2008, mostly 
due to use of xylometazoline (p<0.01) (Table 2). In IT, xylometazoline was hardly prescribed even 
before the warning, and prescription rates decreased to almost 0 in 2008. On the other hand, 
combinations of nasal sympathomimetics were only prescribed in IT, and a strong eff ect of the 
warning was seen on their prescription rates (from 7.3 in 2005 to 0.3/1000 PY in 2008, p<0.01). 
Medicines prescribed in this class were combinations with ephedrine or tuaminoheptane.
Discussion
The formal regulatory review of OTC drugs, including CCMs, started in 1972 in the United States 
[18]. At that time, most OTC CCMs were generally recognized as safe and eff ective. Until recently 
CCMs received little attention regarding their safety and effi  cacy in children. In 2007, this 
changed dramatically by a citizen petition submitted to the FDA, raising signifi cant concerns 
about the safety and effi  cacy of CCMs in children under the age of 6 years. This petition resulted 
in a public healt advisory by the FDA, recommending that CCMs should not be used in children 
under 2 years of age because of the risk of serious and life-threatening eff ects [19]. The FDA 
warning was followed by other countries issuing warnings and several literature publications.
This paper provides information on the eff ects of national and international warnings on rates 
of prescriptions of contra-indicated drugs in a country with and a country without additional 
national warnings. Despite the international warnings and important publications in high 
impact journals and lay press advising against the use of CCMs in young children, overall 
prescription rates for CCMs increased in the Netherlands, where no national warning was 
issued. Use of opium alkaloids and nasal sympathomimetics increased signifi cantly, although 
these drugs are contraindicated in young children [20]. In Italy, where a specifi c warning was 
issued by the Agenzia Italiana del Farmaco only against the use of nasal sy mpathomimetics, a 
signifi cant reduction in use of nasal sympathomimetics was seen and also a decrease in use of 
cough suppressants (opioids and non-opioids).  
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Although the warnings did not show a considerable impact on the overall prescription rates in 
the Netherlands, there were shifts regarding use of individual medicines. Rates for expectorant 
combinations decreased (comprising of promethazine and oxomemazine), whereas the pre-
scription rates for noscapine, an opium alkaloid, increased substantially. Substantial evidence of 
adverse events related to the use of promethazine and oxomemazine in children exists [1, 21]. 
There are no studies evaluating the safety of noscapine in children, and no safety issues have 
been raised so far on the use of these drugs in young children. The Dutch GP society recom-
mends noscapine for the symptomatic treatment of cough in young children [22]. This change 
from expectorant combinations to noscapine may be seen as a favourable trend although 
safety of noscapine in these young children should be further investigated. The observed 
increase in prescription rates of nasal sympathomimetics in the Netherlands is of high concern, 
since these drugs may cause serious adverse events such as lethargy, tachycardia, convulsions, 
and even coma [23-27]. Furthermore, a recent Cochrane review concluded that insuffi  cient 
data are available on safety and effi  cacy of many nasal decongestants in children, which are 
therefore not recommended for use in children <12 years of age [28].In Italy, safety warnings 
were issued in September 2007 advising not to use nasal sympathomimetics in children <12 
years. Prescription rates of these drugs reduced signifi cantly after the warning.
Our data show that CCMs are still prescribed to very young children, and prescription rates 
were hardly infl uenced by the international safety warnings, especially in the Netherlands 
where no national regulatory action was taken. In Italy we could observe positive eff ects from 
the safety warnings in some drug classes. Overall however, more action should be taken since 
use of these drugs in the very young may raise safety issues, and there is no evidence of effi  cacy 
[21, 29-31]. The few studies that evaluated the effi  cacy of CCMs in children with cough and cold 
found no signifi cant benefi t in symptomatic relief when compared to placebo [32-36]. Beside 
a lack of effi  cacy, CCMs are more prone to dosing errors. Variations in liquid CCMs dosing with 
spoons can be as much as 20%, leading to a higher risk of adverse events [37]. A recent study 
investigating therapeutic errors in children found that 23% of the dosing errors were related 
to use of CCMs [38]. Another study exploring pediatric fatalities associated with OTC CCMs 
use concluded that 85% of the fatalities were associated with an overdose of CCMs, mainly in 
children under the age of 2 [39].
Not only the country specifi c diff erences of the international warnings on the prescription rates 
of CCMs are of interest but also the diff erences in the types of CCMs that are prescribed. In 
Italy sympathomimetics are hardly used but very commonly prescribed in the Netherlands, 
whereas in the Netherlands use of mucolytics is very low, but frequently prescribed in Italy. This 
is probably due to country specifi c guidelines on the symptomatic relief of cough and cold. 
Many of the CCMs, which are still prescribed as seen in this study, are contraindicated in children 
younger than 6 years in the United Kingdom and Canada, and younger than 2 in the US [2, 3, 
40]. This makes prescription by primary care physicians to young children even more alarming. 
To minimize the use of CCMs in children, these drugs should no longer be available as OTC; and 
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caregiver and physician education about the self-limiting nature of coughs and colds, the lack 
of effi  cacy and the risk associated with these drugs is needed [1, 41].
As for all observational research, our data has limitations. First of all, since we used primary care 
prescription data, we did not capture OTC use of these drugs, nor had data on actual intake. 
However, our aim was to analyse prescription rates of CCMs by primary care physicians as these 
health professionals are approached directly by regulators/inspectorates. Furthermore, we 
could not compare our results with pre- and post warning prescription rates in countries where 
more extensive warnings have been given, since there is no published data about this subject.
A major strength of our study is the fact that we capture a large number of children in two 
diff erent databases across Europe, resulting in a high generalisability of the study population.
To conclude, our results show that despite international warnings, a negative safety profi le and 
lack of effi  cacy data, CCMs are still prescribed to young children in primary care in Italy and the 
Netherlands, and in the latter country rates even increased. Also, CCMs were prescribed that 
contain specifi c active ingredients proven to be most harmful in young children. Two lessons 
can be learned from this study. First of all, primary care physicians should be more aware of 
the harm and lack of effi  cacy of these drugs and should not prescribe them to young chil-
dren. Secondly, there is heterogeneity in warnings across countries in the EU, which creates 
inequality. In order to increase awareness among physicians and caretakers and to allow for 
consistent warnings, the hazards of use of these medicines have to be explicitly stipulated by 
European Medicines Agency. A concerted action is needed in Europe to advice against the use 
and prescription of cough and cold medicines to young children.
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Abstract
Objective: To provide an overview of the paediatric adverse drug reactions (ADR), related 
to the use of asthma drugs in children, that have been reported to the WHO adverse events 
reporting database. In addition, we want to identify new ADRs associated with use of asthma 
medicines in children.
Design: case non-case study
Setting: worldwide spontaneous reporting database: Vigibase
Participants: children aged 0-≤18 years
Main outcome measure: association between asthma medicines and suspected ADRs using 
the reporting odds ratio (ROR) as a measure of disproportionality while adjusting for gender, 
continent and reporter. To reduce confounding , vaccine-related records were excluded from 
the analysis.
Results: Records for asthma drug related ADRs comprised 3.5% of the non-vaccine related 
records (10,259 records). The majority of the records were for children aged 2-≤11 years (60%) 
and most records concerned short-acting β2-agonists (SABAs) and inhaled corticosteroids. 
Known ADRs such as Churg -Strauss syndrome, paradoxical bronchospasm and adrenal insuf-
fi ciency were amongst the ADRs with the highest RORs. The majority of the identifi ed asthma 
medicines-ADR associations are already described in the literature. New, potential signals that 
we found were intestinal gangrene (ROR 38.2, 95% CI [17-267]) and perforated gastric ulcer 
(ROR 55.3, 95% CI [21-148]) both associated with use of SABAs, and tooth discoloration with the 
use of anticholinergics (ROR 21.4, 95% CI [8-59]).
Conclusion: this systematic assessment of pediatric ADRs for asthma medicines in children 
shows that the majority of ADRs reported to Vigibase are already described in the literature. 
Some potentially new ADRs were identifi ed, which require further exploration. 
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Introduction
Respiratory medicines are amongst the most frequently prescribed drugs in children, and espe-
cially asthma medicines are frequently prescribed [1]. Prevalence rates of asthma medicines use 
range between 4 and 26 percent, depending on country, age range, and study period [1-3]. 
According to the Global Initiative for Asthma (GINA), bronchodilators, (inhaled short-acting 
ß2-agonists, long-acting ß2-agonists, anticholinergics, inhaled corticosteroids and alternative 
(add-on) treatments such as leukotriene receptor antagonists (LTRA), xanthines and anti-
allergics (cromones) all have a place in the treatment of childhood asthma, although at various 
stages depending on severity of illness [4]. As asthma is the most common chronic disease of 
childhood, most of these medicines is used for a long term and for some of them, safety con-
cerns exist with long duration of use [5]. For example, increased risk of death with single use of 
long-acting beta-agonists in adults, and adrenal suppression and growth retardation with use 
of inhaled steroids in children [6, 7]. However, overall the risk-benefi t profi le of these medicines 
has been well studied in randomized controlled trials (RCTs), and is considered to be favorable 
[4, 7]. However, the majority of these studies have been performed in children older than 5 
years and studies in younger children are lacking. Furthermore, RCTs have small sample sizes 
and relatively short follow-up, which makes it diffi  cult to detect adverse drug reactions (ADRs) 
which are rare or those that occur after long-term treatment. The missing data on safety and 
effi  cacy information regarding these medicines has been a reason for the European Medicines 
Agency (EMA) to put many asthma medicines on the pediatric needs list. This list, drafted by 
Pediatric Committee of the EMA, contains medicines for which information on pharmacokinet-
ics, effi  cacy and safety is urgently needed [8]. 
Large spontaneous adverse event reporting databases, such as the Vigibase database of the 
WHO-UMC (Uppsala Monitoring Centre), is a well-recognized source for monitoring the poten-
tial risks of drugs, however there has been no systematic approach to investigate safety signals 
in children. To get a broader understanding of the adverse drug reactions associated with 
asthma medicines use, which is one of the most frequently used drug group in children, we 
analysed the adverse drug reactions in relation to asthma medicines reported to the Vigibase 
database of the WHO-UMC [1].
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Methods
WHO-UMC database
We used data from the Vigibase database of suspected ADRs. This global individual case 
safety report (ICSR) database system, established by the World Health Organisation (WHO) 
in 1968, holds more than 3.7 million ICSRs as of June 2006. It is maintained on behalf of the 
WHO Programme by the Uppsala Monitoring Centre (UMC). More than 80 countries participate 
in the WHO International Drug Monitoring program, and another 17 countries are associate 
members, not yet actively contributing data. ICSRs are submitted through the national pharma-
covigilance centers. WHO Programme member countries submit ICSRs to the UMC on a regular 
basis; preferably once per month, but at least every quarter.[9].
At the time of the data extraction in 2006, all ADRs within Vigibase were coded using preferred 
terms of the WHO-Adverse Reaction Terminology (WHO-ART) coding dictionary. Reported 
drugs were re-coded using the WHO Drug dictionary, and the Anatomical Therapeutic Chemi-
cal (ATC) classifi cation system of the WHO Collaborating Centre for Drug Statistics Methodol-
ogy [10]. Assigned ATC codes of asthma medicines were verifi ed for accuracy in this study. For 
the purpose of this study drugs were further categorized as: short-acting β2-agonists (SABA, 
ATC codes R03AC02, R03AC03 or R03AC04), long-acting β2-agonists (LABA, ATC codes R03AC 
excluding SABA), inhaled glucocorticoids (ICS, ATC R03BA), anticholinergics (ACH, ATC R03BB), 
anti-allergic agents (anti-allergics, ATC R03BC), xanthines (ATC R03DA), leukotriene receptor 
antagonists (LTRA, ATC R03DC), fi xed combinations of β2-agonists+ICS (β2+ICS, ATC R03AK06 
or R03AK07) and fi xed combinations of β2-agonists+ACH (β2+ACH, R03AK03 or R03AK04).
Selection of ICSRs
From Vigibase, all ICSRs in children (age 0 - ≤18 years) with onset date between January 2000 
and December 2006 were extracted. Only spontaneously reported ICSRs and those with a sus-
pected causal relationship between ADR and drug were included. ICSRs for which information 
on the reported drug or reported ADR was missing were excluded.
Record defi nition
One ICSR can contain more than one suspected drug, and more than one ADR. We defi ned a record 
as a unique combination of a drug and an ADR. Hence, an ICSR containing two ADRs with one 
suspected drug counted for two records, and an ICSR containing two ADRs with two suspected 
drugs counted for four records. (In Sandra’s paper kreeg ze vragen over deze keuze van selectie 
van data – kan je evtl verwijzen naar paper van WHO waar ze ook deze method aanhouden?) 
Information on each record include country of origin, reporter, age at onset, year of onset, gender, 
reported drug, reported ADR, starting and stopping date of the drug, starting and stopping date 
of the ADR, dosing regimen of the drug, administration route, and causality assessment.
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Statistical analysis
All analyses were conducted on a record basis, thus using unique drug-ADR combinations. 
Disproportionality was assessed by calculation of the reporting odds ratio (ROR), which is 
analogous to an odds ratio [11]. RORs with 95% confi dence intervals (95% CI) were calculated 
for the diff erent subgroups of cough and cold medicines.
The ROR was only calculated if at least 3 records of the drug-ADR combination of interest were 
available. A ROR of ≥ 2 with a 95% confi dence interval not including 1 is considered a signal 
. Since this method is purely hypothesis generating it must be emphasized that a signifi cant 
signal does not imply causality.
To study the eff ect of age; the ROR was calculated within predefi ned age-categories. In line with 
the guidelines of the International Conference of Harmonization (ICH), age at the time of the 
event was categorized into the following age categories: 0 - < 2 years, 2 - ≤11 years and 12 - ≤18 
years [12].
Since vaccines represent a substantial part of the drugs used in children and may confound 
the RORs of other drug-ADR combinations, vaccine related records were excluded. Additional 
logistic regression analyses using SPSS version 15.0 for Windows (SPSS, Inc., Chicago, Illinois) 
was performed to correct for gender, continent and type of reporter.
Results
In the period between January 2000 and December 2006 221,508 suspected (thus potentially 
causally related) spontaneous ICSRs in children aged ≤18 years were included in the WHO-
Vigibase translating in a total of 845,090 records. After exclusion of records that were vaccine 
related (n= 517,642) and for which information on the reported drug or reported ADR was 
missing (n= 32,675), the total number of drug-ADR combinations in the analysis was 294,773.
The database comprised 10,259 asthma medicines related records (3.5% of all non-vaccine 
related records). Compared to all non-vaccine related records, records of asthma medicines 
related ADRs involved more boys, were more often reported by a general practitioner, and 
involved younger children (mean age diff erence of 1.3 years) (table 1). ADRs were most fre-
quently reported for SABA (24.1%) ICS (23.6%) and LTRAs (20.8%) (table 2).
Drug-ADR combinations with the highest RORs 
Table 3 shows the top ten of strongest associations. The number one was Churg-Strauss 
syndrome (ROR 365, 95% CI 48-2802) followed by paradoxical bronchospasm (ROR (77 95% CI 
21-284) (Table 3) and cortisol decreased. Most of the associations were not seen in the young-
est children, apart from decreased levels of cortisol and tenosynovitis. 
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Analyses by type of asthma medicines showed that for SABAs paradoxical bronchospasm, intes-
tinal gangrene and perforated gastric ulcer were associated with the highest RORs (table 4). In 
Table 1: Characteristics of all non-vaccine and asthma medicines related ADR records
 
All non-vaccine related 
records
% of total 
number of 
records
Asthma 
medicines 
related records
% of all 
records 
(row)
N 294,773   10,259  
Male gender 153,708 52.1 5,787 3.8
Notifi er
General practitioner 53,790 18.2 2,438 4.5
Physician 50,300 17.1 1,368 2.7
Hospital 38,795 13.2 349 0.9
Other 151,888 51.5 5,834 3.8
Country of origin
United States 181,126 61.4 6,367 3.5
France 18,820 6.4 374 2.0
Thailand 16,464 5.6 182 1.1
Other//
Age
Mean / SD (years) 9.7 6.0 8.4
Median (years) 10.0 8.0
0 - < 2 years 45,209 15.3 1,023 2.3
2 - ≤ 11 years 114,704 38.9 6,199 5.4
12 - ≤ 18 years 134,860 45.8 3,037 2.3
Table 2: Distribution of asthma drugs related records by drug class and age category
Drug class 0-2 years 2-11 years 11-18 years Total
N %* N %* N %* N %*
SABA 427 41.7 1,235 19.9 806 26.5 2,468 24.1
LABA 6 0.6 270 4.4 302 9.9 578 5.6
ICS 238 23.3 1,698 27.4 480 15.8 2,416 23.6
ACH 30 2.9 90 1.5 10 0.3 130 1.3
Anti-allerigcs 27 2.6 203 3.3 54 1.8 284 2.8
Xanthines 110 10.8 211 3.4 154 5.1 475 4.6
LTRA 76 7.4 1,505 24.3 557 18.3 2,138 20.8
β-agonists+ICS 10 1.0 747 12.1 440 14.5 1,197 11.7
β-agonists+ACH 12 1.2 17 0.3 8 0.3 37 0.4
Other asthma drugs 87 8.5 223 3.6 226 7.4 536 5.2
Total 1,023 100 6,199 100 3,037 100 10,259 100
* = % of total within this age category
SABA=short-acting beta-agonists, LABA=long-acting beta-agonists, ICS = inhaled corticosteroids, 
ACH=anticholinergics, LTRA = leukotriene receptor antagonists
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age-specifi c analyses the highest RORs were for psychosis in children aged 0-2 years, bronchi-
ectasis in children 2-≤11 years and intestinal gangrene in the oldest age category. 
No LABA related ADRs were reported for children aged 0-2 years, which is not indicated below 
age 5. In children aged 2-≤11 years the highest RORs were for tooth disorders and hemiplegia. 
In children aged 12-≤18 years, sudden death was amongst the ADRs with the third highest ROR 
within this drug group (table 4)
In all 3 three age categories, disorders of the adrenal gland (adrenal insuffi  ciency and decreased 
levels of cortisol) were ADRs with the highest ROR for ICS. Perforation of the nasal septum 
was also among the ADRs with the highest ROR in this drug group in children aged 2-≤11 
and 12-≤18 years. (table 4) Other ADRs with the highest ROR for ICS were hypertrichosis and 
varicella in children <2 years and osteoporosis in children aged 12-≤18 years. 
For anticholinergics respiratory acidosis was strongly associated. When stratifying by age 
categories, drug-ADR combinations with ≥ 3 records for anticholinergics were only observed in 
children aged 2-≤11. The three highest RORs in this category were found for tooth discoloura-
tion, mydriasis and constipation. (table 4)
Table 3: Ten highest reporting odds ratios (RORs) for ADRs associated with asthma drugs stratifi ed 
by age 
All age categories Stratifi ed by age category
Adverse drug 
reaction 
Associated
with 
asthma 
drugs
N 
Associated 
with any 
other drug
N
ROR crude
(95% CI)
ROR* 
(95% CI)
ROR* 
(95% CI)
0-2 yr
ROR* 
(95% CI)
2-≤11 yr
ROR* 
(95% CI)
12-≤18 yr
Churg Strauss 
syndrome
13 1
352.6 
(46-2696)
365.8 
(48-2802)
- Infi nity
244.1 
(29-2031)
Bronchospasm 
paradoxical
10 3
90.4 
(25-328)
77.7 
(21-284)
-
23.3 
(5-99)
Infi nity
Cortisol decreased 30 10
81.5 
(40-167)
73.8 
(36-151)
-
71.8 
(21-251)
105.8 
(41-271)
Adrenal 
Insuffi  cieny
84 34
67.5 
(45-101)
63.1 
(42-94)
19.9 
(6-62)
96.7 
(52-79)
17.5 (7-46)
Intestinal 
gangrene
5 4 33.9 (9-126)
28.4 
(8-107)
- -
49.1 
(11-210)
Nasal septum 
perforation
7 6 31.6 (11-94) 24.1 (8-72) -
32.7 
(3-323)
30.4 (8-114)
Anisocoria 4 4 27.1 (7-108) 23.3 (6-94) -
29.0 
(5-161)
-
Tenosynovitis 4 4 27.1 (7-108)
24.9 (6-
100)
Infi nity - -
Bronchospasm 
aggrevated
16 18 24.1 (12-47)
25.4 (13-
50)
-
24.6 
(8-76)
23.2 (9-62)
Osteoporosis 36 45 21.7 (14-34)
20.6 (13-
32)
-
30.3 
(14-65)
21.7 (12-39)
* = adjusted for gender, continent and type of reporter
- = number drug-ADR combination with ≥ 3 records
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Antiallergics were strongly associated with rhinitis in children aged 2-≤11 and 12-≤18 years. In 
children <2 years, the only ADR with ≥3 records for antiallergics was pneumonia. 
For xanthines, heart rhythm disorders related ADRs (tachycardia, palpitation, extrasystoles) 
were amongst the ADRs with highest RORs in all age categories. (table 4) Acidosis had the high-
est ROR in children aged 2-≤11 and 12-≤18 years. (table 4)
In children < 2 years, the highest RORs for LTRAs were calculated for neonatal jaundice, allergic 
reactions and premature birth. Churg Strauss syndrome had the highest ROR in children aged 
2-≤11 and 12-≤18 years. In children aged 2-≤11 years LTRAs were the only group for which 
Churg Strauss syndrome was reported as an ADR. 
In the overall analysis, leg cramps were most strongly associated with β2+ICS combinations. 
Within the age categories, drug-ADR combinations with ≥ 3 records for β2+ICS were only 
observed in children aged 2-≤11 and 12-≤18 years. The highest ROR in children 2-≤11 years 
were observed for medical device complications and for increased levels of glucocorticoids in 
children aged 12-≤18 years. 
Flushing and coughing were the ADRs with the highest RORs for β2+ACH in the overall analysis. 
Within the age categories, the only drug-ADR combination with ≥ 3 records was coughing in 
children aged 2-≤11 years.
Discussion
This is the fi rst study that analysed pediatric ADRs reported for asthma medicines in the Vigi-
base WHO-UMC database. There are several important fi ndings in our study.
First, asthma drugs related ADRs were infrequently reported (3.5% of the non-vaccine related 
records) although drug utilization studies have shown that 4-26% of children use an asthma 
medicine per year [1, 2]. The low reporting rate could be due to the fact that most asthma drugs 
are on the market for many years, and are thought to have a good safety profi le. Second, most 
asthma medicines related ADRs were reported for children aged 2-≤11 and 12-18 years of age 
although utilization studies have shown that prevalence of use of asthma medicines is highest 
in younger children [1, 3]. There thus seems to be a discrepancy between the percentage of 
asthma medicines use in children <2 and the proportion of ADRs reported for this age group. A 
possible explanation could be that ADRs are not recognized in very young children. Third, most 
asthma medicines related ADRs concerned SABAs and ICS, drugs for which utilization studies 
have shown that these are the mostly used asthma medicines in pediatrics [3]. 
The majority of ADRs with the highest ROR that we found in this study are also described in 
literature and SPCs (e.g. paradoxical bronchospasm, adrenal insuffi  ciency and Churg Strauss 
syndrome) [13-16]. For example, adrenal insuffi  ciency is a well-known side-eff ect of steroids 
(both inhaled and oral) [15]. Another example is the increased risk of serious adverse drug 
reactions when using single LABA. A Cochrane review found that serious adverse events were 
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signifi cantly higher in children using LABA [17]. In 2006, the SMART study showed an excess 
risk of asthma-related deaths in adult patients using LABA [6]. As a result, the Food and Drug 
Administration (FDA) issued a ‘black box’ warning for LABA, warning patients about a fatal 
outcome and recommending never to use LABAs as monotherapy but always to combine it 
with ICS. Recently, the FDA added further safety requirements to the use of LABAs [18]. For 
children and adolescent, the FDA requires that when LABA use is required, this should only 
be a combination product containing both an inhaled corticosteroid and a LABA, to ensure 
compliance with both medications.
 ADRs that were not yet described in literature nor mentioned in the SPC were the following: 
intestinal gangrene, gastric ulcer perforation, heart valve disorders, hemiplegia, tooth disorder, 
hypokinesia and iritis.
Intestinal gangrene, gastric ulcer perforation and heart valve disoders were reported for chil-
dren using SABAs; hemiplegia and tooth disorders for LABAs, hypokinesia for xanthines and 
iritis for LTRAs. Most of these ADRs are serious, and in light of the widespread use of asthma 
medicines in children with asthma, more research is needed to confi rm our fi ndings eventually 
by means of large observational safety studies.
As for all observational research, our data has limitations. First of all, we used data from spon-
taneous reporting systems, which suff er from bias such as under- and overreporting. [19-21]. 
Furthermore, it has to be underlined that a signal with a high ROR does not prove that the 
drug and ADR are causally related. The observed signals are purely hypothesis generating and 
further research is needed to assess these signals in an appropriate setting [22]. Also, some 
of the found ADRs are most likely caused by the underlying condition and treatment failure 
rather than the investigated drugs. This is most probably the case for asthma being reported as 
an ADR, since all analysed medicines are indicated for use in asthma. Also respiratory acidosis 
reported for ACH is most probably caused by confounding or treatment failure. Studies have 
shown that metabolic acidosis occurs in patients with severe acute asthma attacks [18]. Similar 
explanations hold for rhinitis as ADR for antiallergics, sinces antiallergics are also used to treat 
rhinitis [23]. 
Due to the nature of the database, information on indication is missing, and therefore it is not 
possible to identify the underlying condition.
The strength of this study is the large number of pediatric ADRs that was available for analysis. 
To our knowledge, this is the fi rst study to systematically analyse the spontaneous reports from 
the Vigibase database for associations between asthma medicines and ADRs in children. It is 
reassuring to see that the majority of strongly associated ADRs are known already and have 
described in literature and included in the SPC. On the other hand we found some new signals 
regarding events that have not yet been described in literature and more research to explore 
the potential causality is needed. 
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Abstract
Objective: To provide an overview of pediatric adverse drug reactions (ADR) associated with 
the use of cough and cold medicines (CCMs) reported to the WHO adverse events reporting 
database and possibly identify new ADRs associated with CCMs use.
Design: case non-case study
Setting: worldwide spontaneous reporting database: Vigibase
Participants: children aged 0-18 years
Main outcome measure: association between cough and cold medicines and suspected ADRs 
using the reporting odds ratio (ROR) as a measure of disproportionality while adjusting for 
gender, continent and reporter. To reduce confounding, vaccine-related records were excluded 
from analysis.
Results: Records for CCMs related ADRs comprised 1.2% of the non-vaccine related records 
(3,467 records). The majority of the reports were for children aged 2-18 years (80%) and 
most reports concerned mucolytics and opium alkaloids. Severe ADRs such as subarachnoid 
haemorrhage, myocardial infarction and cerebrovascular disorders were amongst the ADRs 
with the highest RORs. Most of the found CCMs-ADR associations are described in literature 
(such as dosing errors, neurologic ADRs associated with opioids use). However, we found 
some new CCMs-ADR associations such as chronic renal failure associated with use of expec-
torants (ROR 22.9, 95% CI [7.2-72]) and cerebral infarction associated with the use of opium 
alkaloids+expectorants (ROR 50.4, 95% CI [23-109]).
Conclusion: this overview of pediatric ADRs associated with CCMs use shows that severe and 
potentially life-threatening ADRs occur in children of all ages. We underline the advice not 
to use CCMs in young children, and recommend that CCMs, in view of their poor benefi t-risk 
profi le should not be given to children over all.
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Introduction
Cough and cold medicines (CCMs) are frequently used to treat upper respiratory tract infections 
in children. In the past years, safety issues have been raised concerning the use of these drugs 
in young children. A growing number of studies associated the use of CCMs to serious adverse 
drug reactions (ADRs) in children, such as cardiac arrhythmias, depressed levels of conscious-
ness and even death [1]. As a result, some countries undertook regulatory actions against 
over-the-counter use of CCMs in young children [2-4].
Most of the published data on the safety of CCMs deal with children <2 years, however con-
cerns also exist about the safety of these drugs in older children. Because of these concerns, 
the safety monitoring of of CCMs in older children is ongoing [3]. It is diffi  cult to assess the 
safety of CCMs via randomized controlled trial fi rst of all because very few RCTs have been done 
in children and the available RCTs have small sample sizes and short follow-up. Spontaneous 
adverse event reporting databases, such as the Vigibase database of the WHO-UMC (Uppsala 
Monitoring Centre), can be a source get a better insight in the potential risks of these drugs.
To get a broader understanding of the adverse drug reactions associated with CCMs use in 
children, we analysed the pediatric adverse drug reactions in relation to CCMs reported to the 
Vigibase database of the WHO-UMC.
Our objective was to analyse and describe: 1) pediatric ADRs with the highest reporting odds 
ratios related to CCMs and 2) possibly identify new safety signals (CCMs-ADR combinations that 
have not yet been described in literature or the summary of product characteristics)
Methods
WHO-UMC database
We used data from the Vigibase database of suspected ADRs. This global individual case 
safety report (ICSR) database system, established by the World Health Organisation (WHO) 
in 1968, holds more than 3.7 million ICSRs as of June 2006. It is maintained on behalf of the 
WHO Programme by the Uppsala Monitoring Centre (UMC). More than 80 countries participate 
in the WHO International Drug Monitoring program, and another 17 countries are associate 
members, not yet actively contributing data. ICSRs are submitted through the national pharma-
covigilance centers. WHO Programme member countries submit ICSRs to the UMC on a regular 
basis; preferably once per month, but at least every quarter.[5].
At the time of the data extraction in 2006, all ADRs within Vigibase were coded using preferred 
terms of the WHO-Adverse Reaction Terminology (WHO-ART) coding dictionary. Reported 
drugs were recoded using the WHO Drug dictionary. 
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Drugs were additionally coded using the Anatomical Therapeutic Chemical (ATC) classifi ca-
tion system of the WHO Collaborating Centre for Drug Statistics Methodology [6]. ATC codes 
of cough and cold medicines were manually checked for accuracy allocated to the following 
subgroups: expectorants (e.g. guaifenesin, althea root etc.), mucolytics (e.g. acetylcysteine, 
ambroxol etc.), opium alkaloids and derivatives (e.g. codeine, dextrometorphan), other cough 
suppressants (e.g. pentoxyverine, levodropropizine), combination products of opium alkaloids 
and expectorants, combinations products of other cough suppressants and expectorants, other 
cold combination preparations, combination products of opium alkaloids and antihistamines 
(e.g. dextromethorphan+chlorphenamine), combination products of opium alkaloids and sym-
pathomimetics (e.g. dextromethorphan+pseudoephedrine), combination products of other 
cough suppressants and antihistamines (e.g. guaifenesin+diphenhydramine), combinations 
products of other cough suppressants and sympathomimetics (e.g. phenobarbital+ephedrine).
Selection of ICSRs
From Vigibase all ICSRs in children (age 0 - ≤18 years) received or with onset date between Janu-
ary 2000 and December 2006 were extracted. Only spontaneously reported ICSRs and those 
with a suspected causal relationship between ADR and drug were included. In addition, those 
ICSRs where information on the reported drug or reported ADR was missing were excluded.
Record defi nition:
An ICSR can contain more than one suspected drug, and more than one ADR. We defi ned a 
record as a unique combination of a drug and an ADR. Hence, an ICSR containing two ADRs 
with one suspected drug counted for two records, and an ICSR containing two ADRs with two 
suspected drugs counted for four records. Information on these records include country of 
origin, reporter, age at onset, year of onset, gender, reported drug, reported ADR, starting and 
stopping date of the drug, starting and stopping date of the ADR, dosing regimen of the drug, 
administration route, and causality assessment.
Statistical analysis: 
All analyses were conducted on a record basis, thus using unique drug-ADR combinations. 
Disproportionality was assessed via the calculation of the reporting odds ratio (ROR), which is 
calculated analogues to and odds ratio [7]. RORs with 95% confi dence intervals (95% CI) were 
calculated for the diff erent subgroups of cough and cold medicines.
The ROR was only calculated if at least 3 records of the drug-ADR combination of interest were 
available. A ROR of ≥ 2 with a 95% confi dence interval not including 1 is considered signifi cant. 
Since this method is purely hypothesis generating it must be emphasized that a signifi cant 
signal does not imply causality.
To study the eff ects of age; the ROR was calculated within predefi ned age-categories. In line 
with the guidelines of the International Conference of Harmonization (ICH), age at the time 
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of the event was categorized into the following age categories: 0 - < 2 years, 2 - ≤11 years and 
12 - ≤18 years [8].
Since vaccines represent a substantial part of the drugs used in children and may bias the RORs 
of other drug-ADR combinations, vaccine related records were excluded.. Additional logistic 
regression analysis using SPSS version 15.0 for Windows (SPSS, Inc., Chicago, Illinois) was per-
formed to correct for gender, continent and type of reporter.
Results 
In the period between January 2000 and December 2006 221,508 suspected (thus potentially 
causally related) spontaneous ICSRs in children aged ≤18 years were reported to the WHO-
UMC, containing a total of 845,090 records. After exclusion of records that were vaccine related 
(n= 517,642) and for which information on the reported drug or reported ADR was missing (n= 
32,675), the total number of drug-ADR combinations in the analysis was 294,773.
General characteristics of all records and ATC R05 related records are presented in table 1. The 
database comprised 3,467 CCMs related records (1.2% of total records). Compared to all drugs 
(including records of CCMs), records of CCMs related ADRs involved more females, were more 
often reported by a physician, were less likely to originate from the United States and involved 
younger children (mean age diff erence of 1 year).
Table 1: Characteristics of all records and cough and cold medicines (CCM) related records
  All records %
CCM related 
records %
N 294,773   3,467  
Gender; male 153,708 52.1 1,628 47.0
Notifi er        
General practitioner 53,790 18.2 456 13.2
Physician 50,300 17.1 759 21.9
Hospital 38,795 13.2 456 13.2
Other 151,888 51.5 1,796 51.8
Country of origin        
United States 181,126 61.4 1,470 42.4
France 18,820 6.4 555 16.0
Thailand 16,464 5.6 170 4.9
Age        
Mean / SD 9.7 6.0 8.7 6.3
Median 10.0   8.0  
0 - < 2 years 45,209 15.3 601 17.3
2 - ≤ 11 years 114,704 38.9 1,477 42.6
12 - ≤ 18 years 134,860 45.8 1,389 40.1
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Distribution of records by drug class
The distribution of CCMs related records by drug class and age category is given in Table 2. Most 
ADR records involved children aged 2-≤11 years (43%), followed by 12-≤18 years (40%) and 
children aged <2 years (17%). ADRs were most frequently reported for mucolytics (30.3%) and 
opium alkaloids and derivatives (20.5%). 
Drug-ADR combinations with the highest RORs 
The highest ROR between CCMs as a group and specifi c events were found for cystic fi brosis 
(ROR 64.0, 95% CI 20-203) and hepatic haemorrhage (ROR (54.2, 95% CI 18-167)) both mainly 
in children aged 12-≤18 years (table 3). Severe ADRs such as subarachnoid haemorrhage and 
cerebral infarction were also among the ADRs with the highest RORs. Subarachoid haemor-
rhage was only reported in children aged 12-≤18 years, and cerebral infarction in both children 
aged 2-≤11 and 12-≤18 years (table 3).
Expectorants: 
Analyses by type of CCM showed that for expectorants the most disproportionally reported 
ADRs were subarachnoid haemorrhage, chronic renal failure and cerebrovascular disorder (table 
4 and 5). When stratifying by age category, ROR for expectorants was the highest for apnoea in 
children aged 0-2 years, chronic renal failure in children 2-≤11 years and cerebrovascular ADRs 
(subarachnoid haemorrhage and cerebrovascular disorder) in the oldest age category. 
Table 2: Distribution of cough and cold preparations related records by drug class and age category
Drug class 0-2 years 2-11 years 11-18 
years
Total
N %* N %* N %* N %*
Expectorants 40 6.7 103 7.0 48 3.5 191# 7.9
Mucolytics 179 29.8 474 32.1 397 28.6 1,050# 30.3
Opium alkaloids and derivatives 92 15.3 259 17.5 359 25.8 710# 20.5
Other cough suppressants 47 7.8 126 8.5 103 7.4 276# 8
Combinations of opium alkaloids and expectorants 15 2.5 104 7.0 156 11.2 275# 7.9
Combinations of other cough suppressants and 
expectorants 0 0.0 12 0.8 0 0.0 12# 0.3
Combinations of opium alkaloids and antihistamines 112 18.6 166 11.2 110 7.9 388# 11.2
Combinations of opium alkaloids and 
sympathicomimetics 80 13.3 149 10.1 160 11.5 389# 11.2
Combinations of other cough suppressants and 
antihistamines 0 0.0 1 0.1 0 0.0 1 0
Combinations of other cough suppressants and 
sympathicomimetics 2 0.3 2 0.1 0 0.0 4 0.1
Other cold combination preparations 34 5.7 81 5.5 56 4.0 171# 2.6
Total 601 100 1,477 100 1,389 100 3,467 100
* = % of total within this age category
# = statistically signifi cant diff erence (p<0.05) between number of records in the age categories for that 
drug class
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Mucolytics: 
Mucolytics were strongly associated with an aggravation of the condition, involuntary muscle 
contractions and angioedema in the children 0-2 years. In older children, haemoptysis, urticaria, 
meningitis and infusion site reaction were the ADRs with the highest RORs.
Opium alkaloids and derivates
Opium alkaloids and derivatives were associated with neurological ADRs in children younger 
than 12 years namely stupor in children < 2 years and ataxia, neurologic disorder and mydriasis 
in children aged 2-11 years. In children 12-18 years, pulmonary problems were most strongly 
associated with opium alkaloids.
Other cough suppressants (e.g. pentoxyverine)
The therapeutic class “other cough suppressants” was most strongly associated with coma in 
children < 2 years. In the category 2-≤11 years, psychiatric ADRs (delirium and hallucination) 
and in children 12-≤18 years increased sweating, coma and increased levels of SGOT were most 
strongly associated. 
Table 3: Ten highest reporting odds ratios (RORs) for ADRs associated with cough and cold 
preparations (CCM) stratifi ed by age 
All age categories Stratifi ed by age category
Adverse drug 
reaction 
Associated 
with CCM
N
Associated 
with any 
other drug
N
ROR crude
(95% CI)
ROR* 
(95% CI)
ROR* 
(95% CI)
0-2 yr
ROR* 
(95% CI)
2-≤11 yr
ROR* 
(95% CI)
12-≤18 yr
Cystic Fibrosis 5 7 60.1 (19-189)
64.0 
(20-203)
- -
2981x103 
(0-infi nity)
Hepatic 
Haemorrhage
5 8 52.6 (17-161)
54.2 
(18-167)
- - 65.2 (21-206)
Infusion site 
reaction
3 12 21.0 (5.9-75)
21.0 
(5.9-75)
- - 35.6 (9.4-135)
Haemoptysis 11 70 13.2 (7.0-25)
13.3 
(7.0-25)
-
23.3 
(7.5-72)
12.3 (5.6-27)
Subarachnoid 
Haemorrhage
6 39 12.9 (5.5-31)
13.7 
(5.8-32)
- - 29.5 (9.7-90)
Incorrect drug 
administration 
dosage
3 21 12.0 (3.5-40)
12.4 
(3.7-42)
12.2 
(3.6-42)
- -
Cerebral infarction 13 130 8.4 (4.8-15) 8.6 (4.9-15) -
4.1 
(1.3-13)
16.2 (8.3-32)
Cerebrovascular 
Disorder
28 284 8.3 (5.7-12) 8.7 (5.9-13)
14.4 
(6.0-35)
8.0 
(4.2-15)
8.0 (4.4-14)
Pleurisy 3 33 7.6 (2.3-25) 6.3 (1.9-21) - - -
Hypernatraemia 5 62 6.8 (2.7-17) 6.9 (2.8-17) - - 21.4 (7.2-64)
* = adjusted for gender, continent and type of reporter
- = number drug-ADR combination with ≥ 3 records
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Combination products
Combination products of opium alkaloids and expectorants were strongly associated with neu-
rological disorders in each age category within the children. In the category 2-≤11 years allergic 
reaction, and in children 12-≤18 heart disorders and myocardial infarction were strongly associ-
ated as well. 
Combinations of opium alkaloids and antihistamines were mostly associated with liver injury 
related ADRs in children <2 years, such as an increased bleeding time, hyperammonaemia and 
Table 4: Three highest reporting odds ratios (RORs) by drug class
Drug class ADR
Number 
of ADRs 
associated 
with drug of 
interest
Number 
of ADRs 
associated 
with other 
drugs
ROR* (95%CI)
Described in 
literature
Expectorants
Subarachnoid 
Haemorrhage
4 41 138.6 (49-393) Yes [24]
Chronic Renal Failure 3 217 22.9 (7.2-72) No
Cerebrovascular 
Disorder
5 307 22.8 (9.3-56) Yes [24]
Mucolytics
Cystic Fibrosis 5 7 216.1 (66-706)
Confounding 
by indication
Infusion site reaction 3 12 74.8 (-20-275) Yes [25]
Haemoptysis 10 71 39.3 (20-77)
Confounding 
by indication
Opium alkaloids and 
derivatives
Pulmonary 
Congestion
6 133 16.1 (6.6-39) Yes [11]
Drug Dependence 5 250 9.5 (3.9-23) Yes [11]
Ataxia 20 525 9.0 (5.1-16) Yes [11]
Other cough 
suppressants
Delirium 3 206 13.9 (4.4-44) Yes [26]
Oedema cerebral 3 231 13.6 (4.3-43) Yes [27]
Arrhythmia 3 411 7.3 (2.3-23) Yes [28]
Combinations of 
opium alkaloids and 
expectorants
Cerebral infarction 7 136 50.4 (23-109) No
Myocardial Infarction 5 115 43.2 (17-107) Yes [24, 29]
Cerebrovascular 
Disorder
11 301 32.6 (18-60) Yes [24, 30]
Combinations of 
opium alkaloids and 
antihistamines
Incorrect drug 
administration 
dosage
3 21 121.6 (36-411) Yes [31, 32]
Bleeding time 
increased
3 42 56.9 (18-185) Yes [33]
Hepatic Necrosis 3 106 22.9 (7.2-73) Yes [34, 35]
Combinations of 
opium alkaloids and 
sympathomimetics
Faeces Discoloured 3 87 25.0 (7.9-80) No
Heart Disorder 4 132 19.8 (7.3-54) Yes [3, 36]
Allergy 3 119 21.4 (6.8-68) Yes [37, 38]
Other cold 
combination products
Angioedema 3 1324 6.3 (2.0-20) Yes [39, 40]
Urticaria 10 7443 5.2 (2.6-10) Yes [39, 40]
Face Oedema 3 2156 5.2 (1.7-17) Yes [40]
* = adjusted for gender, continent and type of reporter
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hepatic necrosis. In children aged 2-≤11 years, neurologic disorder were amongst the most 
strongly associated ADRs (hypertonia, mydriasis). In the older age category, mainly psychiatric 
andneurologic ADRs were found to have the highest RORs (paranoid reaction, apathy and 
abnormal thinking).
For the combinations of opium alkaloids and sympathomimetics the highest RORs were found 
for neurologic ADRs in children <2 years. In children 2-≤11 years, hallucination was most 
strongly associated to these drugs, whereas in children 12-≤18 years heart disorder was the 
ADR with the highest ROR.
ADRs for other cold combination products were only reported for the age categories 0-2 and 
2-≤11 years. Allergic reactions such as urticaria and angioedema were ADRs with the highest 
ROR in both children aged 0-2 and 2-≤11 years.
For the drug groups combinations of other cough suppressants and expectorants, combina-
tions of other cough suppressants and antihistamines, and combinations of other cough 
suppressants and sympathomimetics, no drug-ADR combination with at least 3 records were 
reported to the database.
Discussion
This is the fi rst study that analysed pediatric ADRs reported for cough and cold medicines 
(CCMs) in the Vigibase WHO-UMC database. There are several important fi ndings in our study. 
First, CCMs related ADRs were infrequently reported (1.2% of the non-vaccine related records) 
although studies have shown that in a given week, 10% of the children use a CCM [9]. The low 
reporting rate could be due to the fact that most CCMs are sold over the counter and therefore 
monitoring is lacking. 
Second, most CCMs related ADRs were reported for children aged 2-≤11 and 12-18 years of age 
although utilization studies have shown that prevalence of use of CCMs is highest in younger 
children and decreases with age [9]. There thus seems to be a discrepancy between the per-
centage of CCMs use in children <2 and the proportion of ADRs reported for this age group. 
A possible explanation could be that ADRs are not recognized in very young children. Third, 
most CCMs related ADRs concerned mucolytics and opium alkaloids, although these are not 
the most commonly used CCMs in pediatrics [9].
Forth, among the ADRs with the highest RORs, serious and potentially life threatening reac-
tions such as hepatic haemorrhage, subarachnoid haemorrhage and cerebral infarction were 
reported.
Our results are in line with the existing literature studying CCMs-related ADRs. Most of the 
ADRs that we found in this study, are also described in literature (Tables 4 & 5). For example, in 
our analyses, dosing errors are amongst the ADRs with the highest RORs in children aged 0-2 
years. A recent study conducted by Dart et al. concluded that 85 % of the pediatric fatalities 
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associated with CCMs use, was due to an overdose of CCMs, mainly in children under the age 
of 2 [10]. Another example of known ADRs found in this study are the typical (of characteristic) 
adverse eff ects associated with the use of opium alkaloids, such as stupor, ataxia and mydriasis 
[11]. 
Very few ADRs were not yet described in literature namely chronic renal failure associated with 
expectorants use, cerebral infarction associated with opium alkaloids+expectorants use and 
discoloration of the faeces associated with use of opium alkaloids+antihistamines. As Chronic 
renal failure and cerebral infarction are serious and potentially life-threatening adverse events, 
more research is needed to confi rm our fi ndings eventually by means of large observational 
safety studies. .
When stratifying by age category, no clear pattern in type of ADR and severity could be 
observed. For all all age groups, various ADRs of diff erent levels of severity were reported.
Over the counter use of CCMs in children <6 years has been banned in many countries, because 
of safety concerns [2-4]. Safety issues are probably not only limited to younger children and 
use of CCMs in this age category is substantial. This explains why the safety of these drugs in 
older children is currently under review by the FDA [3, 9, 12]. Lookin at our data, we also found 
several severe ADRs (e.g. subarachnoid haemorrhage, hydrocephalus, hepatic haemorrhage) 
associated with CCMs both in children aged 2-≤11 and 12-≤18 years. The fact that there is no 
evidence of effi  cacy of CCMs in children and our observed fi ndings underline the need for 
further safety data of CCMs both in young and older children [13-16]. 
As for all observational research, our data has limitations. First of all, we used data from spon-
taneous reporting systems, which suff er from bias such as under and overreporting. [20-22]. 
Furthermore, is has to be underlined that a signal with a high ROR does not prove that the drug 
and ADR are causally related. The observed signals are purely hypothesis generating and fur-
ther research is needed to assess these signals in an appropriate setting [23]. Also, some of the 
found ADRs are most likely caused by the underlying condition, rather than the investigated 
drugs (confounding by indication).
 This is probably the case for the ADRs cystic fi brosis, haemoptysis and meningitis reported 
with the use of mucolytics. The mucolytic agent dornase alfa is indicated for use in patients 
with cystic fi brosis [17]. Mucolytics are also used to treat cough, which can cause haemoptysis.
Meningitis is most probably a complication of bacterial rhinosinusitis, for which mucolytics 
could be given. It is described in literature that meningitis can be a severe complication in 
patients with bacterial rhinosinusitis [18]. 
Hydrocephalus associated with use of opium alkaloids+expectorants could also be confound-
ing, since the cough for which these drugs are given for, can be the fi rst symptom of hydro-
cephalus [19]. However, hydrocephalus has also been described as a complication of methadon 
(an opioid) use. Since opium alkaloids and methadon have the same pharmacological origin, 
hydrocephalus could be caused by the use of opium alkaloids+expectorants.
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Due to the nature of the database, information on indication is missing, and therefore it is not 
possible to identify the underlying condition.
The strength of this study is the large number of pediatric ADRs available for analysis. To our 
knowledge, this is the fi rst study analysing the spontaneous reports from the Vigibase database 
for associations between CCMs and pediatrics ADRs. We found some new ADRs associated 
with some drug groups which have not yet been described in literature and more research to 
explore the potential causality is needed. .
Our results show that serious ADRs associated with CCMs occur in children of all ages. We 
underline the advice not to use CCMs in young children, and recommend that CCMs should 
also not be used in pediatrics at all.
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Abstract
Background: Asthma medicines, including glucocorticosteroids (inhaled [ICS or oral [OCS] are 
amongst the most frequently used drugs in childhood. Long term use of these medicines has 
been associated with several side eff ects, including fractures
Objective: To estimate the association between use of inhaled and oral steroid and risk of 
fractures in children
Setting: two primary care information databases in the Europe (IPCI from the Netherlands and 
Pedianet from Italy)
Methods: We conducted a population-based case-control study during 1996-2008, nested in 
a cohort of users of asthma medicines. The risk of fractures with steroids use was calculated 
for current, past and cumulative use of ICS, OCS and ICS+OCS. Each case was matched to the 
maximum number of controls from the asthma medicines users cohort. Odds ratios (ORs) were 
estimated through conditional logistic regression analyses.
Results: The adjusted OR for current exposure to ICS+OCS was 0.80, CI [0.6-1.1] and OR 0.97, 
CI [0.9-1.1] for past use. For cumulative exposure to ICS+OCS the following ORs were observed: 
OR 0.93, CI [0.8-1.1] for <60 days; OR 1.00, CI [0.8-1.2] for 60-120 days; OR 0.98, CI [0.8-1.3] for 
120-180 days; and OR 0.98, CI [0.8-1.2] for >180 days of use. For cumulative exposure to ICS and 
OCS alone we also did not fi nd an association. 
Conclusion: We found no increased risk of fractures for children exposed to ICS alone, OCS 
alone or combined use of ICS+OCS. Our fi ndings, show that ICS, which are the mainstay of 
pediatric asthma treatment, can be used in children without fearing for fractures.
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Introduction
Asthma is defi ned as a chronic infl ammatory disorder of the airways and is associated with air-
way hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest 
tightness, and coughing [1]. In children, asthma is the most common chronic disease and the 
leading cause of childhood morbidity from chronic disease as measured by school absences, 
emergency department visits and hospitalizations [2]. According to the Global Initiative for 
Asthma (GINA), inhaled (gluco)corticosteroids (ICS) are the fi rst choice therapy in the long-term 
management of asthma in children [1]. Besides ICS, oral (gluco)corticosteroids (OCS) are recom-
mended for the treatment of very severe persistent asthma and exacerbations. As a result, ICS 
and OCS are widely used in asthmatic children. Prevalence rates of use ranges between 1 and 
50 percent per year for ICS and between 1 and 40 percent for OCS, depending on country, age 
range and underlying condition [3]. 
Long term use of ICS in children has been associated with major safety concerns such as adrenal 
suppression and growth retardation [1]. The association between the use of ICS and the risk 
of fractures remains controversial and very few studies have been conducted in children. This 
potential association is diffi  cult to investigate by means of randomized controlled trials (RCTs) as 
the follow-up in these trials is often too short and the sample size too small.. To our knowledge, 
there are 2 case-control studies (both in the UK conducted with the general practice research 
database) evaluating the association between ICS use and risk of fractures in children, and one 
cross-sectional study [4-6]. In these studies, use of ICS was not associated with an increased risk 
of fractures. To our knowledge, there are no studies assessing the association between corti-
costeroids use and risk of fracture in children using combined data other European countries, 
where the patterns of use may diff er, for example Italy where use of steroids, especially oral, is 
relatively high.
To quantify the risk of fractures associated with the use of corticosteroids in children, we con-
ducted a population based nested case-control study using two primary care databases: the 
Dutch Integrated Primary Care Information (IPCI) and the Italian Pedianet database, including 
children 0-18 years of age. 
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Methods
Setting
Data were obtained from general practice medical record databases in two countries and were 
extracted and elaborated according to a common protocol. The databases comprised the 
Pedianet database in Italy [7] and the Integrated Primary Care Information (IPCI) database in 
the Netherlands [8]. These databases include complete automated medical records of primary 
care physicians (general practitioner in the Netherlands and family paediatrician in Italy). As 
in Italy children are registered with a family paediatrician up to the age of 14, the Pedianet 
database contains data for children aged 0-14 years. The patient population in each database 
is representative of the respective Dutch and Italian population regarding age and gender. The 
electronic records contain anonymous and coded information on patient demographics, symp-
toms and diagnoses, referrals, clinical fi ndings, laboratory assessments, drug prescriptions, and 
hospitalisations. Details of these databases with regard to their pediatric data are described 
elsewhere [9].
Source population
The source population consisted of all patients registered in the IPCI and Pedianet database 
and with at least 365 days of valid history except for newborns who did not require a previous 
medical history. This meant that the practice had been contributing data to the database for at 
least 12 months and that the patient had been registered with the primary care physician for at 
least 12 months. A one year pre-enrollment period was required (except for newborns) in order 
to be able to characterize the patients in terms of comorbidity and exposure. The study period 
started on January 1996 and ended in June 2008.
Study cohort
The study cohort included all patients who received a prescription for an asthma drug (ATC 
code R03) before or at the age of 18 years.
All patients with a prescription for an asthma drug were followed from cohort entry until the 
occurrence of a fracture, death or end of the study period, whichever came fi rst.
Cases defi nition and nested case-control analysis
Case patients were all patient with a fi rst ascertained bone fracture. We used a 2-step proce-
dure for case ascertainment. First, we identifi ed all the potential cases of a fracture through 
an automatic electronic search on coded diagnosis ( ICPC codes L72-76, ICD-9 codes 800-829) 
in combination with a free text search in the two databases. Second, all hits of fractures were 
manually reviewed by two medically trained experts. Only fractures that were confi rmed by an 
X-ray or medical specialist were included in the analysis. The index date was the date of the fi rst 
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X-ray or specialist confi rmed fracture after study entry. Clavicle fractures occurring during birth 
were excluded from the analysis.
To each case set we matched a maximum number of controls from the asthma drugs users 
cohort on index date, gender, year of birth and general practice. Due to this incidence density 
sampling approach, controls could be re-sampled at diff erent moments in time and their con-
tribution should be considered in person-time (moments) rather than by number of subjects. 
Defi nition of drug exposure
To estimate the association between use of inhaled or oral corticosteroids and fracture, we 
created exposure categories based on timing and duration of use. We obtained data on 
corticosteroid use from prescription fi les and calculated duration of exposure on the basis of 
the prescribed number of units and the dosing regimen. We grouped exposure to steroids in 
the following categories: exposure to inhaled corticosteroids (ICS, this included prescriptions 
for ICS only as well as fi xed combinations of ICS+short-acting beta2-agonists), exposure to 
oral corticosteroids (OCS), and exposure to a combination of inhaled and oral corticosteroids 
(ICS+OCS).
We defi ned drug exposure as ‘current’ if the prescription covered the index date or if the last 
intake occurred within 30 days prior to the index date and as ‘past’ if the child had received a 
prescription anytime before index date and last intake ended more that 30 days prior to the 
index date. 
To analyse the eff ect of cumulative exposure to corticosteroids and risk of fractures, we used 
total duration of exposure. Total duration of exposure was defi ned as the total number of days 
a child was exposed to corticosteroids from start of follow-up until the index date (e.g. if a child 
received two presciptions prior to the index date namely one for 30 days and one for 60 days, 
the total days of exposure will be 90 days). If the indexdate fell between the start and stopdate 
of the prescription, only the number of exposed days prior to the index date were taken into 
account. The eff ect of cumulative exposure was investigated for ICS+OCS (summing days of 
exposure for both types), ICS only and OCS only.
Covariates
Age, gender, a previous history of trauma, diabetes mellitus, epilepsy, history of biliary tract 
disease, hyperthyroidism and hypothyroidism were considered as potential confounders. To 
control for confounding by indication, we also considered other classes of asthma treatment 
namely inhaled short-acting and long-acting beta2-agonists (ATC R03AC), inhaled anticholin-
ergics (ATC R03BB), leukotriene receptor-antagonists (ATC R03DC), anti-allergics (ATC R03BC) 
and xanthines (ATC R03DA)
Current exposure to the following concomitant drug were also taken into account: drugs for 
gastrointestinal disorders (ATC A03), drugs for acid related disorders (ATC A02), drugs used in 
diabetes (ATC A10), psychotropics+antidepressants (ATC N05), cardiovascular drugs (ATC C), sex 
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hormones (ATC G03), anti-epileptics (ATC N03), anti-infl ammatory and anti-rheumatic drugs 
(ATC M01).
Statistical analysis
We compared characteristics of cases and controls by using conditional logistic regression. 
Covariates that were associated (P < 0.05) with fractures were later added to the fi nal adjusted 
model. 
We used conditional logistic regression analysis to assess the matched unadjusted and adjusted 
estimates of risk for the association between exposure to steroids and the occurrence of a 
fracture. We estimated odds ratios (ORs) and 95% confi dence intervals (95% CI) for current and 
total exposure to steroids compared to no exposure.
We performed stratifi ed analyses by gender, to observe whether gender modifi ed the risk of 
steroids on fractures.
We conducted all conditional logistic regression analyses in SPSS/PC, version 13 (SPSS, Chicago, 
Illinois). The level of signifi cance for all statistical tests was set at P-value less than 0.05.
Results
The study cohort comprised of 75,385 children, being 18 years or younger at cohort entry, 
which was a prescription for an asthma drug during the study period. Within this cohort, we 
identifi ed 2,548 cases of incident fractures. 
The fracture site in IPCI was as follows: 395 (40.7%) had a fracture of the arm, 215 (22.2%) had 
a fracture of the hand/fi ngers/wrist, 145 (14.9%) had a fracture of the foot/toe/ankle, 85 (8.8%) 
had a fracture of the leg and 122 (12.6%) had a fracture at another location. The fracture site 
was not available for Pedianet.
The characteristics of case and control patients with regards to age, gender and covariates 
are displayed in Table 1. The mean age of the cases was 8.8 years (standard deviation 4.7) and 
62.8% were males. Cases had a higher prevalence of trauma and current exposure to drugs for 
functional gastrointestinal disorders, sex hormones and anti-infl ammatory and anti-rheumatic 
drugs increased the risk of a fracture. These covariates were adjusted for in the fi nal model. 
Exposure to other asthma drugs is displayed in Table 2. The most commonly used other asthma 
drugs were short-acting beta2-agonists and anticholinergics. Current and past use of other 
classes of asthma drugs were not associated with a higher risk of fractures.
Exposure to corticosteroids and the risk of fractures is displayed in Table 3, the adjusted OR for 
current exposure to ICS+OCS was 0.80, CI [0.6-1.1] and OR 0.97, CI [0.9-1.1] for past use. When 
considering total days of exposure to ICS+OCS, no association was observed between the 
cumulative days of exposure and the risk of fractures: OR 0.93, CI [0.8-1.1] for <60 days; OR 1.00, 
CI [0.8-1.2] for 60-120 days; OR 0.98, CI [0.8-1.3] for 120-180 days; and OR 0.98, CI [0.8-1.2] for 
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Table 1: Risk of fractures according to patient characteristics. * Values are numbers (%) unless stated 
otherwise
Characteristics
Cases
(n=2,548)
Controls 
(n=32,778)
Matched OR# 
(95% CI)
p-value
Age (mean,SD) 8.8 (4.7) 6.9 (3.6)
Male 1,600 (62.8) 21,270 (64.9)
Comorbidity
Trauma 168 (6.6) 203 (0.6) 11.19 (8.85-14.15) <0.0001
Current use of other drugs (use in month before index date)
Drugs for functional 
gastrointestinal disorders (ATC 
A03)
6 (0.2) 117 (0.4) 1.12 (1.03-1.23) 0.01
Sex hormones (ATC G03) 47 (1.8) 111 (0.3) 1.43 (1.06-1.93) 0.02
Anti-infl ammatory and anti-
rheumatic drugs (ATC M01)
24 (0.9) 269 (0.8) 1.09 (1.01-1.18) 0.03
* Only variables with cell count ≥ 5 and p-value <0.05 are shown
# = matched on gender, age, index date and general practice
Table 2: Risk of fractures according to use of respiratory drugs. Values are numbers (%) unless stated 
otherwise
Cases
(n=2,548)
Controls 
(n=32,778)
Matched OR# 
(95% CI)
p-value
Inhaled short-acting beta-agonists
Never used 1,151 (45.2) 17,940 (54.7) 1 (Reference) -
Current use 102 (4.0) 446 (1.4) 1.05 (0.80-1.36) 0.74
Past use 1,295 (50.8) 14,392 (43.9) 1.05 (0.95-1.16) 0.31
Inhaled long-acting beta-agonists
Never used 2,478 (97.3) 32,457 (99.0) 1 (Reference) -
Current use 6 (0.2) 23 (0.1) 0.68 (0.22-2.06) 0.49
Past use 64 (2.5) 298 (0.9) 1.14 (0.83-1.56) 0.42
Anticholinergics
Never used 2,437 (95.6) 31,834 (97.1) 1 (Reference) -
Current use 8 (0.3) 22 (0.1) 1.39 (0.51-3.81) 0.52
Past use 103 (4.0) 922 (2.8) 1.00 (0.77-1.31) 0.99
Anti-allergics
Never used 2,474 (97.1) 32,066 (97.8) 1 (Reference) -
Current use 4 (0.2) 24 (0.1) 1.03 (0.29-3.62) 0.96
Past use 70 (2.7) 688 (2.1) 0.85 (0.64-1.14) 0.28
Leukotriene-receptor antagonists
Never used 2,471 (97.0) 31,652 (96.6) 1 (Reference) -
Current use 19 (0.7) 206 (0.6) 1.48 (0.89-2.47) 0.13
Past use 58 (2.3) 920 (2.8) 1.15 (0.87-1.53) 0.34
Xanthines
Never used 2,534 (99.5) 32,392 (98.8) 1 (Reference) -
Current use 0 1 (0.0) NA -
Past use 14 (0.5) 385 (1.2 1.03 (0.57-1.86) 0.93
NA = not applicable, as no exposed cases
# = matched on gender, age, index date and general practice
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>180 days of use. Although almost children had long term exposure to ICS (50% of the children 
had more than 2 months of ICS exposure, and 11% more than 6 months), no association was 
observed for cumulative duration of ICS exposure. Cumulative exposure of OCS alone was also 
not associated (although few children had long term exposure to OCS). 
In the stratifi ed analysis by gender, the results were similar to the overall results (Table 4). No 
association was observed for exposure to steroids (inhaled or oral) and risk of fractures in males 
and females.
Discussion
In this population based nested case-control study in an Italian and Dutch cohort of pediatric 
asthma drug users, we found no increased risk of fractures for children exposed to ICS alone, 
OCS alone or combined use of ICS+OCS.
Exposure to OCS is a known risk factor for developing fractures, both in children and adults 
[10-12]. However, only few studies have investigated the association between ICS use and the 
risk of fractures in children. To our knowledge, there are only 3 observational studies that have 
Table 3: Exposure to steroids (inhaled or oral) and the risk of fracture
Cases
(n=2,548)
Controls 
(n=32,778)
Matched OR#, 
Crude
(95% CI)
Matched OR#, 
adjusted*
(95% CI)
p-value
Never used 
steroids 
(inhaled+oral)
526 (20.6) 4,022 (12.3) 1 (Reference) 1 (Reference) -
Use of inhaled+oral steroids
Current 92 (3.6) 573 (1.7) 0.81 (0.62-1.06) 0.80 (0.61-1.05) 0.10
Past 1,930 (75.7) 28,183 (86) 0.97 (0.86-1.10) 0.97 (0.86-1.10) 0.62
Total days of use
Inhaled+oral steroids
<60 days 1,381 (54.2) 24,378 (74.4) 0.92 (0.80-1.06) 0.93 (0.80-1.07) 0.28
60-120 days 245 (9.6) 2,180 (6.7) 1.00 (0.84-1.21) 1.00 (0.83-1.20) 0.98
120-180 days 99 (3.9) 704 (2.1) 1.01 (0.78-1.31) 0.98 (0.76-1.27) 0.89
>180 days 297 (11.7) 1,494 (4.6) 0.99 (0.83-1.18) 0.98 (0.82-1.17) 0.80
Inhaled steroids
<60 days 1,322 (51.9) 23,322 (71.2) 0.93 (0.80-1.07) 0.93 (0.81-1.08) 0.33
60-120 days 231 (9.1) 1,863 (5.7) 0.99 (0.82-1.20) 0.99 (0.82-1.19) 0.88
120-180 days 92 (3.6) 664 (2.0) 0.96 (0.74-1.25) 0.93 (0.71-1.22) 0.61
>180 days 295 (11.6) 1,429 (4.4) 1.00 (0.83-1.19) 0.98 (0.82-1.18) 0.85
Oral steroids
<7 days 362 (14.2) 6,897 (21.0) 0.96 (0.81-1.13) 0.95 (0.80-1.13) 0.56
7-14 days 120 (4.7) 2,089 (6.4) 1.01 (0.80-1.27) 0.96 (0.76-1.21) 0.73
14-30 days 52 (2.0) 1,204 (3.7) 0.92 (0.67-1.28) 0.86 (0.62-1.20) 0.38
>30 days 26 (1.0) 464 (1.4) 1.18 (0.73-1.89) 1.17 (0.73-1.89) 0.52
# = matched on gender, age, index date and general practice
* = adjusted for use of drug for functional gastrointestinal disorders, sex hormones, anti-infl ammatory and 
anti-rheumatic drugs and trauma
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analysed this association. Two of these studies used the General Practice Research Database 
(GPRD) from the United Kingdom to perform nested case-control studies [4, 5]. In the fi rst study, 
Schlienger et.al found no increased risk of fractures in children currently exposed to ICS and 
the risk did not increase for higher number of ICS prescriptions [4]. In the second case-control 
Table 4: Exposure to steroids (inhaled or oral) and the risk of fracture stratifi ed by gender
Males Females
Cases
(n=1,600)
Controls 
(n=21,270)
Matched 
OR#, 
adjusted*
(95% CI)
p-value
Cases
(n=948)
Controls 
(n=11,508)
Matched 
OR#,
adjusted*
(95% CI)
p-value
Never used 
steroids 
(inhaled+oral)
319 (19.9)
2,540 
(11.9)
1 
(Reference)
-
207 
(21.8)
1,482 
(12.9)
1 
(Reference)
-
Use of inhaled+oral steroids
Current 63 (3.9) 416 (2.0)
0.83 
(0.59-1.15)
0.25 29 (3.1) 157 (1.4)
0.73 
(0.44-1.20)
0.22
Past
1,218 
(76.1)
18,314 
(86.1)
0.96 
(0.82-1.13)
0.62
712 
(75.1)
9,869 
(85.8)
0.98 
(0.80-1.21)
0.88
Total days of use
Inhaled+oral steroids
<60 days 863 (53.9)
15,679 
(73.7)
0.91 
(0.76-1.09)
0.32
518 
(54.6)
8,699 
(75.6)
0.95 
(0.75-1.19)
0.63
60-120 days 145 (9.1) 1,495 (7.0)
0.90 
(0.71-1.14)
0.39
100 
(10.5)
685 (6.0)
1.19 
(0.75-1.19)
0.26
120-180 days 70 (4.4) 519 (2.4)
1.03 
(0.75-1.40)
0.88 29 (3.1) 185 (1.6)
0.87 
(0.54-1.41)
0.57
>180 days 203 (12.7) 1,037 (4.9)
1.02 
(0.81-1.27)
0.88 94 (9.9) 457 (4.0)
0.89 
(0.66-1.22)
0.47
Inhaled steroids
<60 days 830 (51.9)
15,030 
(70.7)
0.93 
(0.78-1.11)
0.40
492 
(51.9)
8,292 
(72.1)
0.94 
(0.75-1.20)
0.64
60-120 days 140 (8.8) 1,279 (6.0)
0.92 
(0.73-1.17)
0.51 91 (9.6) 584 (5.1)
1.11 
(0.81-1.51)
0.52
120-180 days 63 (3.9) 488 (2.3)
0.91 
(0.68-1.30)
0.71 29 (3.1) 176 (1.5)
0.89 
(0.55-1.45)
0.65
>180 days 201 (12.6) 991 (4.7)
1.02 
(0.82-1.28)
0.84 94 (9.9) 438 (3.8)
0.90 
(0.66-1.23)
0.50
Oral steroids
<7 days 233 (14.6)
4,644 
(21.8)
0.92 
(0.74-1.13)
0.41
129 
(13.6)
2,253 
(19.6)
1.02 
(0.77-1.35)
0.90
7-14 days 79 (4.9) 1,390 (6.5)
0.93 
(0.69-1.24)
0.61 41 (4.3) 699 (6.1)
1.03 
(0.69-1.52)
0.89
14-30 days 36 (2.3) 835 (3.9)
0.83 
(0.56-1.24)
0.36 16 (1.6) 369 (3.2)
0.92 
(0.51-1.64)
0.77
>30 days 19 (1.2) 326 (1.5)
1.14 
(0.65-2.00)
0.66 7 (0.7) 138 (1.2)
1.25 
(0.50-3.12)
0.63
# = matched on gender, age, index date and general practice
* = adjusted for use of drug for functional gastrointestinal disorders, sex hormones, anti-infl ammatory and 
anti-rheumatic drugs and trauma
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study in the same database, Van Staa et. al found a dose-response relationship namely that, 
children exposed to higher doses of ICS had an increased risk of fractures [5]. This association 
disappeared however after adjustment for indicators of asthma severity. In a cross-sectional 
study in Australia, Ma et al. studied risk factors for prevalent fractures in prepubertal children. In 
this study, exposure to ICS in the year before occurrence of a fracture was not associated with 
an increased risk of fractures. Van Staa et al. also studied the association between OCS use and 
fractures in the GPRD in the UK and found that the risk was increased in children receiving more 
than 3 prescriptions [10]. In contrast to the fi ndings from Van Staa, we did not fi nd an increased 
risk associated with exposure to OCS. However, this can probably be explained by the fact that, 
in our study; the majority of the children used OCS for less than 30 days. Indeed, only 1% of 
the children (both cases and controls) used OCS longer than one month, so our exposure to 
long term OCS may be too low to fi nd an association. It does show however, that under the 
general circumstances of use in these two countries, which have quite diff erent user patterns, 
the attributable risk of fractures due to use of ICS and/or OCS is very low.
Similar to what has been published in literature; we also found that occurrence of fractures was 
higher in boys than in girls [13-15]. Our results are also in line with other studies regarding the 
distribution of fracture sites, showing that fractures of the arm and carpal region are the most 
common [14, 15]. 
Strengths and limitations of our study
This study has a number of limitations. Due to the nature of the databases, we did not have infor-
mation on all potential confounders such as the nutritional status of the children, body mass 
index, bone mineral density, physical activity and smoking status. The inability to completely 
adjust for confounding normally results in an overestimation of the risk estimate. However, 
as we did not observe an increased risk of fractures in the matched nor in the fully adjusted 
analysis, we believe that the issue of remaining confounding is probably limited. Selection bias 
was unlikely, as all data was obtained from prospectively collected medical records that are 
maintained for patient care purposes. Information bias by misclassifi cation of the outcome 
is also unlikely, because all fracture cases were retrieved from medical records and reviewed 
by two medical experts who were blinded to the exposure. Misclassifi cation of exposure may 
have occurred, because we used outpatient prescription data and had no information on actual 
fi lling of the medications nor on drug intake. Based on the way the data were collected, we 
believe that this misclassifi cation will probably be non-diff erential between cases and controls 
and therefore the actual risk may have been underestimated. Since we used primary care 
data we may have missed some specialist prescriptions in the Netherlands. However, this will 
minimally infl uence our results since asthma is a condition often dealt with in primary care, and 
asthma drugs originally prescribed by a specialist are often continued or prescribed by general 
practitioners [16].
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A major strength of our study is the fact that we capture a large number of children in two 
diff erent databases across Europe, resulting in a high generalisability of the study population. 
Furthermore, we were able to study the eff ect of total duration of exposure to corticossteroids 
and the risk of fractures, which has never been studied before.
Our fi ndings, as well as other studies, show that ICS, which are the mainstay of pediatric asthma 
treatment, can be used in children without fearing for fractures. Also OCS do not seem the 
increase the risk of fractures in children under the given circumstances of use, we can however 
not exclude that chronic use will not increase the risk since we had few persons exposed to long 
term use of OCS.
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Abstract
Background: Pancreatitis is a relatively rare condition in children and has considerable morbid-
ity and mortality. Althoud drug-induced pancreatitis is rare, a variety of drugs have been associ-
ated to pancreatitis (in children and adults), including steroids. So far, no studies have been 
performed to assess the association between exposure to steroids and pancreatitis in children.
Objective: To estimate the association between use of inhaled and oral steroid and risk of 
pancreatitis in children aged 0-18 years
Setting: the Dutch PHARMO Record Linkage System
Methods: We conducted a population-based case-control study during 1998-2008. The risk 
of pancreatitis with steroids use was calculated for current, past and cumulative exposure to 
inhaled glucocortocosteroids (ICS) and oral glucocorticosteroids (OCS). Up to 20 controls per 
case were selected, matched on year of birth, gender, and calendar time. Odds ratios (ORs) were 
estimated through conditional logistic regression analyses.
Results: 60 cases of pancreatitis (54 acute and 6 chronic) were retrieved from the PHARMO 
database. Current use of OCS was associated with a higher risk of pancreatitis (OR 21.40, CI 
[7.1-64.6]). We also found an increased risk for cumulative exposure of >7 days to OCS. Exposure 
to inhaled steroids was not associated with pancreatitis. In a sensitivity analysis, performed 
in patients with acute pancreatitis, exposure to OCS and acute pancreatitis remained highly 
increased: OR 24.0, CI [7.8-73].
Conclusion: We found that the risk of pancreatitis was approximately 20-fold higher in children 
who were using oral steroids. The use of inhaled steroids was not associated with an increased 
risk, neither with increased duration of use.
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Introduction
Pancreatitis is a relatively rare condition in children and has considerable morbidity and mortal-
ity [1]. Pancreatitis mainly occurs in adult life and the mean age of a fi rst pancreatitis attack 
has been shown to be in the 6th decade of life [2]. The overall incidence of acute pancreatitis 
varies between 4 and 45/100,000, depending on the country being studied. In adults, the most 
common causes of acute pancreatitis are gallstones and alcohol abuse [2, 3]. In children, acute 
pancreatitis has diff erent aetiologies. Reported causes in children include trauma, infection, 
systemic diseases, toxins, structural anomalies of the pancreaticobiliary tract and idiopathic 
[4-6]. Drug-induced pancreatitis is considered to be a rare cause of pancreatitis in both children 
and adults. The available data suggest that between 0.1 and 2% of all acute pancreatitis cases 
may be drug-induced [7-9]. A variety of drugs have been associated to pancreatitis through 
spontaneous reports in adults, including glucocorticosteroids [7, 10, 11]. These drugs have also 
been associated with pancreatitis in children [5, 6, 12]. The pathogenesis of steroid-induced 
pancreatitis remains to be elucidated. Obstruction of the outfl ow of pancreatic secretions has 
been hypothesized as a possible underlying mechanism [13-15]. In contrast, animal studies and 
a study in humans have reported on the protective eff ect of steroids on pancreatitis. Experimen-
tal studies in rats have shown a protective eff ect of dexamethason and methyprednisolone on 
the development and severity of pancreatitis [16, 17]. The real association between exposure to 
steroids and risk of pancreatitis remains to be elucidated and more studies are needed. 
All of the existing data on the association between glucocorticosteroid use and pancreatitis 
in children has been derived from case reports and case series. Although case reports are a 
very effi  cient tool for signal generation, more analytical and epidemiological approaches are 
necessary to actually quantify the risk. To provide the relative risk of pancreatitis in children 
using oral or inhales corticosteroids, we conducted a population-based case-control study. 
To our knowledge, this is the fi rst study in children analyzing the association between use of 
glucocorticosteroids and the risk of pancreatitis.
Methods
Source population
Data for this case control study were obtained from the Dutch PHARMO Record Linkage System 
(RLS). PHARMO RLS (http://www.pharmo.nl) includes the pharmacy dispensing histories of more 
than three million community-dwelling residents in well defi ned areas in the Netherlands, and 
these pharmacy records are linked to nationwide hospital discharge records. Pharmacy data 
include information about the drug dispensed, the date of dispensing, the amount dispensed, 
the prescribed dosage regimen and the estimated duration of use. Drugs are coded according 
to the Anatomical Therapeutic Chemical (ATC) classifi cation system [11]. The Hospital Discharge 
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Register comprises hospitalizations in the Netherlands, including detailed information on the 
primary and secondary discharge diagnoses; diagnostic, surgical and treatment procedures 
and dates of hospital admission and discharge. All diagnoses are coded according to the Inter-
national Classifi cation of Diseases, 9th edition (ICD-9-CM). Validation studies have shown that 
the PHARMO RLS has a high level of data completeness and validity [18, 19].
Case and control ascertainments. 
Cases were defi ned as patients 0- ≤18 years old with a fi rst discharge diagnosis of pancreatitis 
(ICD-9 code 577x) in the period between 1 January 1998 (start of follow-up) until 31 December 
2008 (end of follow-up). Pancreatitis was classifi ed as acute (ICD-9 577.0) or chronic (ICD-9 
577.1). The index date was the date of hospital admission. For each case, up to 20 controls 
without a history of pancreatitis during the study period were matched on year of birth, gender, 
and calendar time (the index date of the corresponding case). Both cases and controls were 
eligible for inclusion if they had a minimum period of 365 days of history in the PHARMO RLS 
prior to the index date.
Exposure assessment
Although various drugs have been associated with pancreatitis the main exposure of interest 
in this study were inhaled (ATC R03BA) and oral glucocorticosteroids (ATC H02AB). Data on 
exposure were obtained from the dispensing records and categorized by timing and duration 
of use. We defi ned drug use as ‘current’ if the prescribed duration of the drug covered the index 
date or if the end of it was less than 30 days prior to the index date. Drug exposure was classifi ed 
as ‘past’ if the child had received a prescription anytime before the index date but the end of it 
was more than 30 days prior to the index date.
To analyse the eff ect of the cumulative use of glucorticosteroids on the risk of pancreatitis, we 
calculated the total cumulative duration of exposure from start of follow-up until the index date 
(e.g. if a child received 2 prescriptions prior to the index date namely one for 4 days and one for 
6 days, the total days of use was 10). The total days of use of oral steroids was categorized into 
the following classes: <7 days, ≥ 7-30 days and ≥ 30 days of use. For inhaled steroids we created 
two categories for total days of use, namely <1 year and ≥ 1 year. If the indexdate fell between 
the start and stopdate of the prescription, only the number of days up to the index date was 
taken into account.
Covariates 
As covariates, we considered co-morbidities or use of drugs that have associated with pan-
creatitis in literature [7, 20]. The following factors were considered: gender and year of birth 
(matching variables), a previous hospitalization for HIV-infection, gallbladder disorders, chole-
lithiasis, trauma, cystic fi brosis, lipid disorders, disorders of calcium metabolism, infl ammatory 
bowel disease, malignancies, elevated levels of lipase/amylase and viral diseases.
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Current use of the following concomitant drugs were also taken into account: acetaminophen, 
azathioprine, cimetidine, enalapril, erythromycin, estrogens, furosemide, hydrochlorothiazide, 
metronidazol, opiates, simvastatin, cotrimoxazol, tetracycline, valproic acid, carbamazepine, 
doxycycline, famotidine, mesalazine, rifampin, NSAID’s, lisinopril, ramipril, losarten, methyldopa, 
chlorothiazide, amiodarone, pravastatin, fl uvastatin, dapsone, nitrofurantoin, clarithromycin, 
isoniazid, nelfi navir, lamivudine, didanosene, interferon, ribavirin, pentamidine, sodium stibo-
gluconate, meglumine antimonite, omeprazole, mercaptopurine, olsalazine, sulphasalazine, 
clozapine, clomifene, tamoxifen, thiamazole, carbimazole, ifosfamide, cytarabine, asparaginase, 
isotretinoin, propofol, cyclopenthiazide, phenformin, cisplatin, octreotide, alendronate, capto-
pril, ciprofi brate and maprotiline.
Statistical analysis
We used conditional logistic regression analysis to assess the matched unadjusted estimates 
of risk for the association between exposure to inhaled and oral steroids and the occurrence 
of a pancreatitis. Adjusted analysis was performed only if more than 5 cases were exposed. For 
model construction, we fi rst included all covariates that were univariately associated with the 
outcome (p<0.10). Each risk factor that changed the OR of exposure to glucocorticosteroids by 
more than 5% was included in the fi nal adjusted model. We estimated odds ratios (ORs) and 
95% confi dence intervals (95% CI) for current and total use of steroids compared to no use.
Sensitivity analyses were conducted in which we excluded patients with chronic pancreatitis. 
All statistical analysis were conducted using SPSS/PC, version 13 (SPSS, Chicago, Illinois). The 
level of signifi cance for all statistical tests was set at p-value less than 0.05.
Results
In the PHARMO RLS source population of children 0-18 years of age we identifi ed 68 cases 
with pancreatitic disorders. Eight cases were excluded because they concerned patients with 
pancreatic cysts. The case-control study population therefore consisted of 60 patients with 
pancreatitis (acute or chronic), ≤ 18 years with a fi rst hospitalization for pancreatitis and 6,487 
age, sex and time matched controls. 
The age distribution of the pancreatitis cases is presented in Figure 1. The number of cases 
increased with age.
Details on prior hospitalizations and concomitant use of drugs in the cases is presented in Table 
1, 54 cases (90%) were hospitalized for acute pancreatitis and 6 for chronic pancreatitis. The 
median age of the cases was 15.9 (range between 1.2 and 18.9) and the majority of the cases 
was between 12 and 18 years of age (71.7%), gender was equally distributed. 
Only few patients had been hospitalized prior to their pancreatitis, the most frequent reasons 
were: abdominal pain (n=5), colitis/gastro-enteritis (n=4) and infl ammatory bowel disease 
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(n=3). The average duration between hospitalization for abdominal pain and hospitalization 
for pancreatitis was 6.3 months (range between 4 and 11 months) 
The most frequently used drugs in the month before the index date were propulsives (e.g. 
metoclopramide, cisapride) (n=4), oral contraceptives (n=4), anti-acne preparations (n=3) and 
azathioprine (n=3), 29 cases (49%) had not any drug dispensed that covered the month before 
the index date.
A hospitalization for infl ammatory bowel disease (OR 41.9, 95% CI [9-188]), gallstones (OR 
120.6, 95% CI [11-1368]) and cystic fi brosis (OR 29.5, 95% CI [3-253]) were all associated with 
pancreatitis although numbers were small (table 2). Also exposure to NSAIDs (OR 4.5, 95% CI 
[2-13), azathioprine (OR 37.8, 95% CI [9-154), mesalazine (OR 69.4, 95% CI [10-466]), metroni-
dazol (OR 69.4, 95% CI [10-466]), opiates (OR 26.9, 95% CI [3-287]) and omeprazole (OR 11.3, 
95% CI [1.4-88]) in the month prior to the index date was associated with pancreatitis (Table 2).
Four cases were currently exposed to oral steroids and one to inhaled steroids (table 3). Due to 
the low number of exposed cases, adjustment for concomitant drug use or a history of prior 
hospitalizations was not possible. 
Despite the low power, current use of oral steroids was associated with a higher risk of pancre-
atitis (OR 21.40, CI[7.1-64.6]). For the total days of oral steroids use we found the following risk 
estimates: OR 2.37, CI [0.32-17.7] for <7 days; OR 5.90, CI [1.8-19.7] for ≥7-<30 days; and OR 5.34, 
CI [1.9-15.3] for ≥ 30 days of use (Table 3). Exposure to inhaled steroids was not associated with 
pancreatitis in any of the exposure categories. 
Since steroids may be used to treat pancreatitis, we restricted the analysis to acute pancreati-
tis, the association between the use of oral steroids and acute pancreatitis remained highly 
increased: OR 24.0, CI [7.8-73].
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Figure 1: Distribution of pancreatitis cases by age
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Table 1: Characteristics of pancreatitis cases in children (0-18 years)
Pancreatitis cases (n=60)
Gender: Male 29 (48.3%)
Age (mean,range) 14.0 (1-18)
0 - < 2 years 1 (1.7%)
2 - ≤ 11 years 16 (26.7%)
12 - ≤ 18 years 43 (71.7%)
Type of pancreatitis
Acute 54 (90%)
Chronic 6 (10%) 
Prior hospitalizations 
Abdominal pain 5 Rheumatoid arthritis 1
Colitis/Gastro-enteritis/proctocolitis 4 Mononucleosis infectiosa 1
Infl ammatory bowel disease 3 Obesity 1
Gallstones/cholecystitis 2 Oesophagitis 1
Juvenile Diabetes 2 Paralytic ileus 1
Cystic Fibrosis 1 Pneumonia 1
Hernia inguinalis 1 Viral infection 1
Intestinal disaccharidase defi ciency 1
Concomitants drugs (use in month before index date) 
No use of any drug 29 chloral hydrate 1
Oral contraceptives 4 Codeine 1
prednisolon 4 ciprofl oxacin 1
propulsives 4 fenoterol+ipratropium 1
anti-acne preparations 3 ferrous fumarate 1
azathioprine 3 fl uticason 1
diclofenac 3 folic acid 1
insulins 2 granisetron 1
mesalazine 2 ibuprofen 1
metronidazole 2 lamotrigine 1
nasal corticosteroids 2 laurilsulfate 1
oxcarbazepine 2 methotrexate 1
proton pump inhibitor 2 methylphenidate 1
short-acting beta-agonists 2 multi-enzymes 1
sodium fl uoride 2 Omeprazole 1
acetazolamide 1 Paracetamol 1
anti-androgens+estrogens 1 Somatropin 1
azithromycin 1 Temazepam 1
bisacodyl 1 Tobramycin 1
budesonide, inhaled 1 Tramadol 1
calcium 1 vitamin D 1
ceftazidime 1 vitamin K 1
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Discussion
In this population based case-control study, we found that the risk of pancreatitis was approxi-
mately 20-fold higher in children who were using oral steroids. The use of inhaled steroids was 
not associated with an increased risk, neither with increased duration of use.
The association between use of oral steroids and pancreatitis has been described in some 
case series and case reports in children [6, 21, 22]. The fi rst case reports on steroid-induced 
pancreatitis in children were published in 1957 by Barr et al and Marczynska-Robowska [21, 
22], followed by several others in children [6, 23-25]. Although case series and reports provide 
important information to signal potential adverse drug reactions, they do not provide proof 
of an association. In some instances, fi ndings from case reports may overestimate the risk of 
medication-induced pancreatitis This occurred in adults for postmenopausal hormone replace-
ment therapy, COX-2 inhibitors and anti-lipemics where data from population-based epide-
miological studies could not confi rm the associations seen in case series [26-28]. However, for 
oral steroids we consistently fi nd an association in case series and in this population based case 
control study. 
The risk factors we observed in children are in line with those published for pancreatitis in 
adults. A history of hospitalization for infl ammatory bowel disease, gallstones, cystic fi brosis 
and trauma were all associated with a higher risk of pancreatitis [4, 29, 30]. We also observed 
a higher risk of pancreatitis for azathioprine, mesalazine, metronidazol, opiates, omeprazole 
and NSAIDs use ,but the prevalence of use was very low, which is usually so in children. All 
Table 2: Covariates and their independent risk of pancreatitis in univariate analyses#
Characteristics Cases n=60 (%) Controls n=6,487 (%) Matched OR (95% CI)* P-value
History of hospitalizations
Infl ammatory bowel disease 3 (5.0) 6 (0.1) 42 (9-188) <0.001
Gallstones 2 (3.3) 3 (0.04) 121 (11-1368) <0.001
Cystic fi brosis 1 (1.7) 5 (0.1) 29 (3-253) 0.002
Trauma 1 (1.7) 19 (0.3) 6.3 (0.8-49) 0.08
Viral diseases 1 (1.7) 61 (0.9) 2.2 (0.3-17) 0.44
Concomitant drugs (use in month before index 
date)
NSAIDs 4 (6.7) 103 (1.6) 4.5 (2-13) 0.007
Azathioprine 3 (5.0) 8 (0.1) 38 (9-154) <0.001
Mesalazine 2 (3.3) 3 (0.04) 69 (10-466) <0.001
Metronidazol 2 (3.3) 3 (0.04) 69 (10-466) <0.001
Opiates 1 (1.7) 3 (0.04) 26 (3-287) <0.001
Omeprazole 1 (1.7) 12 (0.2) 11 (1.4-88) 0.021
Paracetamol 1 (1.7) 61 (0.9) 2.2 (0.3-17) 0.44
# = only covariates with exposed cases are shown
* = matched on age, gender and index date
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of these drugs have been associated with an increased risk of pancreatitis in adults, although 
protopathic bias may also occur with the proton pump inhibitors [7, 10, 31]. 
We did not fi nd an increased risk of pancreatitis for use of inhaled steroids, although power 
was limited and the upper limit of the confi dence interval was 6. If oral sterids are associated 
with pancreatitis inhaled steroids may do the same since they are also systemically absorbed, 
especially when inhaled erroneously. We could demonstrate in this study that at least, there is 
no strong association [32]. In the future larger scale studies are necessary to further assess the 
association between pancreatitis and inhaled steroids in children, as it is a frequently used drug 
by children.
The pathogenesis of steroid-induced pancreatitis remains to be elucidated. Obstruction of the 
outfl ow of pancreatic secretions has been hypothesized as a possible underlying mechanism 
[13-15]. Animal studies and postmortem studies in patients treated with steroids demonstrated 
an increased incidence of focal pancreatic lesions [15, 33-35]. In contrast, animal studies and a 
Table 3: Exposure to steroids (inhaled or oral) and the risk of pancreatitis
Cases
(n=60)
Controls 
(n=6,847)
Matched OR#
(95% CI)
p-value
Never used steroids 
(inhaled+oral)
46 (76.7) 5,470 (84.3) 1 (Reference) -
Oral steroids
Current use 4 (6.7) 24 (0.4) 21.4 (7.1-64.6) <0.001
Past use 4 (6.7) 226 (3.5) 2.56 (0.9-7.3) 0.079
Total cumulative duration of oral steroids
<7 days 1 (1.7) 65 (1.0) 2.4 (0.3-17) 0.398
≥7 -<30 days 3 (5.0) 80 (1.2) 5.9 (1.8-19.7) 0.004
≥30 days 4 (6.7) 100 (1.5) 5.3 (1.9-15.3) 0.002
Use of inhaled steroids
Current 2 (3.3) 201 (3.1) 1.3 (0.6-3.2) 0.54
Past 7 (11.7) 707 (10.9) 1.9 (0.6-6.4) 0.30
Total use
<1 year 6 (10.0) 641 (9.9) 4.7 (0.6-35.6) 0.13
≥1 year 3 (5.0) 253 (3.9) 1.3 (0.6-2.9) 0.46
Subanalysis excluding patients with chronic pancreatitis
Cases (n=54) Controls (n=5,957)
Use of oral steroids
Current 4 (7.4) 22 (0.4) 24.0 (7.8-73.3) <0.001
Past 3 (5.6) 207 (3.5) 2.22 (0.7-7.4) 0.193
Total use
<7 days 1 (1.9) 60 (1.0) 2.71 (0.36-20.27) 0.331
≥7 -<30 days 3 (5.6) 74 (1.2) 6.65 (1.97-22.42) 0.002
≥30 days 3 (5.6) 90 (1.5) 4.87 (1.46-16.25) 0.01
# = matched on gender, age and index date,
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study in humans have also reported on a protective eff ect of steroids on pancreatitis [16, 17] 
A study in humans has demonstrated that the administration of steroids prior to endoscopic 
retrograde cholangiopancreatography (ERCP) resulted in a decrease in the incidence of post-
ERCP pancreatitis [36]. It is clear that more studies have to be performed to understand the 
mechanism of steroid-induced pancreatitis.
As for all observational studies, our study has limitations, the major one is lack of power due to 
the rarity of the event in children. This underlines the need for combining large linked health-
care databases to study serious but rare drug-safety issues in children adequately. In addition, 
we may suff er from residual confounding, Body mass index and alcohol intake are important 
risk factors of pancreatitis in adults. Alcohol consumption, especially in young children may 
be low, and therefore it may not be a confounding factor in this study. Confounding by indica-
tion may also occur: oral steroids might have been initiated to treat pancreatitis, however, the 
association was most pronounced in persons using steroids for more than 7 days, therefore, 
this cannot explain the fi ndings. In addition the association remained upon exclusion of 6 cases 
with chronic hepatitis. Misclassifi cation of the outcome is a potential concern. All potential 
cases of pancreatitis were selected from The Hospital Discharge Register via an automated 
search on ICD-9 codes. However, previous studies have shown the validity of The Hospital 
Admission Register in identifying patients with diseases of interest [37]. Selection bias is unlikely 
as we conducted a population based case-control study using a large database containing 
information on more than 3 million inhabitants from the Netherlands. Our study population is 
representative to the Dutch population so, our data can be extrapolated to the entire pediatric 
population of the Netherlands. Exposure misclassifi cation is unlikely as the PHARMO database 
contains pharmacy dispensing data, on prescriptions from both primary and secondary care, 
ensuring a complete overview of prescription drugs.
The fi rst case reports of steroid-induced pancreatitis in children were published in 1957 [21, 
22]. Since then, several case series on this topic have been published, but well-designed 
observational studies were lacking. We have addressed this gap by performing a population-
based case-control study, analyzing the association between steroid use in children and risk of 
pancreatitis. Our results show that current use and ≥7 days of use of oral steroids is associated 
with an increased risk of pancreatitis in children.
None of the authors has a confl ict of interest. The principal investigator had full access to all of 
the data in the study and takes responsibility for their integrity and the accuracy of the data 
analysis.
Funding: Funded by the European Community’s 6th Framework Programme. Project number 
LSHB-CT-2005-005216: TEDDY: Task force in Europe for Drug Development for the Young.
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In this thesis we present several large scale observational studies on the use and safety of 
asthma and cough and cold medicines in children. These studies were conducted in the context 
of the TEDDY Network of Excellence. TEDDY is a 6th Framework Programme funded Network of 
Excellence aiming to promote the availability of safe and eff ective medicines for children in 
Europe by integrating existing expertise and good practices, as well as stimulating pediatric 
drug development. (www.teddyoung.org) 
The research described in this thesis focuses on the use and the safety of asthma medicines 
and cough and cold medicines. These medicines belong to the group of respiratory medicines, 
which have been demonstrated to be amongst the mostly used medicines in children [1]. 
Asthma is the most common chronic disease of childhood with an estimated prevalence of 
10%, and as a result, asthma medicines are used widely in the pediatric population. Despite the 
widespread use of these medicines by children, very little is know about their long term safety. 
For this reason, regulatory authorities have implemented guidelines to stimulate research on 
safe and eff ective drugs in children, such as the need to get a paediatric investigation plan 
(PID) for each new regulatory submission and the promotion of the Paediatric Use Marketing 
Authorisation for off -patent drugs. In addition, the Pediatric Working Party (PEG) (under aus-
pices of the EMA) has generated, by treatment class, a list of drugs with specifi c needs, in terms 
of pediatric effi  cacy and safety. Among these lists, a list on the “assessment of paediatric needs 
for asthma and other obstructive chronic lung diseases” has been compiled stating the need to 
have information on pharmacokinetics, effi  cacy and safety data of respiratory drugs [2]. As 
proof of concept that these needs could be addressed by using observational studies rather 
than trials we have conducted large observational utilization and safety studies by combining 
several primary healthcare databases in Europe.
Other drugs; also frequently used in children; and for which safety concerns have been raised 
are the cough and cold medicines (CCMs) used for the symptomatic treatment of respiratory 
tract infections. In 2007, the FDA released a recommendation that cough and cold medicines 
should not be used in children below two years of age because of serious side eff ects such as 
cardiac arrhythmias, depressed levels of consciousness and even death [3, 4]. To evaluate the 
eff ect of these recommendations and to complete the available literature on ADRs caused by 
CCMs, we conducted several studies as part of the TEDDY project.
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Main Findings
Utilization studies
Use of medicines in children
In chapter 2.1 and 2.2 we present the studies on the utilization of pediatric medicines in the 
Netherlands, Italy and United Kingdom. In chapter 2.1 we describe utilization patterns of all 
drugs and in chapter 2.2 we focus on the respiratory drug use in children. Using a retrospec-
tive cohort design, the utilization of medicines is described for 675,868 children for the years 
2000-2005. The off -label status was checked for the fi ve drugs with the highest prevalence, by 
anatomic class, in each country. A drug was considered to be ‘off -label for age’ if the child’s age 
at the time of use was below the lowest approved age as mentioned in the Summary of Product 
Characteristics (SPC) of that drug in each of the countries of use [5].
The databases recorded more than fi ve million pediatric prescriptions. The main fi ndings were 
the following: 1) the prescription rate was highest for children aged less than two years in all 
three countries (average of 3.3 prescriptions/year); 2) In children of all ages, the most commonly 
used medicines were anti-infectives (antibiotics), respiratory medicines (asthma medicines) 
and dermatologicals (topical corticosteroids); 3) in the younger age categories, boys had a 
higher user prevalence rate but this pattern reversed with adolescence, where females had 
consistently higher drug use prevalence rates; 4) off -label use was mostly observed for topical, 
inhaled and systemic corticosteroids, oral contraceptives and topical or systemic antifungals.
This was the fi rst study describing pediatric medicines use in diff erent European countries by 
combining databases using the same methodology. This approach changed the landscape 
considerably since previous studies were country or region specifi c with a large heterogeneity 
between studies, making a comparative evaluation often diffi  cult or incomplete [6]. Since we 
used the same methodology across the databases, the diff erences that were observed refl ect 
real prescribing diff erences. The Pediatric Committee of the European Medicines Agency 
(EMA) has compiled a pediatric needs list based on expert opinions and consultations. This list 
provides an overview of drugs for which additional information on use in children is needed. 
The missing information can go from PK/PD studies in children to the need of long term safety 
studies. The drugs mentioned on the list of specifi c needs are also the drugs with the highest 
user prevalence rates (e.g. inhaled and oral corticosteroids, topical and systemic antifungals). 
Our fi ndings reinforce the importance of the need of additional data on drugs that are fre-
quently used. However, there are some off -label drugs with high prescription rates that were 
not mentioned on any of the priority lists of the EMA. One example is the use of sex hormones. 
Our study revealed high prescription rates and mostly off -label use of these drugs. Similar to 
adults, the use of oral anticonceptives by teenagers has been associated with an increased risk 
of cardiovascular events (e.g. myocardial infarction, stroke) as well as with an increased risk of 
venous thrombo-embolism [7-11]. To our knowledge, no RCTs on the safety and effi  cacy of sex 
Elif Fatma Sen BW.indd   152 03-01-11   15:17
Chapter 4: General Discussion
153
hormones limited to teenagers only have been conducted. Therefore we would recommend to 
include sex hormones in the pediatric needs list. This list is used as a tool to enforce pharma-
ceutical companies to apply for a PUMA (Pediatric Use Marketing Authorizations) for off -patent 
drugs to be registered for use in children. If authorized, a PUMA will give the pharmaceutical 
company 10 years of market protection for that specifi c drug. 
The studies presented in chapter 2.1 and 2.2 show that drug utilization studies are important 
to get a clear understanding of the user prevalence rates in children and the diff erences by 
country, gender and age. Information from these studies is important, fi rst of all to prioritize the 
specifi c needs but also to be incorporated into the PIPs 
Use of asthma medicines
Despite the widespread pediatric use of asthma medicines and the large number of single 
center or national studies describing user prevalence rates, there have been very few compara-
tive studies on the extent and patterns of use by region. To address this, we assessed the use of 
asthma medicines in three European countries (Netherlands, Italy and United Kingdom) during 
2000-2005 (chapter 2.3) by using a similar methodology. In addition, we checked the off -label 
use of these drugs per country. 
We found that the prevalence of asthma medicines use was highest in young children and 
decreased with age. The prescription rates were the highest for most asthma medicines in Italy, 
followed by the UK and the Netherlands. ß2-mimetics (salbutamol) and inhaled glucocorticoids 
(fl uticasone and beclomethasone) were the most frequently used asthma medicines in all three 
countries. Overall, off -label use, defi ned as use below the minimum age as mentioned in the 
SPC was low, but most pronounced for short-acting ß2-mimetics in children < 18 months (Italy) 
and fi xed combination of ß2-mimetics+anticholinergics in children <6 years (Netherlands). 
Some of the respiratory drugs are only registered for the treatment of asthma. Off -label use, 
defi ned as “use for other indications than asthma”, was observed in all 3 countries for several 
asthma medicines For some medicines, the percentage of off -label use was considerable (e.g. 
80% of the children receiving budesonide in Italy, 74% of the children receiving ipratropium in 
the UK and 72% of the children receiving salbutamol+ipratropium in the Netherlands do not 
have a diagnosis of asthma, while these drugs are only licensed for use in asthma).
This high percentage of off -label use of asthma medicines in children can be explained by the 
fact that in young children it is diffi  cult to make a diagnosis of asthma. This diagnosis is diffi  cult 
because in young children, it is hard to diff erentiate between respiratory symptoms related to 
asthma or respiratory symptoms related to lower respiratory tract infections. Second, in this 
younger age category, asthma diagnosis by means of spirometry is not possible. 
Use of cough and cold medicines
In 2007 the use of CCMs in young children received a lot of attention from regulatory agen-
cies and scientists; and the Food and Drug Administration (FDA) in the United States issued a 
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recommendation advising parents and caregivers not to use these drugs in children younger 
than 2 [1]. This recommendation was based on information from ongoing studies reporting on 
safety concerns (such as cardiac arrhythmias, depressed levels of consciousness, encephalopa-
thy and even death) of CCMs when used in young children [3, 12]. Following the US, warnings 
were as well issued in Canada, the United Kingdom and a partial warning in Italy on the use of 
nasal sympathomimetics in children <12 years. In the Netherlands, no national warning advis-
ing against the use of these drugs was spread. Although CCMs can be purchased as OTC in 
many countries, they are also regularly prescribed by primary care physicians, especially when 
these drugs are being reimbursed.
We assessed the eff ect of these regulatory warnings on prescription rates of CCMs in children < 
2 years in both Italy and the Netherlands (chapter 2.4). We found that, despite the international 
warnings and important publications in high impact journals and lay press advising against the 
use of CCMs in young children, overall prescription rates for CCMs increased in the Netherlands. 
In Italy, where a specifi c warning was issued against the use of nasal sympathomimetics or 
combinations, a signifi cant reduction in use of nasal combination products and nasal sympa-
thomimetics was observed as well as a decrease in use of cough suppressants (opioids and 
non-opioids).
The increase of the prescription of CCMs in the Netherlands is worrisome, especially since there 
is no evidence of effi  cacy of these drugs [13]. The few studies that have been conducted in 
children found no signifi cant improvement in symptomatic relief when compared to placebo 
[13-17]. Caregiver education and physician reminding on the self-limiting nature of coughs and 
colds and on the lack of effi  cacy of these CCMs is needed [3, 18]. We also would advice the Euro-
pean Medicines Agency to explicitly stipulate the hazards of use of CCMs in young children.
Safety studies
Safety studies within Vigibase
Although randomized controlled trials (RCTs) are considered to be the gold standard for per-
forming safety studies, they are often hampered by small sample sizes and short follow-up. 
Spontaneous adverse event reporting databases, such as the Vigibase database of the WHO-
UMC (Uppsala Monitoring Centre), contain the necessary data to elucidate potential safety risks 
of drugs among all age categories without the need to expose children to unnecessary clinical 
research.
To our knowledge, Vigibase has not been previously used to describe pediatric adverse drug 
reactions (ADRs). In this thesis we present the fi rst studies on pediatric ADRs related to asthma 
medicines and cough and cold medicines using data from the Vigibase.
We analysed all spontaneously reported ADRs for asthma and cough and cold medicines as 
captured in the Vigibase database of the WHO-UMC during the period 2000-2006. Associations 
between the use of these medicines and ADRs were assessed by calculating reporting odds 
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ratio (ROR) as a measure of disproportionality while adjusting for gender, continent and type 
of notifi er.
Asthma medicines related adverse drug reactions in children – data from the Vigibase 
database
The risk-benefi t profi le of asthma medicines has been well studied in randomized controlled 
trials (RCTs), and is considered to be favorable [19]. However, the majority of these studies have 
been performed in children older than 5 years and studies in younger children are lacking. To 
get a broader understanding of the adverse drug reactions associated with asthma medicines 
use in children and to get a better insight in the potential risks of these medicines in children of 
all age categories, we analysed the spontaneously reported ADRs for asthma medicines in the 
Vigibase database.
When the records in the VIGIBASE were limited to paediatric data, only 3.5% of the (non-vaccine 
related) records concerned ADRs related to the use of asthma medicines. This percentage does 
not correlate with the high prevalence of use of these medicines in children, e.g. 4-26% of 
children is being prescribed an asthma medicine (depending on country, age range, and study 
period) [1, 20]. This low reporting rate could be due to the fact that most asthma drugs are 
on the market for many years and treating physicians do not focus on potential (new) ADRs , 
because the medicines are thought to be safe. It could as well be that the low percentage of 
ADRs of asthma medicines, in relation to their high prevalence of use, is a true refl ection of the 
safety of these drugs. This is in contrast to the recent safety concerns on the use of e.g. LABA in 
children with asthma and the risk of serious asthma related events and/or death [21].
The majority of the associations that were observed are also described in literature and in the 
SPCs of the drugs of interest (e.g. adrenal insuffi  ciency and use of ICS and Churg Strauss syn-
drome in relation to LTRA) [22, 23]. We observed very few ADRs with high ROR that were not yet 
described in literature. New ADRs with high ROR were heart valve disorder, intestinal gangrene 
and gastric ulcer perforation with use of short-acting beta-agonists, gastric ulcer perforation, 
hemiplegia and tooth disorder with use of long-acting beta-agonists and hypokinesia with use 
of xanthines.
Although we did fi nd some new signals, we want to re-emphasize that ADRs from spontaneous 
reporting databases are purely hypothesis generating and further research is needed to assess 
these potentially new signals in an appropriate setting [24].
Cough and cold medicines related adverse drug reactions in children - data from the 
Vigibase database
Because of the high use of CCMs and the concerns on the benefi t-risk profi le of these drugs 
in (young) children, we used the Vigibase database to investigate the type of adverse drug 
reactions and ROR that have been reported for CCMs in children aged 0-18 years.
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CCMs related ADRs were infrequently reported (1.2% of the non-vaccine related records), 
although studies in the USA have shown that in a given week, 10% of the children use a CCM 
[25]. Actual use is hard to estimate since many CCMs are sold over the counter, this may also 
have an impact on the reporting rate of spontaneous ADRs, since only few countries allow for 
direct consumer reporting. Similar to what was observed for the asthma medicines, it could as 
well be that CCMs are thought to be safe and potential ADRs are not recognized nor reported. 
Most of the reported ADRs for CCMs concerned mucolytics and opium alkaloids and deriva-
tives. The majority of the observed associations between CCMs and ADRs in the Vigibase were 
already described in literature and SPCs (e.g. dosing errors and the typical side eff ects of opium 
alkaloids) [26, 27]. Two new and potentially life-threatening ADRs were observed namely 
chronic renal failure associated with the use of expectorants and cerebral infarction associated 
with the use of the fi xed combinations of opium alkaloids and expectorants. We want to re-
emphasize that new CCMs-ADRs associations in spontaneous reporting databases are purely 
hypothesis generating and further research is needed to assess these potentially new signals in 
an analytical epidemiological approach. Overall, we found that for all age groups, various ADRs 
of diff erent levels of severity were reported. This shows that CCMs not only cause ADRs in the 
youngest children, but in children of all ages. We underline the advice not to use CCMs in young 
children as evidence of their effi  cacy for the treatment of cough and cold is weak.
Glucocorticosteroids and risk of fractures
According to the Global Initiative for Asthma (GINA), maintenance treatment with low dose 
ICS is the treatment of choice for children with persistent asthma [28]. Oral glucocorticoids 
(OCS) are recommended for the treatment of very severe persistent asthma exacerbations. In 
accordance with the guidelines, the use of ICS in asthmatic children is high [29]. Long term use 
of ICS in children has been associated with major safety concerns such as adrenal suppression 
and growth retardation [28]. Long term use of OCS can cause osteoporosis, diabetes mellitus, 
adrenal suppression, obesity, skin thinning leading to easy bruising, and muscle weakness [28].
The association between the use of ICS and the risk of fractures remains controversial and very 
few studies have been conducted in children. All of these studies have focused on one country 
at the time, and therefore were reduced in size and heterogeneity of exposure was low (United 
Kingdom and Australia). To our knowledge, there are no studies quantifying the association 
between corticosteroids use and risk of fracture in children, combining data from diff erent 
European countries, with diff erent user patterns.
To get a better understanding of the risk of fractures associated with the use of corticosteroids 
in children, we conducted a population based nested case-control study using two primary 
care databases (IPCI and Pedianet) with quite diff erent prescription patterns of ICS and OCS in 
children and including children 0-18 years of age (0-14 for Pedianet). The case-control study was 
nested in a cohort of users of asthma medicines. We analysed the association between cumula-
tive use of inhaled corticosteroids (ICS), oral corticosteroids (OCS), and use of a combination of 
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inhaled and oral corticosteroids (ICS+OCS) and the risk of fractures. No association was found 
between use of ICS or use of OCS and the risk of fractures in any of the exposure categories. 
None of the previously conducted studies in children found an increased risk of fractures fol-
lowing use of ICS [30-32]. In contrast to the studies from Van Staa et al., we did not fi nd an 
increased risk of fractures for children using OCS. Van Staa et al. found that the risk of fractures 
was increased in children receiving more than 3 prescriptions of OCS [33]. In our study, the 
majority of children used OCS for less than 30 days. Indeed only 1% of the children (both cases 
and controls) used OCS longer than one month. This duration is probably too short to increase 
the risk of fractures. 
Our fi ndings, as well as data from other studies, show that ICS, which are the mainstay of pedi-
atric asthma treatment, can be used in children without concerns on a higher risk of fractures. 
We expect that long term use of OCS would increase the risk of fractures. As children are rarely 
chronically treated with OCS, this could not be studied in our database.
Glucocorticosteroids and risk of pancreatitis 
Pancreatitis is a relatively rare condition in children and is associated with considerable morbid-
ity and mortality [34]. Pancreatitis mainly occurs in adult life and the mean age of a fi rst pan-
creatitis attack has been shown to be in the 6th decade of life [35]. In adults, the most common 
causes of acute pancreatitis are gallstones and alcohol abuse [35, 36]. In children, acute pan-
creatitis has diff erent aetiologies such as trauma, infection, systemic diseases, toxins, structural 
anomalies of the pancreatico-biliary tract and idiopathic [37-39]. Drug-induced pancreatitis is 
considered to be a rare cause of pancreatitis in both children and adults. Glucocorticosteroids 
are among the drugs that have been associated with pancreatitis, both in adults and children 
[38-41]. All of the existing data on this subject is derived from case reports and case series. 
To quantify the association between the use of glucocorticosteroids (both inhaled and oral) 
and pancreatitis in children, we conducted a population-based case-control study within the 
PHARMO record linkage system. In a source population of around half a million children we 
identifi ed only 54 children with acute pancreatitis, demonstrating the rarity of the condition. 
Many children with pancreatitis had been previously exposed to some type of drug. Current 
use of oral glucocorticosteroids increased the risk of pancreatitis with a factor 20 compared to 
no use (OR 21.40, p<0.001). Use of Inhaled glucocorticosteroids use was not associated with an 
increased risk. 
Our results are in line with case series in children, observing an association between oral gluco-
corticosteroids use and an increased risk of acute pancreatitis [39, 42, 43]. Similar to what has 
been described in literature, we confi rmed known risk factors of pancreatitis such as a history 
of infl ammatory bowel disease, gallstones, cystic fi brosis and trauma; and concomitant use of 
azathioprine, mesalazine, metronidazol, opiates, omeprazol and NSAIDs. [37, 44-48]. 
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General consideration regarding the use and safety of respiratory medications 
in children
In this thesis we demonstrated that respiratory medicines are amongst the most frequently 
used drugs, particularly the inhaled corticosteroids and bronchodilating agents. These drugs 
merit their place for the treatment of asthma but in young children, these drugs are often used 
whereas the diagnosis of asthma could not be confi rmed. In some countries (e.g. Italy) use of 
oral steroids is quite high but often for a short duration of follow-up. We showed that each 
of the classes of respiratory drugs has ADRs reported to the Vigibase of the WHO-UMC. Most 
ADRs are already known in the literature or in the SPC, but some potential safety signals for 
these drugs were observed which require further formal testing. In particular cerebral infarc-
tion associated with use of opium alkaloids+expectorants, chronic renal failure associated with 
expectorants use, intestinal gangrene, heart valve disorders and gastric ulcer perforation with 
use of short-acting beta-agonists; and hemiplegia and tooth disorders with the use of long-
acting beta-agonists need to be further explored, as these are serious events.
We quantifi ed the association for ICS and OCS with two particular (known) side eff ects (fracture 
and pancreatitis) in children. Use of ICS and OCS was not associated with an increased risk of 
fractures, whereas OCS, but not ICS, increased the risk of pancreatitis in children. 
In the past; children were deprived of new drugs as, for ethical reasons, they were often excluded 
from clinical trials and thus effi  cacy and safety data on use in children were lacking: The pedi-
atric regulation aims to facilitate the development and accessibility of medicinal products for 
use in the pediatric population. For each dossier of a new drug; being submitted for approval, 
the law stipulates the need of a pediatric investigation plan (PIP): A PIP is a development plan 
aimed at ensuring that the necessary data are obtained through studies in children to support 
the authorisation of the medicine for children. The ultimate goal of the new regulation is to 
stimulate drug research in children to ensure the safety and effi  cacy of drugs used in children. 
The implementation of this new regulation should be closely monitored as the drawback could 
be that children are exposed to unnecessary clinical trials when crucial data can be collected 
from other sources. Datasources that can be used for analysis are the electronic health care 
databases which contain information on the incidence/prevalence of the disease, the standard 
treatment of the disease and potential safety concerns. These are aspects that are part of the 
requested information from the PIP [49].
To convince skeptics of the importance and added value of observational databases, collabora-
tive actions should be taken to further improve the quality of observational data. It is known 
that databases on spontaneous ADRs suff er from underreporting. Indeed, it has been estimated 
that less than 10% of all serious, and 2-4% of all non-serious ADRs are reported [50]. Reporting 
of spontaneous ADRs should be stimulated by adequate training and information programs, 
feed back systems and a facilitation of the reporting procedures. The research on rare side 
Elif Fatma Sen BW.indd   158 03-01-11   15:17
Chapter 4: General Discussion
159
eff ects and on long term side eff ects requires databases of considerable size with long term 
follow-up. This can be achieved by linking databases from various sources. Further research and 
development is needed to deal with issues such as database ownership, and transcription to 
uniform disease or drug coding. In addition, databases should try to capture data on important 
confounding factors. With regard to the safety and eff ectiveness of respiratory drugs, factors 
that need to be captured are asthma phenotypes and asthma severity as they modify treat-
ment response. 
In our research on the safety of respiratory drugs, we fi rst checked potential safety signals using 
spontaneous ADR data from the Vigibase database. In addition, we quantifi ed the association 
between the use of glucocorticosteroids and the risk of fractures and pancreatitis. We are 
aware that there are currently other safety concerns in relation to respiratory drugs that were 
not further elucidated. These concerns are the use of LABA in children and the risk of serious 
asthma related events and/or cardiovascular events. These safety concerns were not further 
explored for reasons of low LABA exposure and the very low incidence of cardiovascular events 
in children. 
Methodological considerations
In this thesis we have used several readily available healthcare databases to perform large scale 
pediatric observational studies. The studies performed in this thesis are part of the TEDDY NoE, 
which aims to promote the availability of safe and eff ective medicines for children in Europe by 
integrating existing expertise and good practices
To our knowledge, we are the fi rst to combine data from health care databases by using a 
predefi ned, common protocol. Combining the databases in this manner allowed us to perform 
large-scale pharmacoepidemiological research in pediatrics to get better knowledge about the 
safety and potentially benefi ts of drugs in children, without exposing children to unnecessary 
RCTs.
Primary care physician databases
For several studies in this thesis we used the the Pedianet database (pediatric electronic medical 
records from 150 pediatricians since 2000) in Italy [51], the IPCI database (comprising adult and 
pediatric electronic medical records from more than 400 doctors since 1996) in The Netherlands 
[52, 53], and the IMS DA database (electronic medical records on adults and children from 670 
doctors) in the UK [54] . All of these databases contain the complete automated medical records 
of primary care physicians and have been used and proven valid for pharmacoepidemiological 
research [55]. The age and gender distribution in the various databases is representative for the 
country they originate from. 
In these countries, primary care physicians are the guardians of children’s health, which means 
that all clinical information concerning the patients (including summaries of specialist and 
hospital care) is kept in their medical records. Since all children need to be registered with a GP 
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in the Netherlands and United Kingdom, and with a family pediatrician in Italy, the databases 
are population-based [55]. 
Limitations of these databases in pharmacoepidemiological studies
Exposure, information and selection bias 
One limitation of these databases is that they only capture outpatient, primary care prescrip-
tions and no specialist prescriptions nor over the counter drugs (OTC). In addition, as we only 
had access to prescription data, information on actual refi ll of the prescriptions was missing 
meaning that we overestimated the actual exposure. In the studies on medicines use overall 
and use of CCMs, this may have resulted in underestimation of prevalence of use of medicines 
which are commonly used OTC (e.g. paracetamol, xylometazoline). In our study on asthma 
medicines use, this will minimally infl uence our results since asthma is a condition often dealt 
with in primary care, and asthma medicines originally prescribed by a specialist are often con-
tinued or prescribed by general practitioners [53]. 
In our case-control study on the use of glucocorticosteroids and the risk of fractures, we do 
believe that misclassifi cation of exposure minimally infl uenced our exposure rates as asthma 
is a condition often dealt with in primary care, and asthma medicines originally prescribed 
by a specialist are often continued or prescribed by general practitioners [53]. If present; this 
misclassifi cation is probably non-diff erential between cases and controls, therefore the actual 
risk may have been underestimated.
Selection bias was unlikely, as all data was obtained from prospectively collected medical 
records that are maintained for patients care purposes. 
Information bias via misclassifi cation of the outcome is also unlikely, because all fracture cases 
were retrieved from medical records and reviewed by two medical experts who were blinded 
to the exposure. 
Confounding
A confounder is a factor that is both associated with the disease of interest and associated with 
the exposure but is not part of the common pathway (Figure 1). Due to the presence of the 
confounder, it is not possible to accurately assess the relationship between the exposure and 
outcome of interest. Confounding may be accounted for by  matching participants by likely 
confounders (such as age and sex), or controlling the eff ect of the confounder by stratifying 
the analysis. 
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We used IPCI and Pedianet to assess the association between steroid use and risk of fractures. 
Although we tried to adjust for any potential confounders, due to the nature of the databases, 
we did not have information on all possible confounders such as the nutritional status of the 
children, body mass index, bone mineral density, physical activity and smoking status. Residual 
confounding usually results in an overestimation of the observed risk. However, as we did not 
observe an increased risk we do not believe that the lack of information on these confounders 
infl uences our results. 
Strengths
A major strength of these databases is that they capture a large number of children in databases 
across Europe, resulting in a high generalisability of our fi ndings to the general population. In 
addition, these databases have detailed information on comorbidity and detailed information 
on hospital referral and discharge letters. This results in a good quality of case ascertainment. 
The fact that data on millions of children is available in health care databases should be recog-
nized by researchers and eff orts should be made to extract data on pediatric drug use/safety 
from these databases, instead of performing unnecessary clinical trials.
PHARMO RLS
We used PHARMO RLS to assess the association between the use of glucocorticosteroids and 
risk of pancreatitis. 
Exposure and information bias
In contrast to the IPCI and IMS data, the PHARMO-RLS captures refi ll data. Still, exposure bias 
might be present as the database does not capture actual intake of the drug. If present; we do 
believe that this bias will be non-diff erential as well, leading to an underestimation of the actual 
risk. 
Information bias by misclassifi cation of the outcome may be an issue using the PHARMO data-
base. All outcomes are coded by ICD-9 codes, and manual validation of potential cases is not 
possible as it would require the de-anonymisation of hospital data and permission to review 
the fi les. 
In addition, we may suff er from protopathic bias since steroids are also given to treat pancreati-
tis. This could not be the explanation of our fi ndings since the association was only observed in 
children using oral steroids for 7 days or more.
Confounding
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A major limitation of this study is that, as with each observational retrospective study, the fi nd-
ings were prone to unmeasured confounding as information on body mass index and alcohol 
intake were missing. 
Strength
The Pharmo RLS has as strength that it is a very large database containing information on 
more than 3 million inhabitants from the Netherlands meaning that our results can be extrapo-
lated to the entire pediatric population of the Netherlands. In addition, as PHARMO contains 
pharmacy dispensing data, both prescriptions from general practitioners and specialists were 
captured, ensuring a more complete overview of the drugs used. Although the database is 
large, pancreatitis is very rare and we this lacked power. Future studies should use approaches 
as done in TEDDY: pooling across databases.
Vigibase
Vigibase was used to provide an overview of pediatric ADRs related to asthma and cough and 
cold medicines. Data from spontaneous reporting databases suff er from bias such as under 
and overreporting. [56-58]. Furthermore, is has to be underlined that a signal with a high ROR 
does not prove that the drug and ADR are causally related. The observed signals are purely 
hypothesis generating and further research is needed to assess these signals in an appropriate 
setting [24]. Also, some of the found signals are due to confounding by indication, such as cystic 
fi brosis associated to mucolytics. Due to the nature of the database, information on indication 
is missing, and therefore it is not possible to identify the underlying condition.
The strength of this database is the large number of pediatric ADRs available for analysis.
Recommendations for future research
The studies in this thesis may help to give direction to further research in the fi eld of pediatric 
medicines research.
First, primary care physicians should be aware of the harms of CCMs in children. The fact that 
prescriptions rates of CCMs in the Netherlands even increased after the international warnings 
is alarming. We believe that in Europe, this topic did not receive the attention it deserves. We 
highly recommend that a concerted European action is undertaken to advice against the use 
and prescription of cough and cold medicines to children.
Second, we have shown the potential of linking multi-country databases to study cou ntry 
specifi c pediatric drug use and safety in a systematic manner without being hampered by 
methodological diff erences. Although RCTs are the gold standard for effi  cacy assessment, 
safety studies are more eff ectively conducted through large scale postmarketing observational 
studies [59]. Clinical trials are often small and too short for safety assessment
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Pharmacoepidemiological studies should be promoted to improve the safety assessment of 
pediatric drugs since they assess the safety of drugs under real life circumstances. As safety 
information is lacking on long-term use of controller medication in asthmatic children, health-
care databases throughout Europe should be combined to perform large scale safety studies. 
Also, the ADRs we found within Vigibase, which were not yet described in literature, can be 
assessed in this manner. Combining several databases will make it possible to also detect rare 
ADRs. 
This thesis shows that exposure and outcome information is available on a large pediatric 
population within Europe. Researchers should try to work together on linking the available 
databases within Europe, instead of performing clinical trials on a small scale.
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The Task-force in Europe for Drug Development for the Young (TEDDY) Network of Excellence 
was established in 2005 through funding of the European Community’s sixth Framework 
Programme to contribute to the promotion of safe and effi  cacious medicines for children in 
the context of the impending European Paediatric Regulation that came into force in January 
2007. The overall aim of  the TEDDY NoE is to promote the availability of safe and eff ective 
medicines for children in Europe by integrating existing expertise and good practices, as well 
as stimulating pediatric drug development. The work presented in this thesis is a spin-off  of the 
TEDDY activities. 
In this thesis, we aimed to study the use and safety of two mostly used medicine groups in 
children, namely asthma medicines and cough and cold medicines. We did this through large 
scale observational studies, by combining readily available healthcare databases within Europe.
In chapter 2 we present several multi-national studies on the utilization of medicines in children.
In chapter 2.1 and 2.2 we present the utilization of medicines in children living in Italy, the 
Netherlands and the United Kingdom. Children up to 14 (Italy) or 18 years of age (United King-
dom and The Netherlands) from three primary care databases were included in the studies. 
These were the fi rst studies describing pediatric medicines use in diff erent European countries 
by combining databases using the same methodology
Prevalence of use per year was calculated by drug class (anatomic and therapeutic levels). 
A total of 675,868 children were included in the studies. The mostly used medicines were 
anti-infectives, dermatological and respiratory medicines, whereas cardiovascular and anti-
neoplastic medicines had the lowest use.
In chapter 2.3 we describe the utilization of asthma medicines in children from Italy, the 
Netherlands and the United Kingdom by combining health care databases. For all children, 
prescription rates of asthma drugs were studied by country, age, asthma diagnosis and off -
label status. The cohort consisted of 671,831 children of whom 49,442 had been diagnosed 
with asthma at any time during follow-up. ß2-mimetics and inhaled steroids were the most 
frequently prescribed asthma medicine classes in the studied countries. Xanthines, anticholin-
ergics, leukotriene receptor antagonists and anti-allergics were the least frequently prescribed 
medicines classes. Off -label use was low, and most pronounced for ß2-mimetics in children < 18 
months (Italy) and combined ß2-mimetics+anticholinergics in children <6 years (Netherlands). 
With this study we showed that linking multi-country databases enables us study country 
specifi c pediatric drug use in a systematic manner without being hampered by methodological 
diff erences.
In chapter 2.4 we evaluate the eff ect of international safety warnings on the prescription 
rates of cough and cold medicines in children in the Netherlands and Italy. Cough and cold 
medicines are frequently used in children to treat upper respiratory tract infections without 
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solid proof of benefi ts and risk of serious adverse events. In 2007 international warnings have 
been issued advising against use of these drugs in young children. We analysed outpatient 
electronic medical records of children <2 years in Italy and the Netherlands and calculated pre- 
and post-warning prescription rates. The cohort consisted of 99,176 children < 2 years of age. 
After international warnings, overall prescription rates for cough and cold medicines decreased 
slightly in Italy and increased in the Netherlands. Despite the international safety warnings 
and negative benefi t-risk profi les, prescription rates of cough and cold medicines remained 
substantial and were hardly aff ected by the warnings, especially in the Netherlands.
In chapter 3 we assess the safety of asthma and cough and cold medicines by analysing the 
adverse drug reactions (ADRs) from the WHO Vigibase database and by performing case-
control studies.
Chapters 3.1 and 3.2 give an overview of adverse events related to asthma medicines and 
cough and cold medicines, reported to Vigibase. Of the non-vaccine related records (294,773), 
3.5% comprised of asthma medicines related ADRs and 1.2% of cough and cold medicines. 
For asthma medicines, the majority of the records were for children aged 2-≤11 years and 
most records concerned short-acting β2-agonists (SABAs) and inhaled corticosteroids. For 
cough and cold medicines, most ADRs were reported for children aged 2-18 years and mostly 
concerned mucolytics and opium alkaloids. In both studies, the majority of the found drug-
ADR combinations were already described in literature. New, potential signals that we found 
were were intestinal gangrene and perforated gastric ulcer associated with use of SABAs, 
tooth discoloration with the use of anticholinergics, chronic renal failure associated with use of 
expectorants and cerebral infarction associated with the use of opium alkaloids+expectorants. 
In chapter 3.3 we describe a study on the association between use of corticosteroids (inhaled 
[ICS or oral [OCS]) and risk of fractures in children. Long term use of OCS has been associated 
with an increased risk of fractures both in children and adults; whereas the association between 
the use of ICS and the risk of fractures remains controversial. To assess the risk of fractures 
associated with the use of corticosteroids in children, we conducted a case-control study 
combining data from the Netherlands and Italy. We confi rmed known risk factors for fractures, 
such as trauma and current use of drugs for functional gastrointestinal disorders. For exposure 
to corticosteroids (ICS or OCS), we found no increased risk of fractures. 
In chapter 3.4 a study on the association between use of corticosteroids (inhaled [ICS or oral 
[OCS]) and risk of pancreatitis in children is described. Although drug-induced pancreatitis is 
rare, a variety of drugs have been associated to pancreatitis (in children and adults), including 
steroids. So far, no studies have been performed to assess the association between exposure to 
steroids and pancreatitis in children. We conducted a case-control study within a Dutch hospital 
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discharge registry. Current use of OCS and cumulative use of >7 days OCS was associated with 
a higher risk of pancreatitis. Use of ICS was not associated with pancreatitis.
Chapter 4 includes a general discussion in which the results and conclusions of studies in 
this thesis are summarized and interpreted. Furthermore, methodological considerations are 
discussed and suggestions are given for further research.
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Samenvatting
Gesubsidieerd door de Europese Commissie’s zesde Framework Programma is in 2005 de 
Task-force in Europe for Drug Development for the Young (TEDDY) Netwerk van Excellentie 
opgericht om een bijdrage te leveren aan de bevordering van veilige en werkzame medicijnen 
voor kinderen, in de context van de Europese Pediatrische Wetgeving, welke in Januari 2007 
van kracht werd.
Het algemene doel van TEDDY is het bevorderen van de beschikbaarheid van veilige en werk-
zame medicijnen voor kinderen in Europa, door zowel bestaande expertise samen te brengen 
als ook medicijn ontwikkeling specifi ek gericht op kinderen te stimuleren. De studies die 
gepresenteerd worden in dit proefschrift zijn het resultaat van TEDDY werkzaamheden.
Het specifi eke doel van dit proefschrift was het onderzoeken van het gebruik en de veilig-
heid van twee veel gebruikte medicijn groepen in kinderen, namelijk astma medicijnen en 
Verkoudheidsmedicijnen. Dit hebben wij gedaan door medische databasen binnen Europa te 
combineren en hiermee observationele studies op grote schaal uit te voeren.
In hoofdstuk 2 presenteren we meerdere multinationale studies naar het gebruik van medicij-
nen in kinderen.
In hoofdstuk 2.1 en 2.2 beschrijven we het gebruik van medicijnen door kinderen in Italië, 
Nederland en het Verenigd Koninkrijk. Voor deze studies hebben we gegevens van kinderen uit 
drie huisarten-databasen gecombineerd. 
Deze studies waren de eerste in hun soort, waarin het medicijn gebruik door kinderen uit 
verschillende Europese landen wordt beschreven door medische databasen uit deze landen 
op uniforme wijze te combineren. 
Het gebruik van medicijnen per jaar werd berekend per medicijn-groep (op anatomisch en the-
rapeutisch niveau). In totaal werden 675,868 kinderen geincludeerd in deze studies. De meest 
gebruikte medicijnen waren anti-infectiva, dermatologische preparaten en respiratoire medi-
cijnen. Cardiovasculaire medcijnen en chemotherapeutica werden het minst vaak gebruikt.
In hoofdstuk 2.3 beschrijven we het gebruik van astma medicijnen door kinderen in Italië, 
Nederland en het Verenigd Koninkrijk aan de hand van het aantal voorgeschreven recepten. 
Recepten voor astma medicijnen werden bestudeerd per land, leeftijd, astma diagnose en 
off -label status. In totaal werden 671,831 geincludeerd in deze studie, van welke 49,442 waren 
gediagnosticeerd met astma. β-sympathicomimetica en inhalatiecorticosteroïden waren de 
meest voorgeschreven astma medicijnen. Xanthines, anticholinergica, leukotriene-receptor 
antagonisten en anti-allergica werden het minst vaak voorgeschreven. Off -label gebruik 
van astma medicatie was laag, de middelen die het vaakst off -label werden gebruikt waren: 
β-sympathicomimetica door kinderen <18 maanden oud (in Italië) en β-sympathicomimetica+
anticholinergica door kinderen <6 jaar (in Nederland).
Met deze studie tonen wij aan dat het combineren van multionationale medische databasen 
wetenschappers in staat stelt om medicijn gebruik door kinderen te bestuderen, zonder gehin-
derd te worden door methodologische problemen.
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In hoofdstuk 2.4 wordt het eff ect van internationale veiligheidswaarschuwingen op het 
aantal recepten voor verkoudheidsmedicijnen aan kinderen in Nederland en Italië beschreven. 
Verkoudheidsmedicijnen worden vaak gegeven bij bovenste luchtweginfecties, hoewel hun 
werkzaamheid in kinderen nooit is bewezen en er een verhoogd risico op ernstige bijwerkin-
gen is. Als gevolg hiervan,  zijn er in 2007 internationale waarschuwingen gegeven, waarin 
werd geadviseerd deze medicijnen niet te geven aan jonge kinderen. 
Wij hebben de medische gegevens van kinderen <2 jaar in Italië en Nederland bestudeerd en 
het aantal voorschriften voor verkoudheidsmedicijnen voor en na de waarschuwingen bekeken. 
99,176 kinderen jonger dan 2 jaar werden geïncludeerd in deze studie.  Na de internationale 
waarschuwingen, daalde het aantal voorschriften voor verkoudheidsmiddelen in Italië licht en 
in Nederland steeg het aantal juist. Ondanks de internationale veiligheidswaarschuwingen én 
het risico op ernstige bijwerkingen, werden verkoudheidsmiddelen nog aanzienlijk voorge-
schreven, vooral in Nederland.
In hoofdstuk 3 bestuderen we de veiligheid van astma medicijnen en verkoudheidsmedicijnen 
door bijwerkingen in de Vigibase database te bestuderen en door case-controle studies uit te 
voeren.
In hoofdstukken 3.2 en 3.2 wordt een overzicht gegeven van de bijwerkingen van astma 
medicijnen en verkoudheidsmedicijnen, die gemeld zijn aan de Vigibase database. Van alle 
bijwerkingen die niet aan vaccins waren gerelateerd (294,773), betrof 3.5% astma medicijnen 
en 1.2% verkoudheidsmedicijnen.  De meeste bijwerkingen voor astma medicijnen werden 
gemeld voor kinderen tussen 2-≤11 jaar en betroff en voornamelijk kortwerkende β –sympa-
thicomimetica en inhalatiecorticosteroïden. Voor verkoudheidsmedicijnen werden de meeste 
bijwerkingen gemeld voor kinderen tussen 2-18 jaar en betroff en voornamelijk mucolytica en 
opium alkaloïden.  De meeste van de beschreven bijwerkingen-geneesmiddel combinaties in 
beide studies zijn gekend in de literatuur. Mogelijk nieuwe signalen die wij hebben gevonden 
zijn de volgende: gangreen van de darmen en perforatie van een maagzweer bij gebruik van 
kortwerkende β –sympathicomimetica, verkleuring van de tanden bij gebruik van anticholiner-
gica, chronisch nierfalen bij gebruik van expectorantia en hersen-infarct bij gebruik van opium 
alkaloïden+expectorantia. 
In hoofdstuk 3.3 beschrijven we een studie naar de associatie tussen het gebruik van cortico-
steroïden (zowel inhalatie als oraal) en fracturen. Langdurig gebruik van orale corticosteroïden 
is in de literatuur geassocieerd met een verhoogd risico op fracturen in zowel kinderen als 
volwassenen, het risico bij inhalatie corticosteroïden is tot op heden twijfelachtig. Om de 
associatie tussen corticosteroïden en fracturen te bestuderen in kinderen, hebben wij een 
case-controle studie uitgevoerd waarin data uit Nederland en Italië werden gecombineerd. 
Gekende risicofactoren voor fracturen, zoals trauma en het gebruik van medicatie voor gastro-
intestinale stoornissen, werden bevestigd in onze studie. Het gebruik van corticosteroïden 
(zowel inhalatie als oraal) gaf geen verhoogd risico op fracturen in kinderen.
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Hoofdstuk 3.4 beschrijft een studie naar het gebruik van corticosteroïden (zowel inhalatie 
als oraal) en het risico op pancreatitis bij kinderen. Hoewel pancreatitis veroorzaakt door 
medicijnen zeldzaam is, zijn een aantal medicijnen in verband gebracht met pancreatitis 
(zowel in kinderen als in volwassenen), waaronder steroïden. Tot op heden, zijn er geen studies 
uitgevoerd om het risico op pancreatitis bij gebruik van steroïden te beschrijven in kinderen. 
Om dit gat aan informatie te vullen, hebben wij een case-controle studie uitgevoerd, gebruik 
makend van de Nederlandse Pharmo database. Huidig gebruik van orale corticosteroïden en 
cumulatief gebruik van > 7 dagen waren geassocieerd met een verhoogd risico op pancreatitis. 
Het gebruik van inhalatie corticosteroïden gaf geen verhoogd risico. 
Hoofdstuk 4 bevat een algemene discussie, waarin de resultaten en conclusies van studies in 
dit proefschrift worden samengevat en geïnterpreteerd. Daarnaast worden methodologische 
aspecten besproken en worden suggesties gedaan voor verder onderzoek. 
Elif Fatma Sen BW.indd   177 03-01-11   15:17
Elif Fatma Sen BW.indd   178 03-01-11   15:17
PhD po rtfolio
Elif Fatma Sen BW.indd   179 03-01-11   15:17
Elif Fatma Sen BW.indd   180 03-01-11   15:17
181
PhD portfolio
PhD Portfolio
Research skills
2007-2008 Master of Science in Clinical Epidemiology, Netherlands Institute for Health 
Sciences, Erasmus University, Rotterdam
International conference presentations
2008 11th Biannual Congress of the European Society for Developmental, Perinatal 
and Paediatric Pharmacology, Rotterdam, the Netherlands; poster presentation 
‘Respiratory drug use in children in the Netherlands, Italy and United Kingdom’ .
2008 11th Biannual Congress of the European Society for Developmental, Perinatal 
and Paediatric Pharmacology, Rotterdam, the Netherlands; poster presentation 
‘Use of cough and cold medications in children in the Netherlands and Italy’.
2008 24th International Conference on Pharmacoepidemiology, Copenhagen, Den-
mark; poster presentation ‘Respiratory drug use in children in the Netherlands, 
Italy and United Kingdom’ .
2008 24th International Conference on Pharmacoepidemiology, Copenhagen, Den-
mark; poster presentation ‘Use of cough and cold medications in children in the 
Netherlands and Italy’ .
2009 PRIOMED matchmaking event, Tallinn, Estonia; poster presentation ‘Cough and 
Cold medicine prescriptions in children’.
Elif Fatma Sen BW.indd   181 03-01-11   15:17
182
Ph
D
 p
or
tf
ol
io
Attending international meetings
2007 TEDDY Open Conference, London, United Kingdom
2008 TEDDY NoE annual meeting, ‘ European symposium on ethics and paediatric 
Clinical research in Europe’, Marseille, France.
2010 TEDDY Final Open Conference ‘ Paediatric Medicines in Europe. Past, Present 
and Future’ , Brussels, Belgium.
Teaching
2008-2009 Supervising practicals in Evidence Based Medicine at the Faculty of Medicine, 
Erasmus MC, Rotterdam
2008-2009 Teaching assistant, practicals in (pharmaco-)epidemiology at the Faculty of 
Medicine, Erasmus MC, Rotterdam
Other
2010 Reviewing for the ‘British Journal of Clinical Pharmacology’, and ‘ European 
Journal of Clinical Pharmacology’ .
Elif Fatma Sen BW.indd   182 03-01-11   15:17
Dank woord
Elif Fatma Sen BW.indd   183 03-01-11   15:17
Elif Fatma Sen BW.indd   184 03-01-11   15:17
185
Dankwoord
Na meer dan 3 jaar onderzoek is het dan eindelijk tijd voor het dankwoord! Opgelucht en met 
veel plezier schrijf ik dit laatste onderdeel van m’n boekje. Iedereen die op wat voor manier dan 
ook heeft bijgedragen aan de totstandkoming van mijn proefschift wil ik natuurlijk bedanken 
en een aantal mensen in het bijzonder.
Allereerst wil ik mijn promotor, Miriam Sturkenboom bedanken. Toen ik bijna 4 jaar geleden als 
nacodeur begon op de afdeling Medische Informatica, had ik nooit durven dromen dat ik een 
aantal jaar later met mijn eigen proefschrift in m’n handen zou staan! Miriam, heel erg bedankt 
dat je me die kans hebt gegeven. Jouw begeleiding heb ik al die jaren als zeer plezierig ervaren. 
Tijdens de wat mindere perioden gaven je enthousiasme en positieve energie mij het nodige 
zetje om door te gaan. 
Vervolgens natuurlijk mijn copromotor, Katia Verhamme. Katia de vele uren samen achter de 
pc, zwoegend over Foxpro, hebben hun vruchten afgeworpen. Bedankt ook voor je geduld, 
wanneer ik weer ’s in al mijn ongeduld een syntax of paper had afgeraff eld! Je was een soort 
‘moeder op het werk’, zorgzaam en bezorgd om je promovendi.
Ik wil ook graag prof. Den Jongste, prof van den Anker en prof. Ceci hartelijk danken voor hun 
deelname aan de leescommissie.
Toen ik startte als promovendus, kwam ik in een echte mannenkamer terecht. Gianluca (grote 
broer), Roelof en Seppe, bedankt voor jullie gezelschap! Ik voelde mij binnen no time thuis op 
de afdeling. 
Natuurlijk ook alle andere (oud-)collega’s: Ana, Ann, Carmen, Eva, Inge, Jeanne, Lenonoor, 
Marissa, Nico, Preci, Rene, Sandra, Silvana, Vera.
Tevens wil ik Desiree, Tineke, Carmen en Sander bedanken voor hun hulp bij de administratieve 
problemen en Kris, Mees en Marcel voor de soms broodnodige technische hulp.
Mijn vrienden, ‘the uni-gang’, jullie heel erg bedankt voor de vele uren gezelligheid!
Sevilay (paranimf), Gülhan, Hatice, Nazli, Shakib, Musa, Mo en Memo; zonder jullie was het de 
afgelopen jaren toch maar een saaie boel geweest! Ook al hebben de meesten van ons nu 
andere verplichtingen, ik hoop dat we toch tijd voor elkaar vrij blijven maken.
Mijn familie, pap en mam in het bijzonder, wil ik bedanken voor alle steun en zorg die ik mijn 
hele leven van ze heb gekregen. De vele weekenden samen zorgden voor de nodige ontspan-
ning. Zonder jullie was ik nooit zover gekomen.
Elif Fatma Sen BW.indd   185 03-01-11   15:17
186
D
an
kw
oo
rd
Mijn zus, tevens mijn paranimf, wil ik in het bijzonder bedanken. Mientje, we hebben samen 
een hele lange weg afgelegd. Je bent er altijd voor me geweest, no matter what, ook nu met 
mijn promotie. Ik hoop dat ik hetzelfde voor jou kan doen...
Tot slot mijn man Yavuz. Ook al zijn we nog maar net getrouwd, je hebt de afronding van mijn 
promotie in al zijn hectiek meegemaakt. Hopelijk komen we nu in wat rustiger vaarwater 
terecht waarin we meer van elkaar gezelschap kunnen genieten. Op naar de rest van ons leven 
samen...
Elif Fatma Sen BW.indd   186 03-01-11   15:17
List of publi cations
Elif Fatma Sen BW.indd   187 03-01-11   15:17
Elif Fatma Sen BW.indd   188 03-01-11   15:17
189
List of publications
List of Publications
Sen EF, Verhamme KM, Herings R, Neubert A , Felisi M , Sturkenboom MC. THE TEDDY NETWORK: 
EPIDEMIOLOGICAL TRENDS IN PAEDIATRIC DRUG USE IN EUROPE. European Journal of Hospital 
Pharmacy Practice, 6 (2007), 22–24.
van der Aa MN, Steyerberg EW, Sen EF, Zwarthoff  EC, Kirkels WJ, van der Kwast TH, Essink-Bot 
ML. Patients’ perceived burden of cystoscopic and urinary surveillance of bladder cancer: a 
randomized comparison. British Journal of Urology International. 2008 May;101(9):1106-10.
Sturkenboom MC, Verhamme KM, Nicolosi A, Murray ML, Neubert A, Caudri D, Picelli G, Sen 
EF, Giaquinto C, Cantarutti L, Baiardi P, Felisi MG, Ceci A, Wong  IC; TEDDY European Network 
of Excellence. Drug use in children: cohort study in three European countries. British Medical 
Journal. 2008 Nov 24;337:a2245.
van der Aa MN, Bekker MD, van der Kwast TH, Essink-Bot ML, Steyerberg EW, Zwarthoff  EC, Sen 
FE, Elzevier HW. Sexual function of patients under surveillance for bladder cancer. British Journal 
of Urology International. 2009 Jul;104(1):35-40.
Hsia Y, Neubert A, Sturkenboom MC, Murray ML, Verhamme KM, Sen F, Giaquinto C, Ceci A, 
Wong IC; on behalf of the TEDDY Network of Excellence. Comparison of antiepileptic drug 
prescribing in children in three European countries. Epilepsia. 2009 Oct 8. [Epub ahead of print]
Sen EF, Verhamme KM, Felisi M, ‘t Jong GW, Giaquinto C, Picelli G, Ceci A, Sturkenboom MC. 
Eff ects of safety warnings on prescription rates of cough and cold medicines in children below 
2 years of age. Accepted for publication in the British Journal of Clinical Pharmacology.
Trifi rò G, Gambassi G, Sen EF, Caputi AP, Bagnardi V, Brea J, Sturkenboom MC.  Association of 
community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested 
case-control study. Annals of Internal Medicine. 2010 Apr 6;152(7):418-25, W139-40.
Trifi rò G, Dieleman J, Sen EF, Gambassi G, Sturkenboom MC. Risk of ischemic stroke associ-
ated with antidepressant use in elderly persons. Journal of Clinical Psychopharmacology. 2010 
Jun;30(3):252-8.
Neubert A, Verhamme K, Murray ML, Picelli G, Hsia Y, Sen FE, Giaquinto C, Ceci A, Sturkenboom 
M, Wong IC; TEDDY Network of Excellence.  The prescribing of analgesics and non-steroidal 
anti-infl ammatory drugs in paediatric primary care in the UK, Italy and the Netlerlands. Pharma-
cological Research. 2010 Sep;62(3):243-8.
Elif Fatma Sen BW.indd   189 03-01-11   15:17
190
Li
st
 o
f p
ub
lic
at
io
ns
Sen EF, Verhamme KM, Neubert A, Hsia Y, Murray M, Felisi M, Giaquinto C, t Jong GW, Picelli G, 
Baraldi E, Nicolosi A, Ceci A, Wong IC, Sturkenboom MC. Assessment of Pediatric asthma drug 
use in three European countries; a TEDDY study. European journal of pediatrics. 2010 Sep 2. 
[Epub ahead of print].
Elif Fatma Sen BW.indd   190 03-01-11   15:17
Abo ut the author
Elif Fatma Sen BW.indd   191 03-01-11   15:17
Elif Fatma Sen BW.indd   192 03-01-11   15:17
193
About the author
About the author
Elif Fatma Șen was born on August 5th, 1983 in The Hague, the Netherlands. In 2001 she fi nished 
her gymnasium education at the Atlas College in Rijswijk. She studied Biomedical Sciences 
at the University of Amsterdam for one year and started medical school in 2002. In 2007 she 
obtained her Medical Bachelor and started her PhD research at the department of Medical 
Informatics of the Erasmus MC. There, she performed the research described in this thesis. 
In 2008 she obtained her Master of Science degree in Clinical Epidemiology at the National 
Institute for Health Sciences (NIHES).
In 2011 she will start her internship to obtain her medical degree.
Elif Fatma Sen BW.indd   193 03-01-11   15:17
